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ABSTRACT 
Amorphous solid dispersions are known to improve the oral bioavailability of 
poorly water-soluble drugs. However, the physical instability of solid dispersions leading 
to phase separation and subsequent crystallization is limiting their commercial use. 
Polymers used in solid dispersions have shown to inhibit drug crystallization by either 
increasing the glass transition temperature (T g) of the mixture; and/or by interacting with 
the drug. To effectively inhibit drug crystallization, the polymer has to remain miscible 
with the drug. Drug crystallization could occur if drug-carrier miscibility is adversely 
affected by heat or humidity. It is therefore important to understand the drug-carrier 
miscibility to define strategies for ensuring the physical stability of amorphous solid 
dispersions. 
In this study, an approach is presented with which one can determine the "solid 
solubility", defined as the amount of drug that remains miscible with the carrier under 
specified heat and humidity condition. Modulated differential scanning calorimeter 
(MDSC) was used to determine the solid solubility of trehalose, griseofulvin, and 
indoprofen, in amorphous polymers like PVP and dextran . Solid dispersions that exhibit 
single Tg, were exposed to accelerated storage conditions and their Tg(s) were monitored 
periodically. An increase in Tg or the fonnation of multiple Tgs indicated the phase 
separation of drug from the polymer. The Tg was monitored until a plateau was reached, 
indicating an equilibrium state and no further phase separation. The solid solubility of 
drug in the polymer was detennined from the calibration plot of Tg of freshly prepared 
solid dispersion vs. drug-polymer ratio. 
The mechanism of solid solubility was elucidated and hydrogen bonding was shown to 
play a critical role in enhancing the solid solubility. lndoprofen that hydrogen bonds to 
PVP had solid solubility of l 3%w/w, whereas griseofulvin which had no hydrogen 
bonding to the polymer crystallized completely from the solid dispersions when stored at 
accelerated conditions of 40°C and 69% relative humidity. In the case of trehalose and 
dextran miscible solid dispersions the solid solubility of trehalose seemed to decrease 
with increasing storage temperatures and moisture levels . The kinetic rate of indoprofen 
and griseofulvin phase separation from the polymer was estimated by fitting the Tg of 
miscible mixtures, to the first-order rate equation. The phase separation rate of 
indoprofen was found to be at least 10 times lower than that of griseofulvin. 
The effect of surfactants on the drug solid solubility in the polymer was also investigated. 
To probe into the factors responsible for physical instability of amorphous solid 
dispersions, the molecular mobility of a model drug-griseofulvin and the polymer-PVP 
was studied. Isothermal and non-isothermal crystallization studies were conducted on 
griseofulvin to determine the activation energy for crystallization. Molecular mobility of 
PVP was studied using thermally stimulated current spectroscopy and the factors 
influencing the molecular motions were studied. 
KEY WORDS : Amorphous, glass transition, molecular mobility, thermal analysis, solid 
dispersions. 
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PREFACE 
This work has been prepared in accordance with the manuscript format option for 
dissertation preparation, as outlined in section 11-3 of The Graduate Manual of The 
University of Rhode Island. The entire dissertation has been divided into three sections. 
Section A contains the introduction of the thesis, which describes the subject of this 
dissertation, the need to conduct research in the chosen area and the specific objectives of 
the research. 
Section B is comprised of five manuscripts and forms the heart of the dissertation. It 
contains the significant findings of the research and discusses them in detail. Each 
manuscript has been presented in the format required by the journal to which they have 
been accepted, or they will, or have been submitted. Each manuscript has an abstract 
pertaining to that chapter, followed by introduction, the materials and methods used and 
have a conclusion along with the cited references. The figures and tables have been 
provided at the end of respective manuscript. 
Section C contains six appendices. Except for the first appendix, the last five appendices 
provide additional infomrntion that is essential to, but not usually included for 
publications in the manuscripts. Each appendix contains supporting data corresponding to 
individual manuscript chapter and has been designated accordingly. This dissertation 
closes with a complete listing of all the works cited in this dissertation, arranged in 
alphabetical order by the author's last name. 
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SECTION A 
Overall Thesis Introduction 
Pharmaceutical solid dispersion technology is generally accepted as a technique to 
enhance the dissolution characteristics of drugs with poor water solubility [ 1-3] . The drug 
substance is dispersed in a water soluble inert polymer matrix, sometimes at the 
molecular level, and the higher surface area due to the presence of polymer may increase 
the drug solubility and dissolution rate [4]. If the drug is not dispersed on a molecular 
scale, it is often physically modified from its crystalline to amorphous fonn during 
processing [5]. The presence of high-energy amorphous state leads to enhanced 
dissolution rate and hence bioavailability owing to the lack of crystalline lattice [6]. The 
prime reason for the increasing popularity of solid dispersion technology for oral solid 
dosage formulations is the improvement in the solubility and bioavailability of poorly 
water soluble drugs [7]. 
Solid dispersion technology: an attractive alternative 
For over centuries the water solubility of pharmaceutical drugs was improved by 
techniques like particle size reduction through grinding [8]. Eventually sophisticated 
techniques like modification of the chemical structure of drug molecule via pro- drug 
formation, selection of suitable salt form, and complexation with solubilizing agents 
generated increasing attention [9]. Lately however, increasing number of highly 
lipophilic drug molecules are being synthesized through combinatorial chemistry 
synthesis program and the conventional techniques are unable to enhance the drug 
dissolution rate and bioavailability of such hydrophobic drugs [I OJ. Majority of the drug 
molecules that are recently entering into the pharmaceutical company pipeline have 
intrinsic water solubility of less than 1 µg/mL when compared to conventional I 00 
µg/mL. Therefore there is a need for newer formulation approaches that could help meet 
the challenge of providing adequate drug plasma concentration for therapeutic efficacy. 
Solid dispersion technology proves to be an attractive alternative for such drug 
molecules. 
Conventionally, converting the physical state of drug substance from crystalline to its 
high-energy amorphous state was used as an approach to improve the drug dissolution 
performance. This was primarily done since the aqueous solubility of amorphous drug 
can be as high as 1000 fold greater than the crystalline form [11] . Such an amorphous 
state, however, is thermodynamically unstable and under certain conditions of 
temperature and relative humidity during storage it could crystallize [12]. Solid 
dispersion formulation could be an attractive alternative to stabilize such amorphous drug 
substances while improving the drug dissolution rate and bioavailability [ 13]. 
Solid dispersions: challenges and opportunities 
Although solid dispersion technique has generated several research contributions for over 
four decades, the number of marketed formulations that use this technique is rather 
disappointing. Only a griseofulvin-poly (ethylene glycol) solid dispersion (Gris-PEG, 
Novartis) and a nabilone-povidone solid dispersion (Cesamet, Lilly) were commercially 
available during the past four decades. There can be various subjective reasons for such a 
scenario. A drug candidate that is suitable to be formulated via this technique can 'die' 
during the pharmaceutical pipeline due to reasons like toxicity manifestation, low 
therapeutic efficacy, chemical instability, extremely low water solubility, and various 
formulation challenges. However in the case of solid dispersion, the challenges have been 
on a more generalized scale to prevent commercial products for several years. One of the 
challenges associated with this technology is the physical instability of the amorphous 
drug substance dispersed in the polymeric matrix during shelf life storage [14]. Other 
challenges include the inability to scale-up the solid dosage formulation from the typical 
small-scale melt-quench, or solvent-evaporation technique; inadequate knowledge of the 
mechanism of dissolution of drugs from the dosage forms, prevention of crystallization of 
some drug substances in the gastric fluids; and poor understanding of the in vitro /in vivo 
correlation in these dosage forms [7, 15]. 
The purpose of this dissertation is to address the physical instability of the amorphous 
drug substance dispersed in the polymeric matrix. Specifically, to understand the 
crystallization behavior of the amorphous component from solid dispersions during their 
storage, and to evaluate the factors that could improve the physical stability of these 
dosage forms. 
In this chapter an extensive literature review on the field of solid dispersion is provided, 
more specifically relating to physical stability issues of amorphous components. The 
purpose of this chapter is to increase the appetite of the reader for this field and to get 
familiarized with some of the latest developments. 
Physical state of drug dispersion: amorphous solid solutions 
Solid dispersions have been traditionally formulated by heating the physical mixture of 
drug and carrier to the molten state and solidifying by cooling it either rapidly or slowly. 
Alternate methods involved dissolving the physical mixtures in a common volatile 
solvent and evaporating the solvent to obtain the residual dispersion. The solvent can also 
be spray-dried (organic volatile solvent) or freeze dried (aqueous) to obtain the solid 
dispersion. Recently supercritical fluid processing and hot melt extrusion are being 
explored extensively for a large-scale manufacturing of solid dispersion by 
pharmaceutical companies [16, 17] . Although there are several approaches to formulate 
solid dispersions, the effect of processing conditions on the physicochemical properties of 
the overall formulation and the exact physical state of the drug that is dispersed through 
the polymer is yet to be ascertained. The nature of the drug dispersion i.e. molecular vs. 
phase segregation, amorphous vs. crystalline and the presence of polymer can influence 
the overall free energy and the physical stability of the product. 
In 1961, Sekiguchi and Obi performed the initial work on pharmaceutical solid dispersion 
[ 18]. They classified the physical state of active components in the inert matrix into 
several groups as depicted in table A-1. The group under which a solid dispersion product 
would belong is entirely dependent upon the intrinsic property of the drug and carrier. 
Historically solid dispersions have been preferred in their eutectic fom1 in which the drug 
4 
and carrier are dispersed as fine crystalline particles in close proximity to each other. At 
the eutectic composition, as indicated by the depression in melting temperature of the 
fused material, the active component and the carrier have the maximum possible interface 
with each other. At this composition the active component experiences a maximum 
increase in the surface area and hence the dissolution rate is enhanced. However with 
storage time, crystal growth of active component has been reported leading to reduction 
in surface area and hence dissolution rate [19] . The crystal growth could possibly be 
inhibited if the carrier is dispersed on a molecular level with the active component. The 
molecular dispersion is achieved through formation of solid solution. Since a crystalline 
solid solution is very rare and difficult to formulate, amorphous solid solutions are being 
investigated as a means for drug crystal inhibition. In amorphous solid solution, the drug 
and carrier is dispersed on a molecular level leading to an amorphous product that 
exhibits a single glass transition temperature (T g) . The glass transition temperature is the 
characteristic feature of the miscible mixture and is generally considered as an indicator 
of the degree of molecular mobility. In the following sections some fundamental 
information relating to amorphous forms that is needed to address physical stability 
aspects is provided. 
Glass transition temperature (T J 
In order to elaborate the glass transition phenomenon, let us examine closely into the 
thermodynamics of molecular motion of a crystalline material that is liquefied and is 
maintained above its melting temperature (Tm). Fig A-I describes the changes in specific 
volume of the liquid as it is cooled from high temperatures. Upon cooling, the molecules 
of the liquid may come in close proximity and be bound, resulting in crystalline material 
at T rn· Melting or crystallization is a first order phase transition, where there is a change 
in the first derivative of Gibbs free energy with respect to temperature, and the process of 
crystallization results in a drastic reduction in the specific volume (water is an exception). 
If the liquid manages not to crystallize at Tm, then its specific volume continues to 
decrease with corresponding increase in the viscosity. The system is now termed as a 
'supercooled liquid' and is considered to be in 'equi librium' with properties similar to 
linear extrapolation of enthalpy of a liquid. As a supercooled liquid is cooled to lower 
temperatures, the molecules move more and more slowly and at some temperature they 
do not have a chance to significantly rearrange or to mobilize themselves. At this point 
the system is thrown out of equilibrium and this temperature is termed as the glass 
transition temperature (T g). At temperatures lower than the T g, the time scales of 
molecular motion become drastically long and the material is essentially considered in a 
frozen state and is termed as ' amorphous' or 'glass'. Glass transition temperature is a 
second order transition in which there is no change in the free energy of the system, but 
changes in enthalpy, entropy or viscosity of the material do occur. 
Solid solutions or miscible dispersions are characterized based on their single glass 
transition temperature since both polymer and drug undergo the transformation from 
liquid state to corresponding unique amorphous phase simultaneously upon cooling. The 
presence of two T gS in the mixtures represents a phase separated product. Interested 
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readers on the thermodynamics of amorphous materials are referred to an excellent 
review and references therein by Ediger and co-authors [20] . 
Molecular mobility in amorphous phase 
Molecular mobility in amorphous phase is typically described in terms of relaxation time 
(<) . Relaxation time is the time taken for one molecular motion i.e. rotational or 
translational to occur. In molecular liquids near T g, it may take minutes or hours for a 
molecule less than 10° A in diameter to reorient [21]. Although the molecules in 
amorphous state at temperatures below the T g are in a frozen state, they do possess 
mobility in the order of hundred of hours. The temperature dependence ofrelaxation time 
for supercooled liquids is often described at least approximately by the Vogel-Tammann-
Fulcher (VTF) equation: 
r = r 0 exp(-
8 ) T -T., 
where <o can be considered as a pre-exponential factor, if the equation is considered as 
Arrhenius equation (i .e. when T., = 0). B is then equal to Elk where E is the energy of 
activation for molecular motion and k is the Boltzmann constant. When T., > 0, the 
temperature dependence of relaxation time is non-Arrhenius and the relaxation time is 
predicted to become infinite at T .,. In other words, the molecular mobility is very low at 
temperatures well below the T g· The primary cause of such slow dynamics is due to high 
viscosity and low kinetic energy at such low temperatures. However the slow dynamics 
of amorphous state could in some cases be significant enough for the molecules to orient 
and transform to the low free energy crystalline state [22]. 
Factors influencing physical stability of solid solutions 
In amorphous solid solutions, the presence of polymer having a higher glass transition 
temperature has been suggested as an approach to inhibit drug crystallization [23]. 
Typically a storage temperature of 50°C below the T g of amorphous system is considered 
suitable to minimize the crystallization tendency of the material [24]. When the drug 
substance is mixed molecularly with the polymer, the Tg of the molecular dispersion is 
increased relative to the Tg of drug alone and hence the molecular mobility of the drug 
that is needed for crystallization is reduced. It has also been shown, in specific cases, that 
presence of drug-polymer interactions e.g. hydrogen bonding, could play a role in 
delaying or preventing the drug crystallization from molecular dispersions [25]. However 
mechanism of prevention of drug crystallization from such dispersions is not yet fully 
understood in the presence of moisture and elevated temperature conditions. Moisture is a 
well known plasticizer and is naturally present in the atmosphere. It has a tendency to be 
absorbed by the amorphous materials and reduces the glass transition temperature, 
thereby increasing the molecular mobility and the crystallization tendency of drug 
components [26-28]. The exact extent of increase in the molecular mobility by moisture 
and crystallization rate is not yet clear. Also the effect of moisture on the extent of drug-
polymer interaction is poorly understood. 
The storage temperature is also believed to play a role in crystallization. It is generally 
known that increasing the storage temperature leads to enhanced crystallization kinetics. 
Temperature could also influence the extent of drug-polymer interactions, by decreasing 
the strength of interaction with its increase. Therefore all the issues suggest that 
molecular dispersions are kinetically stable and their physical stability is largely 
influenced by storage conditions i.e. temperature and relative humidity, choice of 
polymer i.e. less hygroscopic polymer is better, absence of nuclei or seed crystals to 
prevent secondary nucleation of drug, nature of drug product packaging i.e. presence of 
desiccants, etc. All of these restrictions make it nearly impossible to formulate a 
successful physically stable molecular dispersion. 
Determination of solid solubility to improve physical stability 
In this thesis, I address the issue of physical stability of solid dispersions by resolving the 
problem into two categories: kinetic stability and thermodynamic stability. A list of 
factors that differentiate the two have been tabulated (table A-II). When a drug is 
formulated as a miscible solid dispersion with a carrier, although it is miscible initially, 
i.e. under low moisture content levels, its extent of miscibility may not be retained in the 
presence of moisture that can be gained by samples during shelf-life storage. Under such 
conditions, the drug or polyn1er could phase separate ffom the mixtures thereby making 
the drug vulnerable to crystallization. 
If a solid dispersion system can be designed where the drug concentration is such that the 
presence of moisture cannot cause phase separation and hence drug crystallization, 
physical stability can be assured. The concentration of the drug that remains miscible 
with the polymer in the presence of accelerated stress conditions i.e. high relative 
humidity and temperature is defined as the "solid solubility" of drug in the polymer. To 
characterize such solid solubility is indeed challenging, as stated by Duncan Q. M. Craig 
in one of his recent reviews on solid dispersions [4], 
" ... unequivocal demonstration of solid solubility is not as simple as one may imagine. " 
The concept of solid solution has been addressed for several years in the metallurgy and 
polymer science fields [29]. However, techniques to characterize solid solubility are very 
limited and restricted to specific fields. Calorimetric techniques are utilized in 
characterizing drug-polymer miscibility (30], and can be of valuable support to quantify 
drug solid solubility as performed in the present research. 
Specific objectives of this thesis 
1. To design and evaluate a screening technique to identify the "solid solubility" of 
drug substances in commonly employed polymeric carriers using calorimetric 
approaches. Also to verify if solid dispersions prepared at solid solubility levels are 
physically stable by storing them under accelerated stability conditions for at least six 
months. 
10 
2. To investigate the influence of factors like storage temperature, moisture content 
drug-polymer interactions, drug loading etc. on the solid solubility and drug 
crystallization from solid dispersions. 
3. To validate the universal applicability of the screening technique by employing 
different hydrophobic drug models and using various analytical tools like X-ray 
diffraction and Fourier transform infrared spectroscopy. 
4. To understand the mechanism of drug crystallization from solid miscible 
dispersions and performing extensive literature review to substantiate the findings 
theoretically. 
5. To characterize the physical stability of model amorphous hydrophobic 
compounds by conducting crystallization studies to investigate the influence of moisture 
and storage temperature on the crystallization kinetics. Eventually compare the drug 
crystallization rate with the kinetics of drug phase separation and crystallization from 
solid dispersions. 
6. If circumstances allow, to design fonnulation approaches like addition of 
surfactant or complexing agents to decrease the kinetics of drug phase separation or 
crystallization and to enhance the drug solid solubility in the carrier. 
7. Finally, to employ a newer sensitive thermally stimulated current spectroscopy 
(TSC) measurement to characterize the molecular mobility of commonly employed 
polymer in solid dispersion. To evaluate the potential of TSC in characterizing 
amorphous formulations and comparing the results with experimental results obtained 
using modulated differential scanning calorimeter (MDSC). 
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Table A- I: Nature of drug dispersed in the polymeric matrix 
Group Dispersion type 
1 simple eutectic mixtures 
2 solid solutions 
3 amorphous (glass) solutions and glass 
suspensions 
4 amorphous precipitation of a drug in 
crystalline carrier 
5 compound or complex formations 
between drug and carrier 
6 any combinations among groups 1-5 
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Table A-II: Physical Stability of Solid Dispersions 
Kinetic Stability Thermodynamic Stability 
Kinetic stability is possessed by the Thermodynamic stability can be 
system initially but not during regular possessed by the system for prolonged 
handling and storage of drug product period and it is a definite value at a 
specified temperature and moisture 
content 
Possessed by supersaturated systems Possessed by saturated or under-saturated 
systems 
Usually characterized by initial drug It can be characterized by drug solid 
miscibility levels solubility levels 
Choice of storage temperature and Less likely influenced by storage 
moisture content is restricted temperature and moisture content 
Unpredictable crystallization of drug No crystallization of drug can occur from 
could occur from the solid di spersions solid dispersions 
Kinetic stability can be influenced by Thermodynamic stability can be improved 
method of solid dispersion preparation by suitable selection of polymer i.e. 
i.e. rate of cooling, extent of mixing with hydrogen bonding, addition of surfactants 
carrier etc. or complexing agents etc. 
Most systems possess kinetic stability Very few systems could possess 
thermodynamic stability 
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Figure A- 1 
Depiction of glass transition temperature in amorphous solids 
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SECTION B 
MANUSCRIPT I 
PHASE BEHAVIOR OF AMORPHOUS MOLECULAR DISPERSIONS I: 
DETERMINATION OF THE DEGREE AND MECHANISM OF SOLID 
SOLUBILITY 
Madhav Vasanthavada1, WeiQin Tong2, Yatindra Joshi2, and M. Serpil Kislalioglu 1•3 
ABSTRACT 
Purpose: To understand the phase behavior, and the degree and mechanism of the solid 
miscibility in amorphous molecular dispersions by the use of thermal analysis. 
Methods: Amorphous molecular dispersions of trehalose-dextran and trehalose- PVP 
were prepared by co-lyophilization. The mixtures were exposed to 23°, 40° and 50°C 
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(75% relative humidity (RH)) and 23°C (69% RH) storage conditions respectively. 
Thermal analysis was conducted by Modulated Differential Scanning Calorimeter 
(MDSC). 
Results: Upon exposure to moisture, two glass transition temperatures (Tgs), one for 
phase separated amorphous trehalose (T gl) and the other for polymer-trehalose mixture 
(Tg2) were observed. With time, Tg2 increased and reached to a plateau (Tg'q), whereas 
T gl disappeared. The disappearance of T gl and the appearance of T "" i.e. melting 
endotherm for trehalose dihydrate was attributed for the crystallization of the phase-
separated amorphous trehalose. It was observed that Tgcq was always less than Tg of pure 
polymer. The lower Tgcq when compared to Tg of pure polymer may be the result of 
solubility of a fraction of trehalose in the polymers chosen. The miscible fraction of 
trehalose was estimated to be 12% and 18% w/w in dextran at 50°C 175% RH and 23°C I 
75% RH respectively, and I 0% w/w in PVP at 23°C/ 69% RH. 
Conclusions: Mixing behavior of trehalose-dextran and trehalose-PVP dispersions were 
examined both experimentally and theoretically. A method determining the "extent of 
molecular miscibility", referred to as "solid solubility'', was developed, and 
mechanistically and thermodynamically analyzed. Solid dispersions prepared at trehalose 
concentrations below the "solid solubility limit" were shown to be physically stable even 
under accelerated stability conditions. 
KEY WORDS: glass transition, solid dispersions, miscibility, phase separation, them1al 
analysis 
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INTRODUCTION 
ln the phamrnceutical literature, publications on the use of solid dispersions to enhance 
the dissolution rate and bioavailability of poorly water-soluble compounds are in 
abundance [1]. However, despite the extensive R&D efforts only a few solid dispersion 
products are commercially available. One of the reasons for this rarity is the 
thermodynamic instability of amorphous active component in dispersed systems [2,3). 
Although recrystallization of amorphous drugs from solid dispersions is reported in 
several publications, the exact mechanism of such recrystallization is not clear. The 
investigators, who extensively evaluated the physical stability of amorphous materials, 
attributed the recrystallization phenomenon mainly to the molecular motions of 
amorphous components even below the glass transition temperature (T g) [ 4-8). 
Lt is generally understood that polymers improve the physical stability of aniorphous 
drugs in solid dispersions by either: a) increasing the T g of the miscible mixture, thereby 
reducing the molecular mobility at regular storage temperatures, or b) specifically 
interacting (e.g. hydrogen bonding) with functional groups of amorphous drug substance 
[9-11 ). For a polymer to be effective in preventing crystallization by either of these 
mechanisms, it has to be molecularly miscible with the amorphous substance. For 
complete miscibility, interactions between the two components are necessary [ 12]. A 
miscible system can phase-separate and become unstable if specific interactions between 
the components are adversely affected by a third component like water. The extent of 
moisture uptake depends upon factors like hygroscopicity of the drug and/or carrier, the 
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concentration of the active substance in the drug product and the storage temperature. 
Due to this complexity, the prediction of physical stability of a drug substance in a solid 
dispersion becomes challenging. In order that the solid dispersion systems can be 
effectively utilized by the pharmaceutical industry, it is critical to understand the role of 
time, temperature, and humidity in determination of the physical stability of solid 
dispersion during its shelf-life. 
The objective of this study was two-fold: The first was to study the phase behavior of the 
selected solid dispersions via thermal analysis, in order to determine the extent of solid 
state miscibility under accelerated stability conditions, and the second was to understand 
the mechanism of physical stability of these amorphous molecular dispersions. 
Molecular dispersions of trehalose-dextran and trehalose- poly (vinylpyrrolidone) (PVP) 
were chosen as models to understand the phase behavior of a crystallizable amorphous 
substance that was molecularly mixed with a polymer. Trehalose is a well characterized 
compound [13]. Amorphous trehalose, which is highly susceptible to moisture, 
crystallizes to a stable di hydrate that can be characterized thermally [ 13]. Although 
hydrogen-bond interactions between trehalose and PVP have been cited [14] , the 
influence of water on these interactions, the phase behavior of the mixtures and the solid-
state miscibility has not yet been demonstrated in the literature. 
22 
MATERIALS AND METHODS 
Materials 
Dextran (polymer containing sucrose having a-1, 6-glucosidic linkage), with Mn of 70 
KDa, and trehalose (a-D-Glucopyranosyl a-D-glucopyranoside) dihydrate were 
purchased from Sigma Chemical Co., (St. Louis, MO). Poly (vinylpyrrolidone) (PVP-
K29/32), (Mw of 58 KDa) was obtained from ISP Technologies (Wayne, NJ). Sodium 
chloride (Fisher Chemicals Co., Fair Lawn, NJ), was used to prepare saturated salt 
solution providing 75% RH conditions. 
Methods 
Preparation of Amorphous Mixtures by Lyophilization: 
Dextran and PVP-K29/32 were dried in a vacuum oven overnight at I 05°C until a 
constant weight was obtained. Trehalose dihydrate was used without any further 
treatment. Physical mixtures of each polymer and trehalose dihydrate were made in dry 
glove bags (RH< I5%) to obtain weight proportions oftrehalose dihydrate in the polymer 
from 0% to 100% at 10% w/w intervals. These mixtures were dissolved in purified water 
to obtain I 0% w/v concentration and stirred overnight at 35°C. Aqueous solutions (2 mL) 
were freeze-dried using a commercial freeze dryer (Dura-Stop µP, FTS System, Stone 
Ridge, NY). Vials containing solutions were transferred onto pre-cooled shelves (-45°C). 
Primary drying was carried out at shelf temperature of - 27°C for 22-24 hrs, followed by 
drying at - l 2°C for 2 hrs, 0°C for 16 hrs, and secondary drying at 30°C for 20 hrs. 
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Vacuum pressure of 15 mTorr was applied throughout the drying. All samples were 
stored over anhydrous calcium sulfate at room temperature, after capping the vials. X-ray 
analysis of these samples showed that all the mixtures were amorphous . 
Isothermal Stability Studies: 
Lyophilized amorphous mixtures of dextran containing I 0, 20, 30, 40 and 70% by weight 
of trehalose were accurately weighed (8-12 mg) in standard DSC pans in a glove bag 
(RH< l5%). These pans were placed in desiccators containing saturated sodium chloride 
solution (75% RH) to expose the miscible mixtures to excess humidity. The desiccators 
were kept at room temperature (23 ± I 0 C) and incubators (Precision Scientific Inc., 
Chicago, IL) at 40 ± I °C and 50 ± I °C. Saturated NaCl solution provides relative 
humidity of 75 ± 0.5% over the temperature range of 23° to 50°C [ 15] . By storing the 
samples in discrete DSC pans, the reproducibility of all measurements was ascertained 
without any interference of sample handling. Samples were taken out for analysis at pre-
determined time intervals for a period of up to six months. They were crimped with 
aluminum lids having I 0 pinholes to facilitate removal of absorbed and bound water 
liberated upon melting of any recrystallized trehalose. 
Thermal Analysis: 
Modulated Differential Scanning Calorimeter (MDSC) (TA Instruments 2920, New 
Castle, DE), with a liquid nitrogen cooling accessory was used for thermal analysis. The 
analysis was performed under a purge of dry nitrogen gas (60cc/min). High purity indium 
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and sapphire were used frequently to calibrate for the heat flow and heat capacity of the 
instrument. Samples were initially cooled to - 30°C for 10 minutes and were heated to 
245°C at 1 °C/min with modulations of 0.266° every 50 seconds. 
MDSC offers an advantage over conventional DSC because it can detect reversible glass 
transition phenomenon in the presence of several other non-reversible relaxation 
processes. Heat capacity changes can be resolved from moisture removal endotherm, 
thereby improving the signal to noise ratio and improving the elucidation of the T g· 
RESULTS 
Modulated DSC Analysis of Trchalosc and Trchalosc-Polymcrs Mixtures: 
Characterization of lrehalose: 
DSC scans of trehalose before and after lyophilization are shown in Fig. B-1-la. A 
heating rate of 1°C/min was employed to minimize polymorphic conversion of trehalose 
dihydrate during heating [ 16]. Upon heating trehalose dihydrate, an endotherm at 96° ± 
1°C (Th) was observed. This was followed by a Tg at 122°C and recrystallization at 
171 °C. The recrystallized anhydrous trehalose melted at 2 l 2°C. Thermo-gravimetric 
analysis (TGA) performed on trehalose dihydrate showed a 9.5% weight loss at 96°C 
confirming that the endothenn at 96° ± 1°C was due to the removal of water of hydration. 
Hot-stage microscopy was conducted on trehalose dihydrate by heating at 1°C/min and it 
was observed that water removal from trehalose resulted in a structural collapse and loss 
of birefringence (indicating amorphous state). At approximately ! 35°C, trehalose 
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liquefied and recrystallized to the anhydrate form. These results agreed with DSC 
characterization and with observations of Taylor and York (13]. 
Lyophilized trehalose was amorphous as determined by X-ray diffraction. DSC scan of 
lyophilized trehalose (Fig. B-1-1 a) showed no endotherm at 96°C, indicating the absence 
of crystalline hydrate structure. For verification, amorphous trehalose that was exposed to 
50°C and 40°C with 75%RH were heated in DSC and examined. One would expect the 
amorphous trehalose to crystallize upon storage and indeed as seen in Fig. B-1-1 b, the 
thermograms are similar. ln conclusion, the water-loss endotherm observed at 96°C is the 
characteristic of crystalline trehalose. 
Molecular dispersions of trehalose and polymer: 
All the freshly prepared co-lyophilized mixtures of trehalose-dextran or trehalose-PVP 
were amorphous exhibiting a composition-dependent single Tg indicating their molecular 
miscibility. The Tg of the mixtures decreased with increasing concentration of trehalose 
as shown in Fig. B-l-2a,b, indicating the plasticizing effect of trehalose on the polymers. 
The Tg values were plotted as a function of weight fraction of trehalose in polymer and 
are shown in Fig. B-J-2c,d for the determination of solid solubility. 
Trehalose-dextran and Trehalose-PVP molecular mixtures: physical stability studies 
MDSC reversing heat flow scans of mixtures containing 40% w/w trehalose-in-dextran, 
which were stored at 50°C/ 75% RH for a period of 2 - 50 days are shown in Fig. B-l-3a. 
A freshly prepared sample showed a single Tg at 169°C, indicating miscibility. 
26 
Amorphous miscible mixtures when exposed to 50°CI 75% RH absorbed moisture, and 
the plasticized Tg of such a system, from the total heat flow scan (data not shown), was 
detected at 22° ± 3°C. The absorbed moisture was removed from the mixtures as the 
samples were heated in MDSC. As opposed to a single Tg of 169°C in the original 
mixture, two distinct Tgs were observed in the 2 and 4-day old samples; Tg values at 123° 
and l21 °C (referred to as Tg1) , and Tg at 203°C (Tg2) . In the 16 - 34 day samples, Tg1 
was not observed. However a water-loss endotherm at 96° ±l °C {Th), characteristic of 
crystalline trehalose, had appeared. In addition, T g2 values had increased and seemed to 
plateau, which is termed as equi librium Tg (Tg•q). There was also a distinct reduction in 
the heat capacity step change, (fl Cp) at T gl· These values decreased initially and seemed 
to reach a plateau as seen from data in Table B-1-1. The thermal events in dextran 
mixtures containing 30% w/w trehalose were also similar to those that were observed for 
40% w/w mixtures when stored at 50°C/ 75%RH (Fig. B-I-3b). 
MDSC reversing heat flow scans of mixtures containing 20% and 40% w/w trehalose-in-
PVP which were stored at 23°C/ 69% RH are shown in Fig. B-l-3c. With this polymer, 
the phase separation of amorphous trehalose was observed (T gl at I 20°C) in the 190, 195 
and 200 day old samples. A water-loss endotherm at 96° ± l °C (T,,) was also observed. 
For 20% w/w samples, the T gl and T,, were not noticeable even after 200 days of storage. 
A reduction in llCp values at Tg2 (given within brackets in Fig. B-l-3c) fol lowed by a 
plateau was noticed in these systems as well . The heat flow scans that are depicted in Fig. 
B-l-3d are to demonstrate the presence ofTg1 & Tg2 values for some selected mixtures. 
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A plot of T g2 values of dextran mixtures containing different weight fraction of trehalose, 
stored at 50°, 40° and 23°C with 75% RH is shown in Fig. B-1-4. It should be noted from 
the figure that T g'q is always Jess than 225°C, which is the Tg of pure amorphous dextran 
(dotted line). This reduction in Tg indicated that a fraction oftrehalose remained miscible 
with the polymer even after being exposed to excessive temperature and humidity 
conditions for up to six months. This fraction was identified as the "solid solubility'' of 
trehalose in dextran. The T g •q of all amorphous mixtures ranged from 207° - 210°C, 
when they were stored at 40° and 50°C with 75% RH, and within 196° - 203°C for 
mixtures stored at 23°C/75% RH conditions. These findings suggested that, at 
equilibrium, irrespective of the initial trehalose-concentrations, the solid solubility limit 
oftrehalose in dextran was the same for a specified storage condition. For instance, when 
stored at 50°C/ 75% RH, 70% w/w trehalose mixture which was initially miscible with 
dextran, formed a dihydrate and demonstrated Tg2 values at 207°-210°C upon 
"equilibrium". This concentration was accepted as its solid solubility limit. 
To exclude the possible interference of moisture on reduction of T gZ. amorphous dextran 
that was equi librated at 50°C I 75%RH for a month and contained 11 % w/w water was 
heated in MDSC. The Tg of the sample was 225°C, which was identical to the Tg of the 
original sample with 3% w/w water content. These findings proved that moisture was not 
the cause ofT g2 reduction. 
On the other hand, trehalose that was liquefied above its Tg of l 18°C could plasticize 
dextran and lower the T g below 225°C. Such a possibility was suggested by Six et al. 
[17] for HPMC- itraconazole dispersions. The MDSC scan of 1: 1 phys ical mixture of 
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amorphous trehalose and dextran, demonstrated Tgs at 119°± 0.5°C and 223° ±0.9°C 
(n; 3) upon heating at 1°C/min rate. The two Tg values coincided with the Tgs of pure 
trehalose and dextran respectively indicating that heating in MOSC did not cause any 
mixing. The reduction in T g2 values from 225°C to T g cq' is indicating the presence of the 
miscible fraction oftrehalose in the polymer. 
Crystallization of trchalose: 
A plot of percent crystallinity of trehalose from the miscible mixtures containing 40% 
and 30% w/w trehalose as a function of storage time is shown in Fig. B-1-5. The amount 
of trehalose crystallized as the dihydrate was calculated from the heat of fusion under the 
water-loss-endotherm (Th) of the total heat flow scan. Amorphous trehalose by itself 
when exposed to 75% RH had enthalpy of fusion equal to untreated crystalline trehalose 
dihydrate indicating 100% crystall ization (Fig. B-1-1 b ). On the other hand, sol id 
dispersion samples showed a maximum of 84% crystallization for samples stored at 
50°C/75% RH for six months. It was also seen that the rate of crystallization, after an 
initial rapid increase, was much less in 30%w/w dispersions when compared to 40%w/w 
dispersions. These findings are consistent with results which suggest that a fraction of 
trehalose remains miscible with the polymer. 
Quantifying the limit of solid solubility: 
To determine the molecularly-dispersed trehalose concentration in the polymer, the plot 
of Tg of the mixtures against the% w/w trehalose concentration was utilized (Fig. B-1-
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2c,d). In this graph, the T g'q values were used to determine the fraction of trehalose that 
remained miscible with dextran (Fig. B-l-2c) and PYP (Fig. B-I-2d). In these graphs, the 
solubility limits are shown by arrows. The corresponding value on the x-axis represented 
the solid solubility of trehalose in the polymer. Table B-I-II demonstrates the solid 
solubility limits of trehalose in dextran at different storage conditions. In this table the 
difference between the storage temperature and the plasticized Tg due to presence of 
moisture (Tgw) is shown as 6 Tg. It is important to note that the samples were stored at 
temperatures above their plasticized Tg. At this region, the system has a high degree of 
molecular mobility and consequently, a higher rate of destabilization. The solid solubility 
of trehalose-in-dextran decreased from 18% w/w at 23°C to 12% w/w at 50°C, whereas 
the total water content decreased from 16.5% w/w to 11% w/w. However, no appreciable 
difference in solid solubility was observed between 40°C and 50°C storage conditions, 
although total water content decreased from 13% to 11 %. 
DISCUSSION 
Mechanism of Phase Separation & Solid Solubility : 
The hypothesized mechanism for phase separation and solid solubility is depicted 
schematically in Fig. B-I-6 for a dextran-trehalose model. The repeat units of dextran and 
trehalose are labeled as ID, 20, and IT, 2T, etc respectively. 
In the absence of moisture, freshly prepared mixtures have high Tg values and hence the 
molecular mobility is very low at the storage temperatures . Trehalose, therefore, remains 
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in a kinetically frozen state of miscibility. Upon exposure to moisture, the mixtures are 
plasticized, and the molecular mobility increases. The exact role of water is not clear yet. 
Water may either weaken the H- bond interaction (between -OH oftrehalose and - OH or 
- 0- groups in dextran, or C=O groups in PVP) by bridging with polymer and trehalose 
structural units, or may merely increase the molecular mobility by plasticizing the 
mixtures. ln either case, diffusion of trehalose through the polymeric matrix could result 
in separation of trehalose into an amorphous phase, and subsequent crystall ization. As 
more and more trehalose phase separates, increasing amounts of "free" polymer units are 
left to interact with the remaining trehalose. Such units possibly orient around and arrest 
the non-diffused trehalose molecules by satisfying their H-bond requirements ( 1 T, in Fig. 
B-1-6). At equilibrium, localized pockets of trehalose molecules are almost entirely 
bonded to the polymer, reaching solid solubility as characterized by T g?. 
Thermodynamic Interpretation of Solid Solubility: 
To analyze the solid-solubility of trehalose in the polymers thermodynamically, the 
energetics of interactions between trehalose and polymers were calculated using the 
Couchman & Karasz theoretical equations [18]. Similar approach was used by Shamblin 
et al. to determine the excess thermodynamic properties of mixing in the binary mixtures 
[ 19]. Using the equations described in detail in the appendix , the enthalpy ( !1H mu ) and 
free energy ( t.G,,," ) of mixing as a function of trehalose weight fraction were calculated 
and plotted in Fig. B-1-7. 
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Since the influence of water on the free energy of mixing is not understood, water was 
not taken into considerat ion in the thermodynamic analysis. The enthalpy of mixing 
(!!Jim,. ) shown in Fig. B-I-7 was positive for the entire composition range and was 
similar in magnitude to those reported for mixtures of sucrose-PVP or sucrose-dextran 
[ 19). The positive !!Ji mi< at all compositions indicates that greater numbers of H-bonds 
are broken between trehalose-trehalose and polymer-polymer than are fonned between 
trehalose-polymer during mixing. Since lesser number of bonds was formed between 
trehalose and polymer when compared to the bonds that they had in their individual 
states, the positive !!Ji"'" would favor trehalose and polymer to self-associate or phase 
separate. The excess entropy of mixtures was positive (not shown) throughout the 
trehalose composition favoring mixing. The negative free energy values for low 
trehalose-containing mixtures are thus driven by the excess entropy. Although the 
dextran-trehalose mixtures studied contained moisture, and a three-phase system could be 
significantly different from the two-phase system, the analysis conducted supports the 
hypothesis that a component dispersed in a solid dispersion with certain solubility can be 
thennodynamically favored. 
Mechanism of crystal growth : 
Upon phase-separation, amorphous trehalose, as characterized by T gt crystallizes in the 
presence of water, and is characterized by T 11 (Fig. B-I-3). The crystallization is 
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dependent upon the initial concentration of trehalose in the mixture and the storage 
conditions employed (Fig. B-1-5). 
The portion of polymer located at the amorphous-crystalline interface has low molecular 
mobility and is termed as "rigid amorphous fraction" as suggested by Lee and Kim (20]. 
This fraction does not contribute significantly to the heat capacity step change values at 
T g2 (6C0) [20-22]. The fraction of amorphous bulk distant from crystalline region is the 
"mobile amorphous phase" and could be responsible for the 6C0 at T g2 as indicated by 
Craig et al. (21 ). As the phase separated trehalose crystallizes, the fraction of polymer in 
close contact with the crystalline surface increases. This explains for the reduction in the 
6C0 values at T g2 (Table B-1-1), until no more "rigid amorphous fraction" is formed. 
Formation of rigid amorphous fraction may also explain the decrease in the rate and 
extent of crystallization in 30% and 40% w/w mixtures with time (Fig. B-1-5). As 
suggested by Crowley and Zografi [23] , the rigid amorphous fraction impedes the 
kinetics of crystallization of trehalose that has already phase separated. This kinetic 
phenomenon is different from the solid solubility, which is characterized by T g2, as 
described in the previous section. 
Effect of temperature and moisture on solid solubility: 
Table B-1-11 demonstrates the effect of storage temperature and moisture content on the 
solid solubility of trehalose. Reduction of solid solubility limit wi th an increase in the 
temperature is probably due to the higher molecular mobili ty of the system at elevated 
33 
temperatures, leading to an enhanced phase separation and crystallization. In addition, at 
50°C, thermal expansion of the mixtures may reduce the degree of interaction between 
the sugar and polymer thereby decreasing the miscibility limit as suggested by Tang et al. 
(24]. Finally, since the miscible mixtures have a higher enthalpy and free energy, it is not 
surprising to see that at higher temperatures, the system proceeds for de-mixing causing 
trehalose to crystallize. Although with an increase in temperature from 23°C to 40°C 
solubility reduction was seen, no difference in solubility was noticed between 40°C and 
50°C. This is possibly due to an associated reduction in water content, where the reduced 
water level compensates the temperature effects. Therefore, water seems to have an 
indirect effect on T g2 reduction and hence solid solubility. Overall, the data obtained 
suggest that both temperature and moisture affect the phase behavior and extent of solid 
solubility. 
CONCLUSIONS 
ln this paper, we have shown application of MDSC in monitoring the phase separation 
and crystallization behavior of trehalose from its amorphous miscible mixtures, at 
ambient temperature and accelerated stability conditions. Upon exposure to moisture, 
trehalose separated as an intermediate amorphous phase which later crystallized to the 
dihydrate form. Based on the experimental data and thermodynamic as well as 
mechanistic assessment, it is postulated that a fraction of trehalose remained miscible 
with the polymers due to extensive hydrogen bonding between the two components. This 
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fraction was analyzed by the changes in the glass transition temperatures and was 
referred to as the "solid solubility" of trehalose in the polymer. Molecular mixtures 
containing I 0% w/w trehalose (i.e., trehalose concentration below solid solubility) did 
not phase separate or crystallize during the six months storage at accelerated stability 
conditions, which substantiated our findings. We also propose that the MDSC technique 
described can be applied to determine the phase behavior and solid solubility limits of the 
hydrophobic drugs that are dispersed in water-soluble carriers. This method can be useful 
in identifying the solid dispersions that will remain physically stable during the she! f-life. 
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Table B-1-1: Effect of storage conditions on thermal behavior of selected trehalosc-
dextran mixtures 
Storage Percent Storage Th* Tg21 !'J.Cp' 
condition trehalose period (J/g) coq at Tg2 
(w/w) (days) (J/g/OC) 
50°CI 40 0 169 0.3727 
75% RH 2 203 0.1710 
4 203 0.1564 
13 17.7 209 0.1095 
23 28.6 206 0.1189 
34 34.9 207 0.0981 
30 0 182 0.3329 
5 200 0.2428 
8 12.9 202 0.1314 
19 13.8 207 0.1214 
31 14.7 208 0.1176 
50 15.I 207 0.1055 
40°CI 40 0 169 0.3727 
75%RH 6 7.6 196 0.1807 
13 23.9 213 0.1076 
23 27.0 207 0.1136 
34 30.6 207 0.0741 
30 0 182 0.3329 
8 6.2 192 0.1579 
19 9.5 202 0.0971 
31 12.2 206 0.1913 
52 12.5 203 0.1192 
90 17.9 205 0.1620 
* Heat of fusion of water-loss-endotherm for recrystallized trehalose dihydrate. 
1 Glass transition temperature ofpolymer-trehalose mixtures. 
1 Heat capacity change 
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Table B-1-1 I: Solid solubility of trehalose in the polymers used as a function of 
storage condition 
Polymer Storage Water (Tstoragc- T cq t Solid g 
condition content at Tg~) = oc solubility' 
°C / %RH equilibrium* 6 Tg§ (oC) o/ow/w 
o/ow/w trehalose 
Dextran 23 I 75 16.5%± 1.0 I 197.8 ± 4.4 18±2.9 
40 I 75 13% ± 1.0 18 208.7 ± 3.8 12 ±2.5 
50 I 75 11 % ± 0.8 28 208.3 ± 1.0 12 ±0.7 
PVP 23 I 69 19.9± I.I 5-15 158 ±2.1 10 ±2.5 
' Determined by thermogravimetric analysis by heating the sample at 5°C/min. 
§ 6 Tg is the difference between storage temperature and the plasticized Tg due to 
presence of moisture (T g w), when the samples were exposed to stability conditions. 
' Mean value of Tg2 (i.e. , Tg of polymer-trehalose mixture) after T g2 reaches a steady 
state. 
1 Calculation of solid solubility limit is described in Fig. B-l-2c,d and the text. 
40 
Figure B-1-1 
DSC total heat fl ow scans of (a) A: lyophilized trehalose; B: untreated trehalose 
dihydrate and C: lyophilized dextran; (b) heat flow due to recrystallization of amorphous 
trehalose by storing it at Al : 50°C/ 75% RH; and A2: 40°C/ 75% RH and B: untreated 
trehalose dihydrate. 
a) 
0.5 
~o.o 
~ 
~ 
'" ; -0.5 x 
o; 
" 
.... 
-1.0 
-1.5 
0 
b) 
0.2 
0.0 
~ 
; -0.2 
'" = x -0.4 
] 
~ 
-0.6 
--0.8 
0 
139.2 Jig 148.6 Jlg 
212.ss·c ~------ 1~~°.:c-~~--6~1-·c...;.._'~,,...o+ri 
B 
50 100 150 200 
Temperature 
250 
A I 142. 1 Jig • 91.4 1 Jig 87.0 Jig 
91 66·c 124.63 c /,_166.53·c 211 7g•c 
-~;--<.~;~~-:Vrl -· 
·._ ' I / '- I ~ ................. 1 /-.~ ·'--.'"' lr-
B ' I . ' \/ 
122.1s·c 
144.0 Jlg 
96.67°c 
11 4.2 Jig 
212.22·c 
50 100 150 200 • 250 
Temperature 
4 1 
Figure B-1-2 
MDSC reversing heat flow scans of mixtures oftrehalose with (a) dextran and (b) PVP, 
showing a composition dependent single Tg Plots ofT8 of mixture oftrehalose with (c) 
dextran and (d) PVP as function oftrehalose composition. Arrows represent the solid-
(a) 
solubility limits oftrehalose in the polymers as explained in the text. 
0.05 ,-------------------~ 
0.00 
~ 
:::: -0.05 
0 
..: 
~ 
"' .. 
80% 
------~ n1.2o•c 
60% ~-----·---
·--·-·-·~ 148.8s·c 
30% ~·----
-·---~ o. 10 10% --~~c ____ _ 
.
0
.
15 
~---------- 209.9s·c 
-0.20 ,__ __________________ _, 
50 75 100 125 150 175 200 
Temperature 
(b) 
-0.10 80% 
l-------~25.87'C 
-0.12 
60% ------
225 
~-0.14 l--·-- ·-·~3·c 
~-0.16 ·- - ·- ·-
" 
0 
~ 
- -0. 18 
"" .. 
::i:: 
> ·0.20 
... 
c:: 
-0.22 
40% 
143.53'C 
---------- -~. 
"'"'1-----+-- - - - - - - . 
20% 154.22'C 
-0.24 +----------------------< 
80 100 120 140 160 180 200 
Temperature 
42 
Figure 8-1-2 (contd.) 
MDSC reversing heat flow scans of mi xtures of trehalose with (a) dextran and (b) PVP, 
showing a composition dependent single Tg. Plots ofTg of mixture of trehalose with (c) 
dextran and (d) PVP as function of trehalose composition. Arrows represent the solid-
(c) 
(d) 
solubility limits of trehalose in the polymers as explained in the tex t. 
240 
220 A 
200 
G 180 
0 
ell 160 
E-< 
140 
__.J. 
120 1 
100 
0 
ISO 
G 
0 140 
E--<"" 
130 
120 
110 
0 
20 
ID 
20 
A 
A 
40 60 80 100 
% w/w Trehalose 
D 
13 
8 
D 
D 
8 
40 60 80 100 
% w/w Trehalose 
43 
Figure B-1-3 
MDSC reversing heat flow scans oftrehalose-dextran mixtures exposed to 50°C/ 75% 
RH conditions for different time intervals: (a) 40% w/w trehalose (A: 0 days, B: 2 days, 
C: 4 days, D: 13 days, E: 23 days, F: 34 days) (b) 30%w/w trehalose (G: 0 days, H: 5 
days, I: 8 days, J: 19 days, K: 31 days, L: 50 days) (c) trehalose-in-PVP stored at 23°C/ 
69%RH (0: 40% w/w, 0 days; P: 20%w/w, 0 days; Q: 0% w/w, 0 days; R: 20% w/w, 
200 days; S: 40% w/w, 190 days; T : 40% w/w, 195 days; U: 40% w/w, 200 days) and (d) 
40% w/w trehalose at M : 4 days, N: 34 days [Tg1: Tg of phase separated amorphous 
trehalose; T g2: Tg ofpolymer-trehalose mixture; Th: water-loss endotherm of crystalline 
trehalose. The numbers within the brackets in Fig. B- l-3c represents the change in heat 
capacity (I'. Cp) at T g2]. 
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Figure B-1-4 
Plot ofTg2 oftrehalose-dextran mixtures: 70% w/w (0), 40% w/w (t:.), 30% w/w (• ), 
and 20% w/w ( .6. ) at (a) 50°C/ 75% RH ; (b) 40°C/ 75% RH; (c) 23°C/ 75% RH. Dotted 
line indicates the Tg of pure dextran. 
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Figure B-1-5 
Percent crystalline trehalose dihydrate present in trehalose-dextran mixtures containing 
(a) 40% w/w trehalose and (b) 30% w/w trehalose under storage conditions: 50°C/ 75% 
RH C• ), 40°C/ 75% RH( • ), and 23°C/ 75% RH( ... ). Error bars represent the range for 
(n=3) measurements whenever shown. The percent crystallinity was calcul ated from the 
heat of fusion values of water-loss endotherrn of the total heat flow and has been adjusted 
a) 
b) 
for the differences in initial trehalose content. 
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Figure B-1-6 
Hypothetical depiction of solid solubility between trehalose ( l T, 2T, 3T, 4T) and dextran 
(repeat units: l 0 , 20, 30, 40). Bridging cylinders represent the hydrogen bonds between 
the acceptor and donor groups of the components. 
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MANUSCRIPT II 
PHASE BEHAVIOR OF AMORPHOUS MOLECULAR DISPERSIONS II: ROLE 
OF HYDROGEN BONDING IN SOLID SOLUBILITY AND PHASE 
SEPARATION KINETICS 
Madhav Vasanthavada1, WeiQin Tong2, Yatindra Joshi2, and M. Serpil Kislalioglu 1.l 
ABSTRACT 
Purpose: To study the factors influencing the 'solid solubility' and phase separation 
kinetics of drugs from solid dispersions using modulated DSC (MDSC). 
Methods: Solid di spersions of PVP with griseofulvin and indoprofen were prepared 
using solvent evaporation technique. MDSC was used to quantify the drug-polymer 
miscibility, the drug solid solubility and the rate of drug-polymer phase separation at 
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40°C/69%RH . Characterization of drug-polymer interactions was performed using FTlR 
spectroscopy. X-ray diffractometry (XRD) was used to detect the levels of crystallinity in 
the solid dispersions. 
Results: ln the freshly prepared solid dispersions, both griseofulvin and indoprofen were 
molecularly miscible with PVP up to 30% w/w drug concentration. FTlR demonstrated 
the presence of hydrogen bonding in indoprofen-PVP dispersions, but not in griseofulvin-
PVP dispersions. When exposed to 40°C/69%RH for 15 days, griseofulvin-PVP mixtures 
resulted in complete phase separation and crystallization which was monitored by the 
changes in their T g· A complete phase separation indicated absence of solid solubility. 
XRD detected crystallinity in 10%w/w griseofulvin dispersions, supporting the MDSC 
analysis. On the other hand, the solid solubi lity of indoprofen in PVP was determined as 
13% w/w and no crystallinity could be detected around this concentration using XRD. 
The rate of phase separation of drug from the polymer was estimated by fitting the 
fraction of drug phase separated from the polymer as determined by analyzing the Tg of 
drug-polymer miscible phase to the use of first order kinetics. The rate constants for 10%, 
20% and 30% w/w griseofulvin-in-PVP were 4.66, 5.19, and 12.50 (xl02) [day"1] 
respectively. lndoprofen-PVP dispersions had rate constants of 0.62, and 1.25 (x 102) 
[day"1] for 20% and 30%w/w solid dispersions respectively. 10%w/w indoprofen solid 
dispersions did not phase separate. 
Conclusions: Although both indoprofen and griseofulvin fonned amorphous solid 
dispersions with PVP at 30%w/w initial drug concentration, the hydrogen bonding ability 
51 
of indoprofen to PVP improved its solid solubility and hence physical stability. The phase 
separation rate was seen to decrease by decreasing drug-to-carrier ratio. 
KEY WORDS: miscibility, hydrogen bonding, amorphous, PVP, crystallization 
INTRODUCTION 
Currently the development of a successful solid dispersion product is dependent upon the 
ability to stabilize the metastable amorphous form of the drug substance. Because 
amorphous form offers high solubility, it is important of retain this form of the drug in 
the solid dispersion [ 1-3]. Several studies have however demonstrated the unpredictable 
crystallization of amorphous drugs by itself and from solid dispersions, which is limiting 
its commercial potential [4-7]. Water soluble polymers have been proposed as a means to 
inhibit or delay the drug crystallization by forming a miscible phase with the drug. In the 
miscible phase, the drug and polymer are molecularly dispersed and crystallization 
inhibition is possible via drug-polymer hydrogen bonding, and/or the anti-plasticizing 
effect (i.e. increase in Tg of solid dispersions) by the polymer [8, 9]. A detailed evaluation 
of the factors influencing the physical stability of amorphous solid dispersions reveals the 
presence of two opposing forces. On one hand, polymer helps in retaining the miscibility 
and prevents the drug crystallization. On the other hand, the uptake of moisture and/or 
exposure to elevated temperatures increases the molecular mobility, thereby increasing 
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the potential for phase separation (de-mixing) and crystallization. The physical integrity 
of the miscible solid dispersion would therefore depend upon the relative magnitude of 
the two opposing forces. 
In an earlier study, we demonstrated that depending upon the nature of drug-polymer 
interactions, a fraction of the drug can remain dissolved in the polymer in the solid-state 
even under high heat and humidity conditions [10]. This fraction is termed as the "solid 
solubility" and one of the factors influencing the solid solubility is the affinity between 
the two components of the dispersion . 
In view of the earlier findings, the purpose of this paper is to provide further evidence to 
substantiate the importance of hydrogen bonding in the solid solubility and physical 
stability of solid dispersions . The solid solubility of two different hydrophobic drugs, 
namely griseofulvin and indoprofen in poly (vinyl pyrrolidone) (PVP), were determined. 
Griseofulvin and indoprofen are highly crystalline in nature as indicated by their high 
melting temperatures and heats of fusion and therefore serve as good model compounds. 
In addition, based on their chemical structures, griseofulvin cannot hydrogen bond with 
PVP whereas indoprofen can participate in hydrogen bonding, thus enabling assessing the 
impact of drug-polymer affinity on the solid solubility. 
The second objective of this study was to detennine experimentally the kinetics of phase 
separation of the drug from the polymer. One may intuitively expect that for a drug to 
crystallize from a miscible solid dispersion, it would have to phase separate first from the 
polymer matrix. Therefore detem1ining the rate of phase separation of drug would serve 
to provide valuable information on the overall rate of physical instability since 
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crystallization of drug substance is often complex to predict. In some cases the solid 
so lubility of the drug in the so lid dispersion may need to be very low in order to 
fonnulate a physically stable miscible solid dispersion that would meet the high 
therapeutic dose requirement. By understanding the drug phase separation and 
crystallization kinetics one can possibly formulate miscible solid dispersions that are 
above the drug's solid solubility and retain their physical stability by either defining the 
shelf life or by choosing appropriate storage conditions. In this study we have employed a 
theoretical rate equation that is typically used in determining crystallization kinetics, to 
analyze the phase separation rate of griseofulvin and indoprofen from their solid 
dispersions. 
MATERIALS AND METHODS 
Materials: 
Plasdone (Poly (vinylpyrrolidone)) PVP K29/32 with Mw 50 KDa was obtained from ISP 
Technologies Inc. , (Wayne, NJ). Samples were dried at I 05°C under vacuum for 20 
hours prior to preparing solid dispersions. Griseofulvin ((2S)-trans-7-Chloro-2 ',4,6-
trimethoxy-6'-methylspiro(benzofuran-2[3H], l '-[2]cyclohexene)-3,4 '-dione)) and 
indoprofen ( a-Methyl-p-( l-oxo-2-isoindolinyl)benzenacetic acid) were purchased from 
Sigma Chemical Company (St. Louis, MO) and were used as received to prepare the 
solid di spersions. Copper chloride that was used to prepare saturated salt solution to 
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obtain 69% RH was purchased from Fisher Chemicals Co. , Fair Lawn, NJ [I I] . The 
chemical structures of all the materials involved in the study are shown in Fig. 8-11-1. 
Methods: 
Preparation of solid dispersions using solvent evaporation technique: 
Solid dispersions of drug (I 0-50% w/w) in PVP were prepared using solvent evaporation 
technique. Crystalline griseofulvin and crystalline indoprofen were dissolved (0.3 - l .5g) 
in dichloromethane and methanol respectively by stirring the solution in a waterbath at 
37°C for about 15 minutes. PVP was added to the drug solution to make the total weight 
of solids as 3g. After all the PVP was dissolved, as determined visually, the solvent was 
evaporated using a rotary vacuum evaporator (Rotavap®) by heating the solution at 37°C 
in a water bath. The residual solid dispersions thus obtained were further dried in a 
vacuum oven at room temperature for 24 hours to remove the remaining residual solvent. 
They were ground with a mortar and pestle and were sifted through sieve # 70 to result in 
particle size $ 21 Oµm. The solid dispersions were stored in vials over anhydrous CaS04 
in a freezer when not being studied in order to minimize the molecular mobility of the 
system. 
Determination of solid solubility 
To determine the solid solubility of drugs in the polymer, solid dispersions containing I 0, 
20, and 30% w/w of griseofulvin and indoprofen in PVP were accurately weighed (8-
l 2mg) in standard DSC pans. The pans were placed in desiccators containing saturated 
copper chloride solution (69% RH) and an oven at 40 ± I °C (Precision Scientific Inc. , 
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Chicago, IL). The 69% RH was chosen in order to prevent deliquescence of PVP at 
higher moisture levels and yet to provide an accelerated storage condition. By storing the 
samples in discrete DSC pans, the reproducibility could be assessed without di sturbing 
the bulk properties of the aging samples. Samples were taken out from the desiccators for 
analysis at regular intervals for up to 90 days. They were crimped with aluminium lids 
having five pinholes to facilitate the removal of absorbed water during heating. The 
resulting thermal scans were analyzed for their changes in the drug-polymer phase 
compositions by measuring the glass transition temperatures (T ,). An increase in the T g 
of the miscible phase implied phase separation of drug from the solid dispersion since 
lesser fraction of drug is present in the polymer phase to plasticize the system (provided 
the Tg of drug is less than Tg of polymer). The increase in Tg of the solid dispersion was 
monitored as a function of storage time until no further increase in the Tg was observed. 
To quantify the solid solubility, the equilibrium Tg value was utilized to identify the 
percentage of drug that would provide the same Tg value in a freshly prepared solid 
dispersion. 
Modulated differential scanning calorimeter (MDSC): 
Thermal analysis was performed using MDSC 2920 (TA Instruments, New Castle, DE), 
with a liquid nitrogen cooling accessory. The analysis was performed under a purge of 
dry nitrogen gas (60cc/min). High purity indium and sapphi re were used frequently to 
calibrate the heat flow and heat capacity of the instrument. Thermal history of the 
samples was not erased. The events were recorded and analyzed during the first heating 
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scan. Samples (- 8-12 mg) were initially cooled to - 10°C for 10 minutes and were heated 
to 245°C at I °C/min with modulations of 0.266° every 50 seconds. The specified 
amplitude and period were optimized to provide the best results for analysis. Each 
measurement was repeated three times at every time point to ascertain the reproducibility 
of the experiments. 
X-ray Powder Diffraction (XRPD): 
The X-ray powder diffractometer (Rigaku RINT (D/Max) 2200 that was equipped with 
an Ultimagoniometer) consisted of a 40 KV, 40mA generator with a Cu Ko radiation 
anode tube. XRD pattern was used to test the presence of crystallinity in the solid 
dispersions. The samples were sifted through 70-mesh and placed on a 0.5 mm quartz 
plate holder prior to exposure to X-rays. They were scanned over a 20 range between 2° 
and 40° at a scan rate of 2° per minute in 0.02° step size. The divergence and scattering 
slits were set at 1.00°, receiving slit at O. I 5mm and monochromator was used at 0.45mm. 
Fourier Transform Infra-red Spectroscopy (FTIR): 
Nicolet spectrometer equipped with a KBr beam splitter was used to obtain the infrared 
spectra. Calibration for wavenumber accuracy was perfonned by using polystyrene 
sample. Dry nitrogen gas was used to purge the beam splitter and the sample 
compartment. IR spectra were obtained using an attenuated total reflectance (A TR) 
accessory (single reflection bounce diamond crystal; Golden Gate accessory). For each 
spectrum, 32 scans were performed and a resolution of 4 cm was chosen. The ATR 
accessory enabled to obtain the spectra by pressing the solid material onto the diamond 
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crystal. This accessory eliminates the use of KBr and yet produces comparable results 
[ 12]. All samples were dried under vacuum for 20 hrs prior to obtaining any spectra, to 
remove the influence of residual moisture. 
RESULTS 
Characterization of drug substance 
A comparison of the physical-chemical properties of griseofulvin and indoprofen is 
provided in Table B-Il-1. Both compounds were seen to have high melting temperatures 
and heats of fusion. The glass transition temperature was obtained by heating the 
amorphous drug substance in DSC at I °C/min. The amorphous drug was formed by 
rapidly cooling the molten crystalline drug. Upon heating both the amorphous drugs 
underwent recrystallization at temperatures above their Tg, indicating their propensity to 
crystallize. 
Characterization of amorphous molecular dispersions 
Griseofulvin-PVP and indoprofen-PYP solid dispersions showed a composition-
dependent single Tg for up to 30% w/w drug concentrations (Fig. B-Il-2). This behavior 
indicated the presence of molecularly dispersed drug in the polymer at these 
concentrations. Above 30%w/w, multiple Tgs were observed in the solid dispersions of 
griseofulvin-PYP, indicating a phase-separated mixture. In the indoprofen-PVP 
dispersions, the Tg of 40%w/w dispersion was higher than the Tg of 30%w/w dispersion 
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thus indicating immiscibility in the sample. For both the drug solid dispersions no 
crystalline peaks were seen at drug levels of 30%w/w or less using x-ray diffraction. 
Although x-ray pattern revealed crystallinity for 40%w/w solid di spersions, no significant 
melting endotherm was detected at this composition for the crystalline drug using MDSC 
(Fig. B-ll-2). This could most likely be due to the solubilizing effect of polymer on the 
crystalline drug while heating in the MDSC. 
In order to probe the interactions between the drug and PVP, the FTIR spectra of freshly 
prepared solid dispersions were compared with the drug - PVP physical mixtures. In Fig. 
B-II-3a, the carbonyl stretching of a 30%w/w griseofulvin-in-PVP solid dispersion is 
compared with the corresponding physical mixture of amorphous griseofulvin and PVP. 
No significant differences were observed between the two spectra, indicating the absence 
of interactions between griseofulvin and PVP in the solid dispersions. Even with an 
increase in griseofulvin concentration from 10 to 30%w/w in solid dispersions, the peak 
carbonyl position of PVP did not shift significantly from I 667cm·1• Only a slight 
broadening of the peak and a shift in the wave numbers towards values of pure 
amorphous griseofulvin was seen most likely due to the presence of higher concentrations 
of griseofulvin. 
For indoprofen-PVP solid dispersions, addition of I 0% and 30%w/w indoprofen caused 
a significant shift in the carbonyl stretching of PVP from 1667cm·1 to 1654cm·1 (Fig. B-
II-3b), suggesting the presence of hydrogen bonding between the two components. The 
spectrum of a 30%w/w solid dispersion, which had the maximum miscibility as 
suggested by MDSC, was clearly different from the corresponding physical mixture. The 
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physical mixtures were prepared using crystalline indoprofen and PVP, because of the 
rapid tendency of indoprofen to crystallize during the preparation and characterization of 
physical mixtures. Pure amorphous indoprofen was however scanned immediately after 
its preparation as was confirmed amorphous even after the scan using optical microscopy. 
To ensure that the crystalline nature of indoprofen in the physical mixture did not 
contribute to the peak shift, the spectra of amorphous and crystalline indoprofen were 
compared and no significant differences were observed in the peak region of interest (i.e. 
1667cm·1 to 1654cm"1). 
Determination of solid solubility 
Griseofiilvin and PVP solid dispersions 
Solid dispersions of griseofulvin and PVP that were exposed to accelerated stability 
conditions of 40°C/69%RH were analyzed periodically by monitoring their Tg, to 
determine any alteration in the miscible phase composition. MDSC reversing heat flow 
scans of 30% w/w griseofulvin and PVP solid dispersions, which were stored at 40°C/ 
69% RH for a period of I - 15 days are shown in Fig. B-ll-4a. While a freshly prepared 
solid dispersion showed a single Tg at 131 °C, two Tgs referred to as Tg1 and Tg2, were 
observed in the stability samples during the 5 day-storage period. T gt corresponded to the 
T g of PVP-in-griseofulvin dispersions and T g2 corresponded to the T g of griseofulvin-in-
PVP dispersions. 
The formation of two T gs indicates the phase separation of griseofulvin and PVP. Upon 
storage, the heat capacity change at T gt decreased and that of T gZ increased in a time-
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dependent manner. The T go and T gz values were seen to increase with storage time, 
indicating a progressive phase separation, except for the 1 day-old sample, where a 
decrease in T gl was noticed. While T gl disappeared in the 9 day-old or older samples, T g2 
values increased and seemed to reach a plateau at 166° ± l.5°C. This plateau value was 
tem1ed as equilibrium Tg (Tg'q). 
The thermal events for 20%w/w griseofulvin and PVP solid dispersions followed the 
same pattern when they were exposed to 40°C/69%RH (Fig. B-ll-4b). However, unlike 
30% w/w dispersions, the T gl decreased during the first 4 days and then disappeared 
subsequently. Such a decrease in T gl is possibly due to the increased plasticization of 
griseofulvin in the griseofulvin-rich fraction of solid dispersion. The Tg1 disappears after 
reducing to a certain value suggesting a threshold level of griseofulvin in the 
griseofulvin-rich phase above which crystallization would occur. Indeed as expected the 
T gl of 20% and 30%w/w solid dispersions reach the same value before disappearing, 
indicating the threshold composition needed for crystallization. This possibility may also 
explain the crystallinity in a freshly prepared 40%w/w solid dispersion which is most 
likely above the threshold drug level. 
Jndoprofen and PVP solid dispersions 
MDSC scans of 30% w/w indoprofen-in-PVP solid dispersions, which were stored at 
40°C/69% RH for a period of 1 - 90 days are shown in Fig. B-ll-4c. In contrast to the 
phase behavior of griseofulvin-PVP solid dispersions, a single T g was detected in the 
indoprofen-PVP solid dispersions throughout the 90 day storage period. The Tg values of 
61 
the solid dispersions increased with storage time, although at a much slower rate, when 
compared to the griseofulvin-PVP solid dispersions. The Tg values reached a plateau at 
Tg'q of 142 ± l.3°C after about 70 days of storage period. The 20%w/w indoprofen solid 
dispersions also showed a similar shift in the T g values representing similar changes in 
phase composition when stored at 40°C/69%RH . 
Quantification of solid solubility 
A plot of T g values of I 0%, 20% and 30% w/w solid dispersions of griseofulvin-in-PVP 
and indoprofen-in-PVP that were subjected to 40°C/69% RH for 3 months is shown in 
Fig. B-11-5. For griseofulvin-PVP solid dispersions (Fig. B-Il-5a), the T gl values of all 
the solid dispersions reached a plateau (Tg'q) at 166° ± l.5°C during the 90 days storage 
period, which is close to the Tg of pure PVP (I 67°C). Since the entire drug phase 
separated from PVP as seen from the increase in Tg to -167°C, the solid solubility of 
griseofulvin in PVP was determined as - 0%w/w at the employed storage condition. The 
solid solubility limit was found to be independent of the initial concentration of 
griseofulvin-in-PVP since the T g'q was independent of the Tg values of freshly prepared 
solid dispersions. 
On the other hand, the solid dispersions of indoprofen and PVP behaved very differently 
as seen from Fig. B-11-Sb. During the 70 days storage period, the Tg values reached a 
plateau at Tg'q of 142 ± l.3°C. As seen clearly from Fig. B-11-Sb, the Tg'q for indoprofen-
PVP solid dispersions is significantly lower than the Tg of pure PVP (167°C). The solid 
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solubility of indoprofen in PVP at storage conditions of 40°C/69% RH was quantified as 
13%w/w. 
X-ray diffraction analysis 
In order to detennine ifthe phase separation and/or crystallization of drugs from the solid 
dispersions indeed resulted in crystallization of drug substance, X-ray diffraction was 
utilized. MDSC was unable to detect a melting endothenn of crystalline drug substance 
possibly due to the solvent effect of polymer at high temperatures as described earlier. 
Hence X-ray diffraction was chosen to validate the experimental solid solubility values. 
Fig. B-II-6a shows the X-ray patterns of solid dispersions containing I 0% and 20% w/w 
griseofulvin-in-PVP after I 0 days of exposure to 40°C/69% RH . The X-ray patterns at 
the same composition of physical mixtures of the crystalline drug and PVP were used for 
comparison. From Fig. B-II-6a, crystallinity is seen within I 0 days even for the I Oo/ow/w 
solid dispersions. Moreover, the peak intensity of the 10% and 20%w/w solid 
dispersions, after exposure to stability conditions, was similar to the corresponding 
physical mixtures thus supporting - Oo/ow/w drug solid solubility. 
In Fig. B-II-6b, the X-ray diffraction patterns of 10% and 20% w/w indoprofen and PVP 
solid dispersions that were exposed to 40°C/69% RH for 90 days are compared with the 
corresponding physical mixtures . No crystallinity in the 1 Oo/ow/w solid dispersions was 
noticed even at the end of 90 days storage period. However 20% w/w solid dispersion 
had small fraction of crystalline drug, as indicated by the smaller peak height in the solid 
dispersion when compared to the corresponding physical mixtures. These findings 
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support the solid solubility of l 3%w/w of indoprofen-in-PVP that was determined using 
MDSC. 
DISCUSSION 
Hydrogen bonding and solid solubility 
The data presented in this study suggests that the presence of hydrogen bonding 
facilitated phase miscibility between indoprofen and PYP even under accelerated stability 
conditions. Griseofulvin and indoprofen are easily crystallisable drugs as seen from their 
high melting temperatures, high heats of fusion and recrystallization. Further both drugs 
demonstrate relatively low glass transition temperatures in their amorphous states and 
recrystallized instantaneously when exposed to relative humidity greater than 57%. 
Therefore to maintain the drugs in their amorphous form in the solid dispersions under 
stability conditions is indeed a challenging and an important task. 
If the chemical structures of PYP, griseofulvin and indoprofen, illustrated in Fig. B-11-1 , 
are examined, it is seen that PVP can act only as a proton acceptor through either the 0 or 
N atoms of the pyrrolidone ring. However due to the steric constraints, the N atom may 
not participate actively in hydrogen bonding [ 13]. The chemical structure of griseofulvin 
reveals two carbonyl and three methoxy groups which can actively participate in 
hydrogen bonding as proton acceptors. On the other hand, indoprofen has four hydrogen 
bond acceptors namely the carbonyl group of- COOH, oxygen atom of hydroxyl group of 
-COOH, the carbonyl group of the pyrrolidone ring and the N atom of the pyrrolidone 
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ring. lndoprofen also has one proton donor which is the proton of the hydroxyl group of-
COOH. Since hydrogen bonding occurs between a hydrogen bond acceptor and a donor, 
for two components to interact one of them should have at least one donor and the other 
at least one acceptor [14]. 
When griseofulvin and PVP are molecularly mixed, no hydrogen bonding between the 
two components is demonstrated through the FTIR spectra since neither component have 
hydrogen bond donor. On the other hand, a hydrogen bond interaction between the 
hydroxyl group of - COOH of indoprofen and the carbonyl group of the pyrrolidone ring 
in PVP is likely to occur. This is evidenced by a decrease in the carbonyl stretching of the 
carbonyl group of PVP from 1667cm·' to 1654cm·' in the 10% and 30%w/w solid 
dispersions. 
Despite the absence of hydrogen bonding in griseofulvin and PVP solid dispersions, a 
30% w/w initial miscibility is seen in these dispersions, similar to the indoprofen-PVP 
solid dispersions that demonstrate hydrogen bonding. Such miscibility in the absence of 
interactions is possibly favored through gain in the entropy of the system. Griseofulvin is 
dispersed in PVP in its amorphous phase, which is entropically favored when compared 
to its crystalline form. The solid dispersions thus formed remained miscible at regular 
storage temperature most likely due to the lack of molecular mobility, due to their high T g 
values. In the presence of moisture however, plasticization of solid dispersion could lead 
to an increase in the molecular mobility and thereby induce de-mixing and crystallization. 
One of the factors offering resistance for physical instability could be the extent of drug-
polymer affinity. Although indoprofen and PVP solid dispersions have moisture levels 
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comparable to those of griseofulvin and PVP solid dispersions, the presence of hydrogen 
bonding between indoprofen and PVP could possibly explain for the enhanced solid 
solubility. 
Kinetics of phase separation 
Often times the therapeutic dose requirements of the drug substance is very high and the 
solid solubility of drug in the solid dispersions may not be high enough to formulate a 
physically stable solid dispersion. ln such a case, it is important to understand the rate of 
drug phase separation under the regular storage conditions. Such estimation should 
provide a general understanding as to how various storage conditions influence the phase 
separation process. Phase separation of drug from the miscible phase could be the very 
first step towards drug crystallization and hence monitoring this process is very essential 
to better define physical stability. It is evident from Fig. B-ll-5 that both the solid 
dispersions clearly had different rates of phase separation despite having similar moisture 
contents, same storage temperatures, same polymer and similar initial and moisture-
plasticized Tg values. In order to detennine and explain for the differences in various 
rates with which griseofulvin and indoprofen reach their solid solubility limit, the kinetic 
rate constants for phase separation of the drugs from the solid dispersions were calculated 
by fitting the fraction of drug phase separated to the kinetic rate equations. The phase 
separated fraction was determined from the shifts in the Tg values of the solid dispersions 
with storage time. Such a technique to interpret the physical stability of solid dispersions 
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based on the changes in Tg as an indicator of phase composition has not been 
demonstrated earlier. 
Since griseofulvin and indoprofen have tendency to crystallize instantaneously when 
stored at 40°C/69%RH, a phase separation would immediately result into crystallization 
of these drug substances. Therefore, phase separation (i .e. fonnation of a heterogeneous 
phase), is considered to be the rate-limiting step for destabilization. Destabilization is 
defined as the physical state where a two-phase solid dispersion results. In order to 
estimate the rate constant for destabilization, the Kolmogorov-Johnson-Mehl-Avrami 
(KJMA) first order equation was used. KJMA equation is typically used to fit 
experimental crystallization patterns [ 15] and to obtain their rate constants and is 
described as: 
[-ln(l-a)] =kt (I) 
where (I-a) is the fraction phase separated, k is the rate constant for phase separation, 
and I is the storage time. 
In equation (1), the fraction crystallized (I-a) was obtained using the following 
expression: 
(I - a), =I T g(polymu) - T82(t) 
T g(polymer) - T g ( initial) 
(2) 
The fraction of drug phase separated was obtained by determining the average of 
triplicate measurements of T g of the solid dispersions at storage time t and using equation 
2. The rate constant for phase separation was obtained using equation I and determining 
the slope of the linear equation. By obtaining the rates of phase separation, the physical 
67 
instability (i.e. crystallization) rate can be estimated, since the phase separation step is 
considered as the rate limiting step (/qe.-ystomw;on) >> k(phoseseparat ;on))-
As inferred from the kinetic rate constants provided in Table B-11-11, the phase separation 
rate is higher for solid dispersions containing higher drug levels. This behavior agrees 
with the regular solution theory that higher the extent of super-saturation, the greater is 
the difference in the chemical potential in the supersaturated and saturated state and 
hence higher would be the driving force for crystallization. For a given drug level, the 
phase separation rate was found to be higher for griseofulvin-PVP solid dispersions when 
compared to indoprofen-PVP system. This behavior may be explained on the basis of the 
differences in the extent of interactions between individual drug and the polymer. 
Hydrogen bonding therefore seems to influence the solid solubility and thereby affect the 
kinetic rate of phase separation in amorphous solid dispersions. 
CONCLUSIONS 
The solid solubility of two crystallizable hydrophobic drugs namely griseofulvin and 
indoprofen in PVP has been experimentally determined using modulated DSC. 
Griseofulvin did not provide any solid solubility in PVP whereas a 13%w/w indoprofen 
remained miscible in the polymer under accelerated stability conditions of 40°C/69%RH. 
The higher solid solubility of indoprofen in PVP was attributed to the presence of 
hydrogen boning between the two components in their solid dispersions. X-ray 
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diffraction provided supporting results to confirm the MDSC obtained solid solubility 
values. 
The kinetics of phase separation of both drugs from the polymer was obtained by fitting 
the fraction of drug phase separated, as obtained from the shifts in Tg values of solid 
dispersions, to the KJMA rate equation. The rate of phase separation was found to be 
proportional to the extent of drug super-saturation and the strength of drug - polymer 
interactions. The technique described in this study monitors the very first step of 
destabilization process i.e., the phase separation that eventually leads to crystallization. 
Moreover, it does not rely upon the relatively unpredictable crystallization pattern of the 
drug substance and hence can be a better predictive tool of the physical stability of drugs 
in amorphous miscible solid dispersions. 
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Table B-11-1: Physical chemical properties of drug substance 
Drug Tm /\.Hr Tg T, L\. H, MW H-bond 
Substance Acceptors 
& Donors§ 
Griseofulvin 218 98 86 133 81 352 6&0 
lndoprofen 214 127 50 75 58 28 1 4&1 
MW: Molecular weight; Tm: Melting temperature; L\. Hr: Heat of fusion ; Tg: Glass 
transition temperature of amorphous sample; T, : Recrystallization temperature upon 
heating at 1 °C/min; L\. H, : Heat of recrystallization; § From the chemical structure (Fig. 
B-11-1). 
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Table B-11-11: Drug-to-polymer ratio and kinetics of phase separation at 
40°Cl69%RH 
Solid Dispersion o/owlw Rate constant for KJMA 
(% wlw drug) moisture phase separation linear fit 
k (da~s- 1 ) (x 102) (R2) 
Griseofulvin 30 6.6 ± 1.5 I2 .50 0.868 
20 7.8 ± 0.6 5. I9 0.958 
IO 9.8 ± 0.7 4.66 0.970 
Indoprofen 30 6.0 ± 0.5 1.25 0.988 
20 9.3 ± 0.5 0.62 0.968 
IO 7.9 ± 3.0 NIA NIA 
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Figure B-Il- 1 
Chemical structures ofa) griseofulvin; b) indoprofen and c) repeat unit of PVP. 
B) 
8 ~  0 
HO 
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Figure B-ll-2 
MDSC reversing heat flow scans of solid di spersions of PVP and a) griseofulvin and b) 
indoprofen. Composition dependent single T g indicates molecular miscibility for up to 
30%w/w of both drugs in PVP. 
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Figure B-II-3 
Comparison of the infrared spectra of the carbonyl stretching region of solid dispersions 
and physical mixtures of(a) griseofulvin & PVP and (b) indoprofen & PVP. The 
percentages refer to the amounts of drug substance present. 
(a) (b) 
Griscofulvin-PVP 
1750 
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lndoprofcn-PVP 
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Figure B-Il-4 
MDSC reversing heat flow scans of solid dispersions exposed to 40°C I 69% RH for 
different time intervals: (a) 30% w/w gri seofulvin -PYP; (b) 20% w/w griseoful vin-PYP; 
and (c) 30% w/w indoprofen-PVP. [Tg1: Tg of phase separated PVP-in-griseoful vin 
mixture; Tg2 : Tg ofgriseofulvin-in-PYP mixture]. 
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Figure B-ll-4 (contd.) 
c) 30% lndoprofen-PVP solid di spersions. 
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Figure B-II-5 
Changes in the glass transition temperatures of 30% w/w ( • ), 20% w/w ( tJ. ), and 10% 
w/w (o) of(a) Griseofulvin-PVP and (b) lndoprofen-PVP solid dispersions. The dotted 
line represents the T g of PVP ( l 67°C). 
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Figure B-11-6 
X-ray diffraction patterns of solid dispersions and physical mixtures of(a) griseofulvin-
PVP and (b) indoprofen-PVP. 
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PHASE BEHAVIOR OF AMORPHOUS MOLECULAR DISPERSIONS fll: 
CHARACTERIZATION OF THE SURFACTANT EFFECT ON THE SOLID 
SOLUBILITY OF A DRUG IN A SOLID DISPERSION 
Madhav Vasanthavada1, WeiQin Tong2, Yatindra Joshi2, and M. Serpil Kislalioglu 1.J 
INTRODUCTION 
Studies conducted in the field of solid dispersions have underlined the significance of 
drug-carrier interactions in preparation of a miscible and physically stable solid 
dispersion product(!]. Although the polymer poly(vinylpyrrolidone), used inhibits drug 
crystallization in solid dispersions, the moisture and temperature variations during its 
shelf-life storage may adversely impact drug-carrier interactions towards drug 
crystallization. The physical stability of the drug product would depend upon factors 
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which include hygroscopicity, glass transition temperature of the product, and the 
strength of the drug-carrier bonding. 
Surfactants may be added in such binary mixtures of drug and polymer to improve the 
drug-polymer interactions and to create a miscible phase. In the miscible phase, the drug 
is molecularly dispersed in the carrier and could have a lower tendency to crystallize. 
Although in pharmaceutical studies surfactants are added in drug-polymer dispersions 
mainly to improve the solid solubility and dissolution of the poorly soluble drug (2-6) , 
the function and behaviour of the surfactant molecules in the physical stability of the 
system has never been investigated. The solid solubility of griseofulvin was increased 
from 3%w/w to 40%w/w in polyethylene glycol 6000 (PEG 6000) by adding 5%w/w of 
sodium dodecyl sulphate (SOS) (7, 8). SDS also improved the solid solubility of 
griseofulvin in PEG 3000 and PEG 20000 in concentrations from 3%w/w to 25%w/w. 
Pluronic® F-68 increased the solid solubility and dissolution rate of a poorly water 
soluble drug, nifedipine, in its solid dispersions (9) . Tween 40 (0.5% w/w) and SDS 
(0.5% w/w) were incorporated in solid dispersions to double the dissolution rate of 5-
lipoxygenase inhibitor [I OJ. Dissolution studies may be accepted as an indirect measure 
of the physical stability of solid dispersions. The mechanism suggested for the 
enhancement of drug solubility in a carrier and its dissolution in the aqueous media is the 
ability of surfactant to solubilize greater quantity of drug and hence to release it in 
molecular form during the dissolution process. 
82 
Solid solubilities of drugs that have been cited in the literature were investigated in the 
crystalline polymeric carriers like PEG and quantified by measuring the heat of fusion of 
the non-solubilized drug in the vehicle. These values were compared to that of the 
original drug. Although PEG has been shown to enhance the dissolution of hydrophobic 
drugs to fom1 a solid solution, it has not been able to prolong or retain the physical 
stability (i.e. amorphous fomi) of the drug. For instance, upon aging, triamterene and 
temazepam crystallized from solid dispersions of PEG 1500, PEG 2000, PEG 400 and 
PEG 6000 [ 11]. On the other hand, amorphous polymers like PVP have been shown to 
retain the amorphous nature of the drug, as well as improving its dissolution. The effects 
of surfactants in amorphous miscible mixtures would therefore be of value to understand 
whether and how added surfactant would influence the solid solubility of drugs. 
Griseofulvin was selected as the model drug compound because it was shown earlier to 
have no solid solubility in PYP (chapter 11 thesis of Yasanthavada M.). A linear chain 
non-ionic surfactant exhibiting axial polarity with its sucrose hydrophilic head and a 
stearic acid lipophilic chain, was the surfactant used. The presence of hydroxyl units in 
the sucrose head of the surfactant could interact with the drug as well as the polymer and 
improve the solid-solubility of the drug. The studies were carried out by detemiining the 
morphology and the themiodynamic behaviour of the griseofulvin-PVP solid dispersion 
in the presence and absence of sucrose stearate. Ternary solid dispersions containing the 
three ingredients were prepared and characterized by measuring the solid solubility of the 
drug in the polymer [12]. The effect of surfactants on the solid solubility of the 
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hydrophobic drug that were dispersed in the amorphous polymers has not yet been 
reported in the literature. 
MATERIALS AND METHODS 
Materials: 
Plasdone (Poly (vinylpyrrolidone)) PVP K29/32 with M., 50 KDa was obtained from ISP 
Technologies Inc. , (Wayne, NJ). Samples were dried at 105°C under vacuum for 20 
hours prior to preparing solid dispersions. Griseofulvin ((2S)-trans-7-Chloro-2',4,6-
trimethox y-6' -me th ylspiro(benzo furan-2 [3 H], l '-[2]cyclohexene)-3,4 ' -dione)) was 
purchased from Sigma Chemical Company (St. Louis, MO) and was used as received for 
the solid dispersion preparation. A sucrose stearate (Ryoto Sugar Ester 01570, a food and 
pharmaceutical grade surfactant, Mitsibushi-Kagaku Food Corp, Tokyo, Japan) was used 
as the surfactant. The chemical structures of all the materials used in this study are 
provided in Fig. B-111-1.The surfactant (sucrose stearate) used was non-ionic and 
hydrophilic with an HLB value of 14 and was amorphous in nature. We measured its 
glass transition temperature (T g) as 34°C. 
Methods: 
Preparation of Solid Dispersions - Solvent Evaporation Technique: 
Solid dispersions of PVP-surfactant, surfactant-drug and PVP-drug-surfactant were 
prepared using solvent evaporation technique. Ternary solid dispersions were prepared by 
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dissolving crystalline griseofulvin in dichloromethane. A pre-calculated amount of PVP 
and surfactant was added to the drug solution. The surfactant concentrations of the 
batches were increased from 10%w/w to 40%w/w at 10% weight increments and the 
weight proportion of griseofulvin was altered from 10%w/w of griseofulvin-in-PVP to 
60%w/w of griseofulvin-in-PVP. After all three ingredients thoroughly dissolved in 
dichoromethane, the solution was sonicated for 15 minutes in a water-bath that was 
maintained at 37°C, to complete clarity. The solvent was removed using a rotary 
evaporator (Rotavap®) at 37°C, leaving the residual drug product. Solid dispersion 
obtained in this manner was further dried in a vacuum oven at room temperature for at 
least 24 hours to remove the remaining residual solvent. The batches thus obtained were 
ground with a mortar and pestle and were sifted through a sieve# 70 to result in particle 
size $ 21 Oµm. The dispersions were stored in vials over anhydrous CaS04 in a freezer 
until use. 
Modulated Differential Scanning Calorimeter (MDSC): 
The glass transition temperature (T g) of the solid dispersions were analyzed using 
Modulated DSC 2920 (TA Instruments, New Castle, DE), with a liquid nitrogen cooling 
accessory. The analysis was performed under a purge of dry nitrogen gas (60cc/min). 
High purity indium and sapphire were used frequently to calibrate for the heat flow and 
heat capacity of the instrument. Thennal history of the samples was not erased unless 
mentioned specifically. The events were recorded and analyzed during the first heating 
scan. Samples (- 8-12 mg) were initially cooled to - 10°C for 10 minutes and were heated 
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to 245°C at I °C/min with modulations of 0.266° every 50 seconds. The specified 
amplitude and period were optimized to provide the best results fo r analysis. 
X-ray Powder Diffraction (XRPD): 
The crystallinity of solid dispersions was tested using X-ray powder diffractometer 
(Rigaku RINT (D/Max) 2200 that was equipped with an Ultimagoniometer). The 
instrument consisted of a 40 KV, 40mA generator with a Cu Ko. radiation anode tube. The 
samples were sifted through sieve # 70 and placed on a 0.5 mm quartz plate holder prior 
to exposure to X-rays. They were scanned over a 29 range between 2° and 40° at a scan 
rate of 2° per minute in 0.02° step size. The divergence and scattering slits were set at 
1.00°, receiving slit at O. l 5mm and monochromator was used at 0.45mm. 
Fourier Transform infra-red Spectroscopy (FTJR): 
Nicolet spectrometer equipped with a KBr beam splitter was used to obtain inrrared 
spectra. Calibration for wavenumber accuracy was performed by using polystyrene 
sample. Dry nitrogen gas was used to purge the beam splitter and sample compartment. 
IR spectra were obtained using an attenuated total reflectance (A TR) accessory (single 
reflection bounce diamond crystal; Golden Gate accessory) . For each spectrum, 32 scans 
were performed and a resolution of 4 cm was chosen. The ATR accessory enabled to 
obtain the spectra by pressing the solid material onto the diamond crystal. This accessory 
eliminates the use of KBr and yet produces comparable results. All samples were dried 
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under vacuum for 20 hrs prior to obtaining any spectra, to remove the influence of 
residual moisture. 
RESULTS AND DISCUSSION 
Thermal and Spectroscopic Analysis of PVP - Sugar ester Solid Dispersions: 
The glass transition temperatures of PVP-sucrose stearate solid dispersions are shown in 
Fig. B-III-2a. The Tg of PVP mixtures decreased from 141 °C to 91 °C as the surfactant 
concentration increased from 10% w/w to 50% w/w. Such a composition-dependent 
single T g indicates a molecularly miscible mixture. At surfactant concentration of 60% 
w/w and above, two Tgs were observed, indicating a phase-separated mixture. In Fig. B-
m-2b the Tg values have been plotted as a function of weight fraction of the surfactant. 
In order to detect the presence of any specific interactions e.g. hydrogen bonding between 
the polymer and surfactant, FT-IR spectra were obtained. In Fig. B-III-3, the PVP 
carbonyl stretch in the wave-number region of l 750cnf 1-1550cm-1 is shown. As a control 
the FT-IR scans of physical mixtures of corresponding weight fractions of surfactant and 
PVP are provided. It is seen from the spectra that the presence of I 0%w/w surfactant 
decreases the carbonyl stretch of PVP from l 666cm·1 to l 653cm-1, whereas no such 
reduction is evident in the corresponding physical mixtures. This suggested the presence 
of interactions between the polymer and surfactant most likely between the carbonyl 
group of PVP and the hydroxyl groups of the sucrose moiety of surfactant. Presence of 
specific interactions could be a cause for the miscibility of surfactant in the polymer. The 
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importance of interactions for miscibility in macromolecules has been reported earlier 
[13-18). 
Thermal and Spectroscopic Analysis of Griseojiilvin-Sugar ester Solid Dispersions: 
The MDSC reversing heat flow scans of griseofulvin-sugar ester solid dispersions are 
shown in Fig. B-IIl-4a for up to 50% w/w griseofulvin loading. Also the heat flow scans 
of amorphous griseofulvin and sucrose stearate demonstrating T g values at 89°C and 
34°C respectively are shown as Fig. B-IIl-4b. In Fig. B-lll-4a, the Tg values were 
recorded for the freshly prepared solid dispersions and for the samples whose thermal 
history was removed (treated samples), in order to minimize the effect of sample 
preparation on the Tg values [19). The thermal history was erased by heating the mixtures 
to temperatures just below the Tg of pure griseofulvin, to prevent the crystallization of 
any amorphous drug substance, and rapidly cooled to -10°C. The samples were reheated 
to record their Tgs. In Fig. B-111-4, the lower Tg is for the freshly prepared solid 
dispersion and the higher Tg is for the treated samples. A difference of 10°-l5°C was 
seen between the Tg values of freshly prepared and treated samples, possibly due to the 
differences in the rate of cooling of solid dispersion. Nevertheless, no appreciable 
difference was observed in the T g values obtained for the first scan (or the second scans) 
as a function of drug composition. This behavior indicated minimal or no miscibility 
between the drug and the surfactant. 
In order to investigate the presence of any specific interactions between the two 
components, i.e. hydrogen bonding or hydrophobic interactions, FT-IR spectra of the 
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( solid dispersions were obtained and were compared with corresponding physical mixtures 
as seen rrom Fig. B-lll-5. The shift in the wave-number of peak at l 713cm-1 to l 700cm-1 
in the solid dispersions in comparison to shift of l 713cm-1 to l 704cm·1 in physical 
mixtures suggested the presence of weak interactive of dispersive forces between the 
drug and the surfactants. 
?VP-drug-surfactant ternary solid dispersions: 
It was demonstrated earlier that griseofulvin had a miscibility of up to 30% w/w in PVP. 
At drug concentration of 40% w/w and higher, the samples were found to be crystalline 
(Fig. B-Ill-6). ln order to investigate the effects of the surfactant on the extent of 
miscibility between griseofulvin and PVP, sucrose stearate was added to the binary 
mixture to provide 10%, 20%, 30% and 40% (w/w) of total sample weight. The Tg 
values of various mixtures along with the XRD results verifying amorphous or crystalline 
are shown in Table B-Ill-1. The raw XRD patterns of the mixtures are also provided in 
Fig. B-lll-7 and 7a. 
As seen rrom Table B-lll-1, an increase in the surfactant concentration, rrom 10% to 20% 
w/w, increased the amorphous fraction of drug in the solid dispersion. At 20% w/w 
surfactant concentration, 50% w/w of drug in the polymer can be incorporated in the 
system in the amorphous fonn whereas the solid dispersion that contains 10%w/w 
surfactant facilitates only 30%w/w griseofulvin in the system. However, when the 
surfactant loading increased from 20% w/w to 30% w/w, the fraction of drug that was 
present in the amorphous form was dropped from 50% w/w to 40%. Such a 
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crystallization behavior can be explained by the increased molecular mobility in the 
system in the presence of higher amounts oflow-Tg sucrose ester. 
The Tg values of ternary solid dispersions of PVP and griseofulvin containing varying 
levels of surfactants are shown in Fig. B-111-8. Also the Tg values are plotted in Fig. B-
111-9 for different sugar ester containing system as a function of griseofulvin 
concentration. As it is seen from the figures, at a given surfactant concentration, with an 
increase in the drug concentration in PVP, the Tg of the mixture decreases. Moreover for 
a fixed ratio of griseofulvin and PVP, the Tg decreased with an increase in the surfactant 
concentration indicating a miscible mixture. The ternary phase diagram for PVP, 
griseofulvin and sucrose stearate system is shown in Fig. B-Ill-10. It can be seen from the 
shaded region of the plot that surfactant facilitates the miscibility of griseofulvin in PVP. 
Effect of sugar ester on the solid solubility limit of griseofulvin: 
To investigate the effect of the sucrose stearate on the solid solubility, the ternary solid 
dispersions were exposed to accelerated stability conditions of 40°C/69%RH for over 30 
days. The MDSC reversing heat flow scans of ternary solid dispersion of PVP: 
griseofulvin: surfactant in the ratio of 40:40:20 that were subjected to accelerated stability 
conditions are shown in Fig. B-IIl-11. It can be seen from the figure that the Tg values 
increased and after a storage period of 35 days had a Tg of 104°C. This T8 is much less 
that the T g of pure PVP of I 68°C. Although it is evident that the reduction observed in 
the Tg value is due to the plasticization of PVP with either griseofulvin or sucrose 
stearate, it cannot be ascertained as to which of the two components are responsible for 
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the reduction in Tg. If the plasticization were the result of the solid solubility of drug as 
well as the surfactant, then a solid dispersion containing a different composition would 
also provide T g values of I 04°C, upon storage. ln order to test this, a ternary solid 
dispersion containing PVP: griseofulvin: surfactant in the ratio of 45:45: I 0 were exposed 
to 40°C/69%RH conditions. A solid dispersion of 45:45: I 0 was chosen since it had 
griseofulvin and PVP in 1: 1 ratio, which was comparable to 40:40:20 and only the 
sucrose ester concentration decreased from 20% to 10%w/w. The MDSC scans shown in 
Fig. B-lll-11 demonstrate that the Tg values had reached a plateau at around 125°C, 
which is significantly different from 104°C, thus suggesting the presence of either 
griseofulvin or the sucrose stearate alone. 
If complete phase separation of griseofulvin is assumed, the concentration of surfactant 
remaining miscible in PVP would be arithmetically 18% w/w (since 10 parts of surfactant 
is present in 55 parts of mixture) . Therefore, a 20% w/w surfactant dispersed in PVP that 
contained no griseofulvin was exposed to 40°C/69%RH. The MDSC scans of such a 
sample are shown in Fig. B-111-1 la. At the end of 16 days the Tg values did not change 
significantly from the initial Tg of 121 °C. Based on these results it is assumed that 
surfactant remains miscible in the polymer and may be lowering the Tg values in the 
ternary solid dispersions. The fact that the Tg of ternary solid dispersions of 45:45:10 
mixtures reaches a value close to 123°C, which corresponds to Tg of soluble fraction of 
surfactant in PVP, further strengthens the argument that surfactant causes the reduction in 
the T g values. 
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It can be similarly argued in the case of 40:40:20 mixtures that the Tg of 104°C coincides 
with the T g of freshly prepared mixture of 30%w/w solid dispersion of surfactant in PVP. 
The arithmetically calculated value of surfactant in PVP in the absence of griseofulvin is 
33%w/w. Therefore it can be concluded that sucrose stearate did not improve the solid 
solubility limit of griseofulvin in PVP. 
CONCLUS IONS 
ln this study a ternary solid dispersion of drug, polymer and a sugar ester surfactant was 
prepared and characterized using MDSC and XRD. The surfactant interacted with the 
polymer through hydrogen bonding and was miscible in it up to 60%w/w concentration. 
Although the surfactant-drug mixtures did not exhibit composition dependent miscible 
Tg, FTIR demonstrated the presence of weak interactions between the two components. 
Therefore, the effect of surfactant on the extent of miscibility between the drug and the 
polymer was investigated. When present at 20%w/w concentrations, the surfactant 
increased the extent of miscibility from 30%w/w in PVP to 50%w/w. Such an increase in 
the miscibility was attributed to the physical interactions between the three components. 
The effect of surfactant on the solid solubility limit of griseofulvin in PVP was 
investigated by exposing the mixtures to 40°C/69%RH conditions. From the MDSC 
analysis of Tg values, it was concluded that this surfactant did not improve the solid 
solubility limit of griseofulvin in PVP. 
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Table B-111-1: Surfactant effect on the morphology and thermal properties of 
griseofulvin and PVP solid dispersions 
Wrvr Wcris Wrvp:Wcris Wsurfactant T g of freshly XRD 
prepared solid 
dis crsion 
72 18 8:2 IO I 19 Amorphous 
63 27 7:3 10 102 Amorphous 
45 45 5:5 10 80; 96 Crystalline 
56 24 7:3 20 97 Amorphous 
48 32 6:4 20 92 Amorphous 
40 40 5:5 20 84 Amorphous 
32 48 4:6 20 80 Crystalline 
56 14 8:2 30 93 Amorphous 
42 28 6:4 30 80 Amorphous 
35 35 5:5 30 77 Crystalline 
28 42 4:6 30 88 Crystalline 
48 12 8:2 40 99 Amorphous 
42 18 7:3 40 83 Amorphous 
35 35 5:5 40 73 Crystalline 
35 15 7:3 50 79 Amorphous 
30 20 6:4 50 73 Crystalline 
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Figure B-111-1 
Chemical structures of(a) griseofulvin; (b) repeat unit ofpoly(vinylpyrrolidone) and (c) 
Ryoto® food-grade sugar ester 01570 (sucrose stearate). 
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Figure B-lll-2 
(a) MDSC reversing heat flow scans of solid di spersions of sucrose stearate and PVP 
demonstrating the composition dependent single Tg indicating miscibility until two Tgs 
are seen. The percentages refer to the amounts of surfactant (b) Plot ofTg values against 
the sucrose stearate ( o: single T g values; t. : second T g value in a phase separated mixture) 
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Figure B-lll-3 
FT-IR spectra showing the carbonyl stretch region of 1750 - l 550cm-1 in solid 
dispersions and physical mixtures of sugar ester and PVP as a function of changes in the 
sugar ester composition. The percentages refer to the amounts of sugar ester present. 
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Figµre B-111-4 
(a) MDSC reversing heat flo w scans of solid dispersions of gri seofulvin and sucrose 
stearate. The Tg values shown are for the 'as is' samples and after erasing the thermal 
hi story. The higher Tg value at any specific composition is for the samples with thermal 
history erased. Percentages refer to the amounts of griseofulvin present. (b) MDSC 
reversing heat flow scans pure sugar ester and amorphous griseofulvi n prepared by melt-
quench technique. 
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Figure B-III-5 
FT-lR spectra showing the carbonyl stretch region of 1750 - l 550cm-' in solid 
dispersions and physical mixtures of sugar ester and griseofulvin as a function of changes 
in the sugar ester composition_ The percentages refer to the amounts of sugar ester 
present 
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Figure B-111-6 
X-ray diffraction pattern demonstrating the presence of crystallinity in 40%w/w 
griseofulvin-PVP solid dispersions. No crystallinity is seen in the 30%w/w solid 
dispersions (duplicates). 
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Figure B-lll-7 
X-ray diffraction pattern of ternary solid di spersion of PVP I griseofulvin I sugar ester 
showing the presence of crystallinity for 50:50 and 40:60 parts of PVP and griseofulvin 
in the presence of 30%w/w surfactant 
4000 
~ 3000 
= 0 
" 
.c 
·;;; 2000 
c: 
~ 
.s 
1000 
5 10 15 20 25 
2-Theta (0 ) 
103 
30 
Crystalline 
griseofulvin , 
35 40 
Figure B-lll-7a 
X-ray diffraction pattern of ternary solid dispersion of PVP I griseofulvin I sugar ester 
showing the absence of crystallinity for 50:50 parts of PVP and griseofulvin in the 
presence of20%w/w surfactant. However 60%w/w griseofulvin in PVP (i.e. 32 I 48 I 20) 
shows crvstallinitv. 
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Figure B-Ill-8 
MDSC reversing heat flow scans of ternary solid dispersions of PVP, griseofulvin and 
sugar ester. The fraction of sugar ester was kept constant at 30%w/w of the total sample 
weight. The percentages shown are for the fraction of griseofulvin in PVP. A 
composition dependent single Tg indicates a miscible mixture till 60%w/w limit. 
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Figure B-III-8a 
MDSC reversing heat flow scans of ternary solid dispersions of PVP, griseofulvin and 
sugar ester. The fraction of sugar ester was kept constant at 20%w/w of the total sample 
weight. The percentages shown are for the fraction of griseofulvin in PVP. A 
composition dependent single Tg indicates a miscible mixture till 60%w/w limit. 
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Figure B-lll-8b 
MDSC reversing heat flow scans of ternary solid dispersions of PVP, griseofulvin and 
sugar ester containing 50:50 ratio of griseofulvin and PVP, but with sugar ester 
concentration increasing from 10% to 40%w/w. 
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Figure B-Ill-9 
Tg values of ternary solid dispersions as a function of increasing griseofulvin 
concentration in PVP in the presence of varying levels of sugar ester 01570. Symbols 
represent the sugar ester concentration : D. I 0% w/w; • 20%w/w; A 30%w/w; and 0 
40%w/w 
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Figure B-IIl-10 
Miscibility of PVP, griseofulvin and sucrose stearate. The shaded zone indicates the 
enhancement in the miscibility of griseofulvin in PVP achieved by the addition of sucrose 
stearate. The dotted line represents the possible extrapolation of miscibility region at 
higher surfactant concentrations. 
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Figure B-lll-11 
MDSC reversing heat flow scans of PVP I griseofulvin I sugar ester solid dispersions in 
the ratio 40 I 40 I 20 that were exposed to 40°C I 69% RH conditions. The Tg values 
increases and reaches a plateau at I 04°C. 
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Figure 8-lll-l la 
MDSC reversing heat flow scans of PVP I griseofulvin I sugar ester solid di spersions in 
the ratio 45 I 45 I I 0 that were exposed to 40°C I 69% RH conditions. The upper three 
scans are for the 20%w/w sugar ester-PVP solid dispersions exposed to 40°C I 69% RH 
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MANSUCRIPT IV 
MOISTURE EFFECT ON GRISEOFULVIN CRYSTALLIZATION KINETICS 
Madhav Vasanthavada 1, WeiQin Tong2, Yatindra Joshi\ and M. Serpil Kislalioglu 1•3 
ABSTRACT: 
Purpose: To study the isothermal crystallization of griseofulvin at low moisture contents. 
Also, to determine the energy of activation (E,) for griseofulvin crystallization using 
modulated differential scanning calorimeter (MDSC) and non-isothermal crystallization 
studies. 
Methods: Griseofulvin was made amorphous by rapidly cooling from its molten state. X-
ray diffraction and MDSC were used to generate the calibration plot for isothermal 
crystalli zation studies. Amorphous griseofulvin was exposed to 0%, 32% and 43% 
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2 Pharmaceutical & Analytical Development, Novartis Pharmaceutical Corporation, East 
Hanover, NJ 07936. 
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11 2 
humidity conditions at 23°C using saturated salt solutions. Samples were analyzed 
periodically using MDSC to quantify the fraction of griseofulvin crystallized based on 
their heats of recrystallization and the generated calibration plots. The isothermal 
crystallization rate constants were determined using the established theoretical equations 
of Hancock-Sharp and Kolmorgorov-Johnson-Mehl-Avrami (KJMA). Non-isothennal 
crystallization kinetics was determined using Kissinger's analysis. 
Results : XRD did not prove to be a useful technique because of the large relative 
standard deviations in the peak height ratios of crystalline griseofulvin and lithium 
fluoride (internal standard) for the calibration plot. Hence calibration plot was 
constructed using the MDSC heat of recrystallization values of amorphous griseofulvin. 
From the Hancock-Sharp experimental fit, the crystallization mechanism was estimated 
to be as first order rate process. Hence, KJ MA equation was employed for the 
determination of kinetic rate constants. With an increase in relative humidity from 0% to 
43%, an increase in the crystall ization rate constants was observed from 0.016 to 0.067 
days·1• Even at 43% RH, the sample had a total moisture content of < 2%w/w and yet 
crystallized in a short period of less than 30 days . Crystallization was noticed at 23°C I 
0% RH although the glass transition temperature (T g) of amorphous griseofulvin was 
found to be at 92°C. The non-isothermal Ea for amorphous griseofulvin was calculated 
from the Kissinger's analysis as 239 KJ/mol. 
Conclusions: Crystallization of amorphous griseofulvin was detected at very low 
moisture contents and storage temperatures that was 65°C below the Tg of amorphous 
sample. High molecular mobility of griseofulvin at temperatures well below its Tg is 
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believed to be the primary cause for griseofulvin crystallization. Kissinger's analysis 
provides very low crystallization energy of activation, which agrees with the above 
findings. MDSC proved to be a sensitive technique for the isothermal crystallization of 
griseofulvin. 
Keywords: griseofulvin, crystallization, thermal analysis, XRD, glass transition 
INTRODUCTION: 
ln the manufacturing of pharmaceuticals, commonly employed processes like milling, 
melt extrusion, spray-drying and freeze-drying may generate partial or complete disorder 
in the crystalline lattice leading to a metastable amorphous form [l-4]. For drugs with 
extremely low aqueous solubility in the crystalline state, conversion to amorphous form 
has been shown to result in its higher solubility [5] . The meta-stable amorphous phase 
could however interact with moisture during its shelf life storage and undergo 
crystallization, thus influencing attributes like dissolution, bioavailability and chemical 
stability of the drugs [6]. Working with amorphous materials, Zografi et. al. [7] have 
shown that moisture could be selectively absorbed by the disordered regions of 
amorphous phase, thereby increasing the molecular mobility and inducing crystallization. 
Crystallization of amorphous drug substances may be prevented by either minimizing 
exposure to high humidity conditions, or storing them in low temperatures. It is generally 
understood that storing the amorphous drug substance at 50°C below its glass transition 
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temperature (T g) could significantly reduce the molecular mobility that initiates 
crystallization process although this may not be a feasible approach in many instances 
[8]. 
If the drug crystallization cannot be prevented, retention of the drug product attributes in 
a predetennined period (during the shelf life) may be acceptable. In order to do so one 
must understand the impact of moisture and temperature on the kinetics of drug 
crystallization. Crystallization kinetics is typically determined by quantifying the percent 
crystallinity in the drug substance or a drug product as a function of storage time. There 
are also reports of conducting non-isothermal crystallization studies [9]. To quantify the 
fraction of crystalline component in a drug substance, various techniques like X-ray 
diffraction [10-14] , DSC [15, 16], solution calorimetry [17, 18], water vapor sorption [17, 
19], thermally stimulated currents [20], density measurements [13, 14, 21], isothermal 
microcalorimetry [22, 23] etc. have been used. Table B-IV-1 summarizes the techniques, 
their sensitivity level, advantages & disadvantages. Since detection of crystallinity in the 
early stages of the crystallization process is important, sensitive techniques like solution 
calorimetry, water vapour sorption, and isothermal micro-calorimetry offer advantages. 
However these techniques have inherent disadvantages like producing and using an 
amorphous reference with known energy levels. This was demonstrated in the case of /3-
lactam antibiotics like cefazolin sodium, cefamandole nafate, cefamandole sodium, and 
cephaloridine, where the amorphous materials that were prepared by different techniques 
like freeze-drying and precipitation from solution had different energy contents [ 17]. 
Although thermally stimulated currents are very sensitive to molecular mobility, they 
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may not be able to accurately characterize the crystalline phases. One of the techniques 
that have been widely used for over three decades is the X-ray diffraction technique (24]. 
This technique has the advantage of being non-thermal in nature but has a disadvantage 
of detecting only levels as low as 5 - 10%w/w. 
In this study, modulated DSC was used to study the isothermal crystallization kinetics of 
amorphous griseofulvin at 0%, 32% and 43% relative humidity conditions. Modulated 
DSC was chosen since it provided greater reproducibility and had ability to differentiate 
between the effects of slight variations in the amorphous and crystalline griseofulvin 
ratios when compared to the X-ray diffraction technique. The calibration plot generated 
using known levels of crystalline and amorphous griseofulvin had higher slope with 
MDSC when compared to XRD. 
Griseofulvin was chosen as the model compound since it is poorly a water-soluble 
hydrophobic substance and has tendency to crystallize from its amorphous state. It also 
has a relatively high Tg of 90°C which makes it possible to study the crystallization 
pattern of the drug well below its Tg, i.e. room temperature (65°C below the Tg), without 
refrigeration. In addition, since the amorphous samples were exposed to low relative 
humidity conditions (a maximum of 43%RH), their Tgs were not plasticized to lower 
values from 90°C. In this study the non-isothemrnl Kissinger's analysis was used to study 
the energy of activation for drug crystallization (E.). A review of the pharmaceutical 
literature to probe into the mechanism of drug nucleation and crystallization at such low 
relative humidity and storage temperatures has been provided. 
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MATERIALS AND METHODS 
Materials: 
Griseofulvin ((2S)-trans-7-Chloro-2', 4, 6-trimethoxy-6'-methylspiro (benzofuran-2[3H], 
l '-[2] cyclohexene)-3, 4'-dione)) was purchased from Sigma Chemical Company (St. 
Louis, MO). The amorphous form was prepared for the stability studies. Anhydrous 
calcium sulfate, magnesium chloride and potassium carbonate were purchased from 
Fisher Chemical Co., Fair Lawn, NJ to prepare saturated salt solutions that would provide 
0%, 32% and 43% RH at room temperature respectively. The chemical structure of 
griseofulvin is shown in Fig. B-IV-1. 
Methods: 
Preparation of amorphous griseofulvin: 
Amorphous griseofulvin was prepared by melt-quenching the crystalline drug substance. 
The drug was weighed (3g) in a stainless steel beaker and was placed in an oven 
maintained at 2 I 7°C (i .e., 5°C above the melting temperature of drug), for 5 minutes. At 
the end of 5 minutes, it was ensured that drug was in a complete molten state. The 
stainless steel beaker was immediately immersed in a pool of liquefied nitrogen to rapidly 
cool (quench) the molten drug. The solidified drug was then grounded in a mortar and 
pestle and was sifted through sieve # 70 to result in particle size less $ 21 Oµm. Drug 
substance obtained this way was stored in a freezer in vials over anhydrous CaS04 until 
use. 
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Assay for drug degradation: 
The melt-quenched drug substance was analyzed using High Performance Liquid 
Chromatography (HPLC) for any chemical degradation during heating. The HPLC 
consisted of a pump (Waters model), 15 cm (C 18) reversed phase chromatographic 
column (XTerra™ MS 5µm; Waters, a division of Millipore (Canada) Ltd., Mississauga, 
ON), a 20-µL injector loop attached to a model 7125 injector (Rheodyne, Cotati, CA), a 
variable-wavelength UV detector (Waters Lambda Max model 481 LC 
spectrophotometer) set at 290nm and attached to a Photo Diode Array (PDA) having 
wavelength ranging from 200nm to 600nm. The experimental running conditions were 
chosen from previously published method by Vudathala and Rogers [24]. The mobile 
phase was 45% acetonitri le in 0.1 M acetic acid (pH 3.5) at a flow rate of I mUmin. 
A HPLC calibration plot was first generated before assaying for the drug content. For the 
calibration plot, untreated crystalline drug substance was dissolved in a mixture of 4: I 
parts of methanol: water to result a concentration of3.33 mg/mL. Several dilutions of this 
stock solution were made using the solvent. Each solution was analyzed according to the 
HPLC method described above. A plot of the area under the peak against the 
'concentration' of drug substance was generated. Later, a known amount of melt quench 
drug substance was dissolved in 4: I methanol: water solution and the percent drug was 
quantified by obtaining the area under the drug analysis peak and using the calibration 
plot. 
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X-ray Powder Diffraction (XRPD): 
The X-ray powder diffractometer (Rigaku R!NT (D/Max) 2200, equipped with an 
Ultimagoniometer) consisted of a 40 KV, 40mA generator with a Cu Ka radiation anode 
tube. XRD pattern was needed to test the presence of any crystalline drug substance in 
the melt quenched drug substance. The sample was placed on a 0.5 mm quartz plate 
holder. They were scanned over a 20 range between 2° and 40° at a scan rate of 2° 20 per 
minute and step size 0.02°. The divergence and scattering slits were set at 1.00°, 
receiving slit at 0.15mm and monochromator was used at 0.45mm. X-ray pattern of melt 
quenched drug substance showed no crystalline peak indicating an amorphous material 
(Fig. B-lV-2). In addition no birefringence was seen under a polarized light microscope, 
thus supporting the X-ray analysis. 
Preparation of calibration plot: 
X-ray diffraction: 
A calibration plot was constructed in order to quantify the percent crystallinity in 
amorphous sample during stability studies. Conventionally, X-ray diffraction technique is 
utilized to study isothermal crystallization kinetics (25]. A physical mixture of 
amorphous griseofulvin, crystalline griseofulvin and an internal reference as lithium 
fluoride (20% w/w) was prepared in 300mg quantities to fit in entirely on the X-ray slide. 
Mixing was achieved using Turbula MixerT" used at 46 rpm for 3 minutes . Each mixture 
was then X-ray scanned using the method described in triplicate. The peak height ratio of 
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crystalline griseofulvin and lithium fluoride were then plotted against the weight fraction 
of amorphous griseofulvin to generate the calibration plot. 
Thermal Analysis: 
The crystallization kinetics of amorphous griseofulvin was monitored using MDSC. 
MDSC is a sensitive tool to measure the heat flow associated with thermal events like 
melting, crystallization, glass transition phenomenon etc. Upon heating, amorphous 
griseofulvin undergoes a glass transition and crystallizes in sit11 in the DSC pan. The heat 
of recrystallization (i.e. area under the exothermic area of non-reversing heat flow scan) 
was found to be experimentally reproducible and was used to obtain a measure of the 
percent amorphous sample in a given mixture [26]. In order to generate a calibration plot, 
physical mixtures of crystalline and amorphous griseofulvin, were weighed accurately in 
known weight proportions in a DSC pan. Calibration plot was constructed by plotting the 
in sit11 heat of recrystallization of the physical mixture against the percent amorphous 
griseofulvin. 
Mod11lated Differential Scanning Calorimeter (MDSC): 
Thermal analysis was performed using MDSC 2920 (TA Instruments, New Castle, DE), 
with a liquid nitrogen cooling accessory. The analysis was performed under a purge of 
dry nitrogen gas (60cc/min). High purity indium and sapphire were used frequently to 
calibrate for the heat flow and heat capacity of the instrument. Samples (- 8-12 mg) 
heated from 0°C to 245°C at 1 °C/min with modulations of 0.266° every 50 seconds. The 
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specified amplitude and period were optimized to provide best results for analysis. The 
heat of crystallization was obtained by measuring the area under the non reversing heat 
flow signal of crystallization exothermic peak using the TA Instrument Software for 
Universal Analysis. Measurement were conducted times n=3 for each time-point to 
ascertain the reproducibility of experiments. 
Isothermal crystallizatian studies: 
Studies were conducted at 23°C with 0%, 32% and 43% relative humidity conditions. 
The amorphous drug substance was accurately weighed (8-J 2mg) in standard DSC pans. 
The pans were exposed to isothermal stability condition by placing them in desiccators 
containing anhydrous calcium sulfate (0% RH), saturated magnesium chloride solution 
(32% RH) and saturated potassium carbonate solution (43% RH) [27]. By storing the 
samples in discrete DSC pans, the reproducibility of the results could be assessed without 
any interference due to sample handling. Samples were taken out for analysis at pre-
determined time intervals for a period of up to seventy days or until near complete 
crystallization. The sample pans were crimped with aluminum lids having pinholes to 
facilitate the removal of absorbed water during heating. The heat of recrystallization of 
the sample was determined and the percent crystallinity at a specific time point was 
quantified using the calibration plot. 
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Non isothermal crystallization studies: 
The energy of activation E, for the crystallization of griseofulvin was determined non-
isothermally using Kissinger analysis [28, 29]. 
ln(Jf 2) =(-E~T )+cons tant (1) 
In Kissinger's analysis, the energy of activation E, is determined by measuring the peak 
crystallization temperature (Tc) at several heating rates (/J). The slope of a plot of ln(p I 
T/ ) against I/Tc gives - E,/R, where R is the gas constant. Amorphous griseofulvin 
samples were weighed in DSC pans and were heated at scanning rates of 1, 5, 7.5, 10, 15, 
20 and 25°C/min. The peak crystallization temperatures Tc was obtained from the 
software. 
Determination of moisture content: 
The moisture content of the sample was analyzed using the Karl Fischer (KF) titration. 
KF titration detects the bound as well as unbound water present in a sample by dissolving 
it in the KF reagent. The sample is titrated coulometrically. A small quantity of sample 
was accurately weighed (15 mg) and was titrated with the Karl Fisher reagent to 
determine the moisture content. The endpoint, provides the total amount of water present 
was provided by the instrument. 
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RESULTS 
Chromatographic analysis to assess the drug degradation: 
The data pertaining to the calibration plot for HPLC is provided in Appendix I. The test 
solution concentration used for analysis of melt quenched drug substance was 0.3 
mglmL. Table B-IV-11 provides data on the assay for the melt quench drug substance of 
four different lots. As seen from the assay values, no drug degradation was noticed due to 
melt quenching of crystalline griseofulvin. 
X-ray analysis for the construction of calibration plot: 
The X-ray scans for physical mixture of 40%: 40%: 20% w/w of crystalline griseofulvin, 
amorphous griseofulvin and lithium fluoride respectively four reproducibility scans are 
shown in Fig. B-lV-3. The peak height ratio of crystalline griseofulvin to lithium fluoride 
for a specific ratio of 40%:40%:20%w/w of amorphous griseofulvin, crystalline 
griseofulvin and lithium fluoride were not reproducible. Also, the peak height ratio of 
crystalline griseofulvin and lithium fluoride, when plotted as a function of percentage 
w/w of griseofulvin yielded a straight line with very poor slope of 0.0097, as seen in Fig. 
B-lV-4. The slope obtained was too small to be able to accurately resolve the differences 
in the percent amorphous griseofulvin in the mixture. Hence X-ray analysis was not 
chosen as a suitable technique to study isothennal crystallization of griseofulvin. 
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Thermal analysis ofgriseofit!vin: 
The DSC scans of amorphous and crystalline griseofulvin are shown in Fig B-IV-5 . The 
amorphous griseofulvin undergoes a non-reversible exothermic recrystallization during 
the heating scan with peak maxima at around 81 ° and l l 9°C. It appears from the two 
distinct exothermic peaks that recrystallization occurs in two phases involving a 
structural transformation from a metastable crystalline form at lower temperature into a 
stable crystalline one at elevated temperatures. A similar observation in the 
recrystallization behavior was found in the case of nifedipine and a solid-state 
transformation was accounted as the reason for two exothermic crystallization peaks [30]. 
The glass transition event of amorphous griseofulvin was characterized at 92°C from the 
reversing heat flow scan and is shown as an inset in Fig B-IV-5. After recrystallization, 
amorphous griseofulvin undergoes melting at 2 l 2°C. The heats of fusion and the melting 
temperatures of the recrystallized and original crystalline griseofulvin were the same, 
indicating that amorphous griseofulvin undergoes complete crystallization during the 
heating scan. Overall the heat of recrystallization was used to quantify the fraction of 
crystalline drug. 
Construction of calibration plot: MDSC 
Since X-ray diffraction did not prove to be a suitable technique for this compound, 
MDSC analysis of drug was performed. A calibration plot was generated based on the 
DSC heat of crystallization of known physical mixtures of amorphous and crystalline 
griseofulvin. The non-reversing heat flow scans of the physical mixtures are shown in Fig 
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B-IV-6. It is seen from the figure that with an increase in the weight fraction of 
amorphous griseofulvin, the heat of recrystallization (i .e. area under both the peaks) 
increases. To generate the calibration plot, the heat of recrystallization (J/g) that was 
obtained from the area under the recrystallization peaks was plotted against the 
percentage of amorphous griseofulvin present (Fig. B-IV-7). As seen from Fig. B-IV-7, 
the calibration plot has a much higher slope when compared to the plot generated using 
X-ray analysis and hence was found more suitable to interpret the crystallization studies. 
Isothermal stability studies: 
Amorphous griseofulvin samples that were exposed to 0%, 32% and 43% RH conditions 
were analyzed periodically to monitor the changes that occurred in their crystallinity. The 
MDSC non-reversing heat flow of griseofulvin exposed to 23°C I 43% RH conditions as 
a function of storage time is shown in Fig B-IV-8. It is seen from the figure that the area 
under the exothermic peak decreases in magnitude with storage time. This indicates 
progressive crystallization of amorphous griseofulvin. The percent crystallinity in the 
sample was obtained using the calibration plot and is shown in Fig. B-IV-9. As can be 
seen from the plot, the rate and extent of crystallization of the samples stored at 43% RH 
was much greater than those stored at 32% RH. Even the samples stored at 0% RH 
showed significant crystallization although at a much smaller rate. 
The total moisture absorbed by the samples was obtained using the Karl Fischer 
titrimetric analysis and are tabulated in Table B-IV-IV. 
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Non-Isothermal stability studies: 
Non isothem1al crystallization studies were perfonned using Kissinger's analysis. The 
peak crystallization temperature of amorphous griseofulvin was recorded by heating it at 
different rates. The non reversing heat flow scans of amorphous griseofulvin are shown in 
FigB-fV-10. 
DISCUSSION 
Isothermal crystallization kinetics: 
The crystallization kinetics was monitored with time as a function of relative humidity by 
storing the samples in isothennal stability conditions. The rate and extent of 
crystallization of griseofulvin have been plotted in Figure 9 and the crystallization 
kinetics was calculated based on Hancock-Sharp equation [3 I) . 
Hancock-Sharp equation: 
Unlike the chemical degradation rates in solution, the rate of alteration in the physical 
state of a powder is difficult to detennine from accelerated stability studies . However, 
predictions of some physical alteration pathways such as crystallization, dehydration, 
polymorphism etc., have been attempted. The Hancock-Sharp equation is often used to 
describe the kinetics of reversion of amorphous phase to its crystalline fonn and is 
written as follows: 
ln[- ln(J -a)) = lnB +mint (2) 
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where a the fraction of drug that has crystallized, t is the storage time, B is a constant 
and m is a constant relating to the mechanism of griseofulvin crystallization. The kinetic 
equations for the most common mechanisms that are believed to operate in solid-state 
decomposition are presented in Table B-IV-111. Upon plotting the experimentally 
obtained results with Hancock-Sharp equation as ln[- ln(l -a)] with the logarithm of 
storage time t, a linear relationship was obtained as shown in Fig B-IV-11. In order to 
chose the appropriate mechanism that would fit the experimentally obtained 
crystallization data, the results were fit to all the equations provided in Table B-IV-Ill. 
The results of such fit are provided in Table E-lll of Appendix E. Although the same fit 
to KJMA, and Avrami-Erofeev A2 and A3 were obtained, because of the m value 
(m= 1.08) that was obtained by Hancock-Sharp equation we selected KJMA for further 
modelling. 
Kolmorgorov-Johnson-Mehl-Avrami (KJMA) equation: 
A first order degradation mechanism has often been chosen to plot crystallization kinetic 
plots [32, 33]. The relationship pertaining to this mechanism is given by the KJMA 
equation and is described as: 
- ln(l -a)= k (t-to) (3) 
where k is the rate constant for crystallization, t is the storage time and to is the induction 
or the nucleation time. The rate constants for crystallization obtained from the slope of 
the linear equation are given as a function ofrelative humidity in Table B-IV-IV. The rate 
constants were found to be higher at high relative humidity conditions. This was not 
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surprising because at higher relative hwnidity, water in the samples could cause an 
increased molecular mobility and hence increased crystallization rates. 
Non-isothermal crystallization: 
Non isothennal crystallization was performed using Kissinger's analysis to determine E •. 
The E, value was determined from the slope of the linear plot of ln(jJ I T/ ) and l/T, as 
shown in Fig. B-lV-13. In this plot, fJ is the heating rate and T, is the peak crystallization 
temperature. With an increase in the heating rate, an increase in the peak crystallization 
temperature was noticed (Fig. B-IV-10). Although the area under the exothermic 
crystallization peak appears to increase with an increase in the heating rate, the absolute 
values were found to be constant (Fig. B-lV-10). This indicated that irrespective of the 
heating rate employed in this study, amorphous griseofulvin crystallized completely. 
Similarly at higher heating rates, most of the crystallization probably occurred over a 
narrow temperature domain and hence, a greater peak appeared compared to the ones 
obtained with slower heating rates, where crystall ization occurred gradually over a larger 
temperature domai n. 
The slope of the line in Fig. B-IV-13 provided -E,/R values, where R is the gas constant, 
and E, was calculated as 239 KJ/mol. The E, value for the crystallization of griseofulvin 
has not been reported in the literature for comparison with the values obtained in this 
study. However, the E, value of griseofulvin was found to be much lower than the E, of 
317 KJ/mol reported for crystallization of lactose by Schmitt et. al [32]. This agrees with 
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the isothermal crystallization rates which seem to be very high at experimental conditions 
employed. 
Mechanism of crystallization: 
The mechanism of crystallization of amorphous materials has been studied extensively in 
the literature [34-36] . The process of crystallization involves nucleation and crystal 
growth. It is generally considered that crystallization from amorphous state can occur 
only at temperatures above the T g of the material where the viscosity of the amorphous 
state is low and conducive for nucleation and subsequent crystal growth. However for 
amorphous indomethacin, crystallization has been shown to occur at temperatures 30°C 
below the Tg [37]. In our case griseofulvin crystallized at temperatures as low as 65°C 
below the T g· The crystallization at this low temperature was expressed by the Turnbull 
and Fischer equation [20]: 
V• {NkT) (llG0 +llGK) = -- exp-
/, kT 
(4) 
where V* is the nucleation rate per unit volume, N is the number of molecules per unit 
volume, k is the Boltzman constant, h is Planck's constant, and Tis the temperature. The 
term llG K is the Gibbs free energy change for the formation of nucleus with a critical size 
and llG 0 is the free energy associated with transportation of molecules from the 
amorphous bulk onto the growing nucleus. 
It can be seen from the equation shown above that nucleation rate is the result of net 
effect between two opposing factors: temperature and super-cooling. When temperature 
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decreases, the degree of super cooling increases. This may correspond to the increase in 
the temperature difference between the melting temperature and storage temperature. 
Under such conditions, the nucleation rate would be expected to increase exponentially. 
However, temperature reduction also causes reduction of the molecular mobility and 
hence decreases nucleation probability. Although in varying amounts, molecular mobility 
changes will impact both f'.G K and !'.G 0 . In equation 4, the term f'.G K is dependent 
upon the interfacial energy between the nucleus and amorphous bulk as well as degree of 
super cooling, and is less influenced by the magnitude of changes in the molecular 
mobility of a system at a constant temperature. f'.G 0 on the hand, encompasses the 
energy of activation for diffusion through the bulk phase and this factor is largely 
affected by molecular mobility. 
For griseofulvin crystallization, it can be assumed that the molecular mobility is still 
strong even at temperatures as low as 65°C below the T g and hence nucleation, and 
crystal growth, results. A similar explanation was provided for the crystallization of 
amorphous indomethacin at temperatures below T g and nucleation was explained by the 
rotational motion of molecules. This assumption can be true for griseofulvin considering 
its small chemical structure and ease of rotation. The increased moisture content of the 
drug probably increases the ease of rotation and translational diffusion (Table B-IV-IV). 
Increased molecular mobility is likely to increase the crystallization rate constant. 
Interestingly significant crystallization of griseofulvin was observed in the samples 
containing O. I 5%w/w moisture, indicating the high proximity for griseofulvin to 
crystallize at temperatures as low as 65°C below its T g· 
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CONCLUSIONS 
ln this paper, the isothermal and nonisothermal crystallization of amorphous griseofulvin 
has been reported. Isothermal crystallization was performed by storing the samples at 
various relative humidity conditions and monitoring the extent of crystallization of 
griseofulvin from the heat of crystallization process in DSC heating scan. Nonisothermal 
experiments were calculated by using Kissinger's analysis and the apparent energy of 
activation for griseofulvin crystallization (E,) was calculated as Ea = 239 KJ/mol or 
57Kcal/mol (I joule = 0.2388 calories). The isothermal experimental data was treated 
using the Hancock-Sharp equation and the mechanism of solid-state physical alteration 
was explai ned as the first-order random nucleation process. The data was accordingly fit 
to the KJMA equation, and the kinetic rate constant and induction time fo r crystallization 
were calculated. An increase in the rate constant and decrease in the induction time with 
increasing relative humidity indicated higher molecular mobility at high relative 
humidities, which enhanced the crystallization process. High molecular mobility was the 
cause for crystallization at 0% RH and temperatures as low as 65°C below T g· No 
crystallization from amorphous phase was noticed in samples stored at -20°C (i .e. 110°C 
below T g) . The theory of crystallization and the factors affecting the nucleation and 
crystallization growth rate have also been reviewed. According to the data obtained, it 
can be concluded that amorphous griseofulvin should be stored at very low temperatures 
in order to retain its amorphous form. 
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Table 8-IV- l 
Methods used in isothennal crystallization studies 
Technique Principle Advantages & Limit of Reference 
Disadvantages Detection 
(amorphous) 
X-ray Peak height ratio of I. Non-thennal 5 - 10% w/w [10-14] 
Diffraction crystalline drug and technique Model 
an internal reference 2. Measures compounds: 
average degree of Succinylsulfath 
disorder, indirect iazole, 6-
measure of mercaptopurine 
amorphous , indomethacin, 
material 
Differential Heat of I. Sensitive, no 2 - 3%w/w (15, 16] 
Scanning crystallization of mixing issues Model 
Calorimeter amorphous; heat of 2. Not suitable for compounds: 
fusion of crystalline thermally sensitive Lactose, 
content compounds cephalothin 
sodium, 
sul fathiazo le 
Solution Heat of solution and I. Ease of 2%w/w (17, 18] 
Calorimeter energy difference experiment Model 
between amorphous 2. Amorphous compounds: 
and crystalline standard is difficult ,8-lactam 
content to obtain antibiotics 
Water vapor Percent weight loss I. Sensitive tool, l-2%w/w (17, 19] 
sorption due to de-sorption direct measure of Model 
when known amorphous control compound: 
amount of 2. Not applicable Sucrose, P. 
amorphous material to all drugs that lactam 
crystallizes could form antibiotics 
h drates etc 
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Table B-IV-1 (contd.) 
Methods used to detect crystallization in drug products 
Technique Principle Advantages & Limit of Reference 
Disadvantages Detection 
{amorphous) 
Thermally Polarization or I. Very sensitive 1 % w/w [20] 
Stimulated depolarization tool Model 
Current current intensity 2. Reproducibility compound: 
as a function of limits the undisclosed 
amorphous measurements 
content 
Density Density I. Easy Model [13 , 14, 
Measurements differences experiments compound 21] 
between 2. Differences Adipic acid, 
amorphous and between samples acetaminophen, 
crystalline solids. may not be Calcium 
significant feno~rofen 
Isothermal Measurement of 1. Sensitive tool. 0.5-1%w/w [22, 23] 
Microcalorimetry power-time 2. Direct measure Model 
output as the of amorphous compounds: 
amorphous content. Lactose 
component 3. Not suitable for 
crystallizes and rapidly 
comparison with crystallizing 
the amorphous compounds 
standard 
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Table B-IV-11 
HPLC assay to assess griseofulvin stabi lity during melt-quench preparation 
Lot Retention Peak Arca Peak Assay Average 
Time Height Assay 
(minutes) 
5.508 20269286 1802267 98.26 
5.508 20328777 1804940 98.55 
2 5.508 20629266 1825700 100.01 
5.508 20633751 1823565 100.03 
3 5.508 21055119 1849861 102.07 100.40 ± 
5.508 21045734 1853770 102.03 1.45 
4 5.500 208698 14 1833286 101.17 
5.508 20853720 1832506 101.10 
Standard 5.508 20619686 182405 1 99.96 
(Crystalline 5.508 20633751 1823577 100.03 
drug) 
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Table B-IV-Ill 
List of various solid-state transformation kinetic rate mechanisms and their equations 
Symbol Equation m value Mechanism 
R1 a=kt 1.24 Zero-order mechanism (Polani -
Wigner equation) 
R1 I-(1-a)Y, =kt I. I I Phase boundary reaction; 
cylindrical symmetry 
RJ 1-(I -a)X =kt 1.07 Phase boundary reaction; 
spherical symmetry 
F1 - In(I-a) =kt 1.00 Random nucleation, one nucleus 
on each particle (Kolmorgorov-
Johnson-Mehl-Avrami (KJMA) 
equation) 
A1 [-ln(I-a)]Y, =kt 2.00 Random nucleation, two 
dimensional growth of nuclei 
(Avrami-Erofeev equation) 
Ai [-ln(I-a)]X =kt 3.00 Random nucleation, three 
dimensional growth of nuclei 
(Avrami-Erofeev equation) 
01 a ' =kt 0.62 One-dimensional diffusion 
02 (1-a) ln(l -a) +a= kt 0.57 Two-dimensional diffusion 
03 [1-(1 - a)X l ' =kt 0.54 Three-dimensional diffusion 
(lander equation) 
04 (I - 2a I 3) - (I - a )Y, = kt 0.57 Three-dimensional diffusion 
(Grinstring-Brounshtein 
equation) 
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Table B-IV-IV 
Hancock-Sharp fit of the experimental data and the Isothermal crystall ization rate 
constants as a function ofrelative humidity 
Relative Moisture Hancock-Sharp Fit KJMA Fit (average n=3) 
humidity content m R k to R 
(% w/w) 
value (days-1] [days] 
0 % 0.15 ±0.02% 0.916 0.987 0.016 2.07 0.955 
32% 0.41 ±0.04% 1.57 0.984 0.051 2.03 0.988 
43 % 0.49±0.06% 1.02 0.980 0.067 0.66 0.992 
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Figure B-IV-1 
Chemical structure of griseofulvin ((2S)-trans-7-Chloro-2 ', 4, 6-trimethoxy-6'-
methylspiro (benzofuran-2[3H], l ' -[2] cyclohexene)-3, 4 ' -dione)) 
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Figure B-IV-2 
X-ray diffraction patterns of griseofulvin untreated (crystalline) and melt-quench treated 
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Figure B-IV-3 
X-ray diffraction patterns of repetitions (n=4) of I: I physical mixtures of amorphous and 
crystalline griseofulvin containing 20%w/w lithium fluoride as an internal standard. 
Notice that the peak heights for the griseofulvin (29 = 16.5°) and lithium fluoride (29 = 
39°) are not of the same height for all the four scans. 
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Figure B-IV-4 
X-ray di ffraction calibration plot of: percentage crystalline griseofulvin vs. peak height 
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Figure B-IV-5 
DSC heat flow scans of griseofulvin amorphous and crystalline. Inset demonstrates the Tg 
of amorphous sample on the reversing heat flow. Exothennic peak of the amorphous 
sample indicates its recrystallization. Heats of fusion of the recrystallized and crystalline 
griseofulvin are similar indicating complete crystallization of amorphous griseofulvin 
during the heating scan. 
0.0 
1 ll.65°C 220.73°C 
59.43 Jig ~~I I 06.9 Jig 
Amorphous 
~ -0.2 Crystalline ~ 
-~ 220.88°C 
..:: .. 
""" 
-0.4 ~ 102. 1 Jig ..... 
~ 
"" 
Q,I 0 
::i:: ~ 
~ ::; 92 .7l°C 
..... :I: 
0 ,.. 0.1077 J/g/°C E-- -0.6 .. 0: 
50 70 90 110 
-0.8 ~--------------------~---< 
0 50 100 150 200 250 
Temperature 
146 
Figure B-IV-6 
MDSC non-reversing heat flow scans of physical mixtures of crystalline and amorphous 
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Figure B-IV-7 
DSC calibration plot of: percentage amorphous griseofulvin vs. heat ofrecrystallization 
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Figure B-IV-8 
MDSC non-reversing heat flow scans of amorphous griseofulvin as a function of storage 
time. Decreasing exothermic peaks ofrecrystallization indicates increasing crystalline 
content of the samples. 
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Figure B-!V-9 
Percentage griseofu lvin crystallized as a function of storage time upon storing at 23°C 
with 43% RH ( m); 32% RH (+ ); and 0% RH (e ). The percentages are calculated 
from the heats of crystallization measuring three di fferent batches (n=3) for each time 
point. 
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Figure B-IV-10 
MDSC non-reversing heat flow scans of amorphous griseofulvin as a function of heating 
rate. The peak recrystalli zation temperature increases with an increase in the heating rate, 
but the total area under the recrystallization peak (J/g) does not change significantly. 
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Figure B-IV-11 
Hancock-Sharp fit of the experimental data to determine them values. Depending on the 
m values, the order of the crystallization rate is determined. Details are provided in the 
text. 
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Figure B-IV-12 
Fit of the stability data to the first-order KJMA rate equation to determine the isothermal 
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MANUSCRIPT V 
MEASUREMENT OF SUB-GLASS TRANSITION MOLECULAR MOTIONS OF 
POLY(VINYLPYRROLIDONE): COMPARISON OF THE UTILITY OF 
THERMALLY STIMULATED CURRENT (TSC) AND MODULATED 
DIFFERENTIAL SCANNING CALORIMETER (MDSC) 
Madhav Vasanthavada 1, Yatindra Joshi2, and M. Serpil Kislalioglu 1•3 
ABSTRACT 
Purpose: To compare the utility of Thermally Stimulated Current Spectroscopy (TSC) 
and Modulated Differential Scanning Calorimetry (MDSC) in detennining the effects of 
the molecular weight on the molecular motions of Poly (vinylpyrrolidone) (PVP). 
Methods: PVP of three different molecular weight grades namely PVP Kl 7, PVP K30 
and PVP K90 were used as model polymers. TSC was used in the polarization mode. The 
samples were subjected to a thermal treahnent by heating to temperatures 25°C above 
1 Department of Applied Pharmaceutical Sciences, The University of Rhode Island, 
Kingston, RI 02881. 
2 Pharmaceutical & Analytical Development, Novartis Pharmaceutical Corporation, East 
Hanover, NJ 07936. 
3 To whom correspondence should be addressed. (Telephone: (401) 874 5017; Email : 
skis@uri.edu) 
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their glass transition temperature (T g), and quench-cooling to l 50°C below their T g· They 
were then aged at Tg-5°C, Tg-15°C and Tg-30°C for different storage periods and 
reheated at 3°C/min. The aging period extended for up to 16 hours with MDSC with 
samples analyzed at 1, 2, 4, 8 and 16 hours. For TSC measurements, the samples were 
aged for up to 8 hours with time points of 0.25, 0.5, 1, 2, 4, 6, and 8 hours. The 
polarization current was measured at 175 V/mm by heating the samples at 3°C/min. 
Results: A reproducible sub-Tg relaxation peak in addition to the Tg peak was observed 
at 82 ± 3°C for PVP Kl?, at 132 ± 2°C for PVP K30, and at 143± 3°C for PVP K90 
using TSC. No such peak was detected using MDSC. Upon aging, the polarization 
current peak under sub-T g peak decreased and the area under T g peak increased with 
aging time. However no significant change in the "total peak area" was observed. 
Modified experimental protocols helped to estimate the enthalpy relaxation. From 
MDSC, the average relaxation time constants were estimated. A linear empirical rel ation 
was established between the TSC and MDSC results. 
Conclusions: TSC provided additional infonnation about the molecular motions of PVP 
below Tg when compared with MDSC. The results suggest the rank order of decreasing 
molecular mobility at a specified temperature below the respective Tg as PVP Kl 7 > PVP 
K90 > PVP K30. Overall TSC proves to be a powerful , sensitive complimentary tool to 
characterize the molecular mobility of amorphous solids. 
Keywords: Glass transition temperature, enthalpy relaxation, thermally stimulated 
current, molecular mobility, modulated differential scanning calorimeter 
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INTRODUCTrON 
Polymers are widely used in the pharmaceutical industry as excipients in several dosage 
forms like tablets, capsules, trans-dermal dosage forms, inhalation products, suppositories 
and many other formulation types [I]. They have also been used to modify the drug 
dissolution profile and to create a sustained or delayed release effect to meet therapeutic 
requirements [2]. The usage of polymers to improve the aqueous solubility of poorly 
soluble drugs and to inhibit the drug crystallization has also been reported in the 
pharmaceutical literature extensively (3-6]. The mechanism of crystallization inhibition 
by polymers in amorphous solid dispersions has been postulated to be the ability of the 
polymer to form a miscible phase with the drug [7]. In this molecularly miscible phase, 
the coupling molecular motions of long chain polymers reduce the net molecular motion 
of small drug molecules and hence delay the crystallization of the amorphous drug. It is 
important however to monitor the molecular mobility of the system since the 
thermodynamic non-equilibrium nature of amorphous drug would always favor 
crystallization to the lower energy state, which is poorly water soluble. 
An amorphous material constantly undergoes structural or enthalpy relaxation to achieve 
its low-energy super-cooled equilibrium state or a crystalline state as depicted in Fig. B-
Y- I. Retention of the amorphous state of the solid would therefore depend upon the 
extent to which the material can structurally relax to lower its enthalpy or heat content. 
The higher the molecular mobility of the material, the higher would be the rate at which it 
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will structurally relax. Therefore molecular mobility measurements are necessary to 
understand the dynamics of crystallization. 
It is however, difficult to quantify directly the structural relaxation or the mean relaxation 
time, which is an indicator of molecular mobility for amorphous solids below their T g· 
Such difficulty is due to (a) long time scales of molecular motions and (b) complex 
relationship between the mean relaxation time and storage temperature [8, 9]. Despite 
these challenges, various techniques including enthalpy relaxation measurements [I 0-12] , 
dielectric spectroscopy [ 13], viscosity measurements [14] , and nuclear magnetic 
resonance [ 15, 16] have been used to estimate the mean relaxation time. 
The purpose of this study was firstly to conduct enthalpy relaxation measurements and to 
characterize molecular motions to estimate the mean relaxation time of different 
molecular weight grades of poly (vinylpyrrolidone) (PVP). PVP was chosen as the model 
compound because it is one of the widely used polymers in the pharmaceutical industry 
to prepare solid dispersions of the poorly soluble drugs. The molecular mobility of PVP 
can be characterized with a sensitive thennal technique called thermally stimulated 
current spectroscopy (TSC). TSC involves heating a sample across its transition 
temperature in the presence of an electric field. At the solid-transition temperature, the 
molecular mobility of sample generates an electric current, which is amplified and 
measured. TSC offers the advantage of being very sensitive to the molecular motions of 
the sample that it is measuring and, it can measure the molecular mobility recovery. 
Comparison and interpretation of the results obtained by molecular mobility recovery 
(TSC) and those of enthalpy recovery experiments (MDSC) are very useful to gain 
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insight into the relative extent of molecular mobility of PVP and identify the factors 
influencing it. 
MATERIALS AND METHODS 
Materials: 
Plasdone® (Poly(vinylpyrrolidone)) with K value (as designated by the supplier) 17, 
29/32 and 90 having Mw of I 0, 58 and 130 KDa respectively, as determined by the 
supplier from light scattering measurements, was obtained from ISP Technologies Inc. , 
(Wayne, NJ). The molecular weight distribution around each mean molecular weight was 
4-6 KDa, as described by the supplier. Samples were dried at I 05°C under vacuum for 20 
hours prior to running experiments. 
Methods: 
Modulated Differential Scanning Calorimeter (MDSC): 
A Modulated Differential Scanning Calorimeter (MDSC) (TA Instruments 2920, New 
Castle, DE), with liquid nitrogen cooling accessory was used for the enthalpy recovery 
measurements. Analysis was performed under a purge of dry nitrogen gas (60cc/min). 
High purity indium and sapphire were used bimonthly to calibrate for the heat flow and 
heat capacity of the instrument. 
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MDSC Experimental Protocol: 
The experimental protocol is provided in Fig. B-V-2. The glass transition temperatures of 
samples (8-l 2mg) were determined by first heating to 25°C above the T g (Tr in Fig. B-V-
2), to erase the thermal history, and then quench cooling to l 50°C below their Tg (T0). 
The Tg was detected upon a second heating scan as the midpoint of the inflection in the 
heat capacity or the reversing heat flow signal. A heating rate of 3°C/min, with 
modulations of ±I 0 every 60 seconds was used for all analysis. Following the Tg 
determination, the samples were aged at T., which were 5°, 15° and 30°C below the 
respective T g for a period (T,) of 1, 2, 4, 8 and 16 hours. At the end of each aging period, 
samples were rapidly cooled to l 50°C below the T g and subsequently reheated to 25°C 
above the Tg. The enthalpy-recovery of the aged samples (t.H) was obtained as a function 
of aging time and temperature, from the area under the non-reversing heat flow signal at 
Tg. 
Thermally Stimulated Polarization Current (TSPC): 
The principle of TSPC is depicted schematically in Fig. B-V-3 . The sample is heated 
across its transition temperature(s) in the presence of a high voltage electric field and the 
movement of the polar groups (dipoles) of molecules is measured as they orient to the 
applied field. The sample is placed between two electrodes of a parallel plane capacitor. 
As the temperature is increased, the molecular mobility rises and the dipole orients to the 
applied field when sufficient mobility exists. The motion of the dipole generates a 
polarization current (I) which is amplified and detected. The intensity of the polarization 
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current (output signal) provides a direct probe into the degree of molecular mobility of 
the materials as a function of temperature. 
Thermally Stimulated Depolarization Current (TSDC): 
The TSDC experiments are similar to TSPC measurements, with an exception that the 
samples are first heated to temperature above the suspected transition and are then 
polarized by applying an electric field. The polarization is frozen by rapidly cooling the 
samples to low temperatures. The depolarization current (opposite in direction to 
polarization current) is measured in the absence of electric field, by heating the sample 
across the suspected transition(s). The driving force for molecular motion upon reheating 
the sample is the restoration of neutrality or the original configuration. The molecular 
motion causes a depolarization current which is amplified and detected. The glass 
transition temperature is characterized by the temperature of peak maximum of the broad 
peak as shown schematically in Fig. B-V-3b. 
TSPC Experimental protocol: 
In this study, TSPC experiments were perfom1ed unless specified. TSPC or TSDC 
experiments were carried out using TSC/RMA 9000 Instrument (TherMold Partners, 
Stamford, CT). All experiments were conducted in an atmosphere of high purity helium 
gas. Samples (13.5 ± O.Smg) were placed in aluminium pans, covered with teflon lid and 
placed between the screw electrodes. This assembly was enclosed in a Faraday cage that 
was evacuated to 104 mbar and flushed several times with helium gas prior to 
experiments. The experimental procedure used to measure enthalpy recovery using TSPC 
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is depicted in Fig. B-V-2 . As seen from Fig. B-V-2, in step 1 and 2, the thermal history of 
all samples was erased by heating to Tg + 25°C followed by a rapid cooling to Tg -
l 50°C. The glass transition temperature of the samples was then determined by heating 
the samples at 3°C/min in the presence of electric field (step 4). The samples were kept 
isothermal at step 5 in the absence of electric field and were quench-cooled (step 6) to 
form the fresh amorphous sample. Isothermal storage was carried out in step 7 for period 
of 0-8 hours in the absence of the field and the current produced due to molecular motion 
of the aged samples were recorded in step 8 in the presence of electric field by heating at 
3°C/min. During isothermal storage, the electric field was turned off in order to 
eliminate any possible effects on enthalpy relaxation of samples and to closely match the 
treatment with MDSC. As with the MDSC experiments, the Ta was varied from 5°, 10° 
and l 5°C below the respective Tg. An electric field of 175 V/mm was employed for all 
TSPC studies. Aging time varied as 0.25, 0.5, 1, 2, 4, 6 and 8 hours. 
RESULTS AND DISCUSSIONS 
Characterization of poly (vinylpyrrolidone): 
MDSC: 
The changes in heat capacity for different molecular weight grades of PVP obtained 
using MDSC are shown in Fig. B-V-4a. Glass transition temperatures T g, is denoted as 
the midpoint of inflection in the heat capacity step-change. As seen from the Fig B-V-4a, 
each molecular weight grade of PVP exhibits a characteristic Tg that increased with an 
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increase in the molecular weight. ln addition, an increase in the heat capacity step-change 
!!. Cp was also observed with increase in the molecular weight. 
TSPC: 
In Fig. B-V-4b, thermally stimulated depolarization current (TSDC) profiles for PVP 
K30 is shown. Unlike the MDSC plots, two distinct global relaxations peaks designated 
as P1 and P2 were seen at temperatures near I 30°C and I 75°C respectively. The 
depolarization currents were found to be reproducible and are representative of the 
molecular motions of polymer. The current peak at P2 had a peak maximum temperature 
(T2.,.,), that corresponded to the Tg obtained from the MDSC experiments for PVP K30. 
Similarly the T2max of a specified polymer corresponded to respective Tg obtained from 
MDSC as seen in Table B-V-1. In addition, the current intensity was proportional to the 
applied electric voltage, indicating that the signal generated was indeed from the sample 
and not due to any mechanical or charge dissipation. 
It was interesting to see that there was a difference of at least 30°C between the two 
depolarization peaks Pl and P2 for all molecular weights reported so far. The peak 
differences may indicate entirely different modes of molecular motion. 
It is generally understood that the activation energy (Eae1) for the relaxation of dipoles is 
not singular in nature and is a function of temperature [ 17]. Usually there is no significant 
difference between the activation energies for dipole relaxations that constitute a specific 
molecular motion e.g. side chain motion of a polymer, enthalpy relaxation, main chain 
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relaxation etc. In such cases, the Eae1 of different dipoles that constitute the overall 
relaxation overlaps to result in a continuous distribution as a function of temperature. The 
result is a single broad peak in the depolarization or the polarization current output. In the 
present case, however, a difference of at least 30°C was seen between two peaks 
indicating that molecular motions ti-om entirely different domains exist. This can be 
explained further by noting that the dipolar side group - pyrrolidone can rotate locally 
through its C-N amide linkage, besides moving in union with the main chain . With 
increase in temperature, a ' localized cooperative rotational relaxation motion' of the 
pyrrolidone side group is possible and this may constitute the P- current peak (P1). A P-
relaxation peak has been reported fo r PVP samples containing 23% w/w water at - 60°C 
using dielectric analysis [18]. ln a different study, PVP was shown to exhibit P-relaxation 
at approximately -73°C (MW 40 KDa) [ 19]. A similar explanation for P-relaxation peak 
was given in the case of polyester liquid crystalline polymer films, polycarbonate phenyl 
rotation, polystyrene phenyl rotation etc. [20]. 
The molecular motions of PVP that are believed to be due to the cooperative rotational 
motion of the side chains did not produce appreciable changes in the heat capacity and 
therefore remained undetected by MDSC. At higher temperature regions, the main chain 
motion results in the CL- peak (P2) that is characterized by the glass transition temperature 
by MDSC as well. Moreover, since the two dipole peaks are broad, they can be 
considered to occur ti-om distribution of Eact of several side group and main-chain 
dipoles. We also observed that with an increase in the applied voltage, the intensity of 
polarization current increases at P 1 and P2. This phenomenon further indicated that the 
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peaks are indeed due to the molecular motions in the sample rather than resulting from 
di ssipation of unknown trapped charges or any other mechanical stress. 
Enthalpy relaxation measurements with MDSC and TSPC: 
The protocol described in Fig. B-V-2 was followed to understand the structural relaxation 
behavior in PVP. 
Enthalpy relaxation measurements using MDSC: 
The non-reversing heat flow signals of different molecular weight grades of PVP that 
were aged at an aging temperature (T,) of l 5°C below the respective Tg is shown in Fig. 
B-V-5. An increase in the area under the non-reversing heat flow was observed with 
aging time for all the three polymers. As the sample was held isothennally at temperature 
below its Tg, it underwent structural relaxation process, which led to its densification. The 
increase in the area under the curve is due to the increasing magnitude of heat input that 
is necessary to overcome the densified state of the polymer and to reach the supercooled 
equilibrium state. In addition, the temperature of heat-flow maximum (Tn,,x) shifts to 
higher values, indicating the need for higher energy of activation to mobilize the 
structurally relaxed segments of the polymer. These results are consistent with the results 
published by other groups [21 ]. The enthalpy recovery values were obtained by 
integrating the area under the curve and were plotted as a function of aging time (Fig. B-
V-6). No significant differences were seen in the enthalpy recovery values for a 
corresponding aging time and temperature for the samples with different molecular 
weights. 
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Estimation of relaxation time constants: 
From the enthalpy relaxation measurements, it appears that significant molecular 
mobility exists below the glass transition temperature. ln order to compare the degree of 
molecular mobility between different polymers, it is necessary to calculate their 
relaxation time constants ("r). Relaxation time constants (-r) is the average time taken for 
one relaxation event. These constants can be calculated by fitting the enthalpy recovery 
data to stretched-exponential equation known as Kolrausch-William-Watts equation [22, 
23) and obtaining adjustable relaxation time constants T and Pas follows : 
(1) 
where<P is a distribution function of different relaxation times occurring for a specific 
molecular relaxation process, t is the storage period, -r is the mean relaxation time 
constant and j3 is the relaxation time distribution parameter with a values between 0 and 
1. 
The relaxation distribution function can be obtained from the enthalpy recovery 
measurements by using the relationship: 
(2) 
where<P, is the extent to which the material relaxes; !!Ji, is the experimentally measured 
enthalpy recovery and !!Ji w is the enthalpy recovery of a fully relaxed material. !!Ji w is 
calculated as : 
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Ml~ =(T, -T)t:,Cp (3) 
where Tg is the glass transition temperature, T is the experimental storage temperature 
and t:,C Pis the heat capacity step-change at the glass transition. 
By rearranging and equating equation 1-3, an expression to estimate the relaxation time 
constant can be obtained as follows: 
(4) 
The experimental enthalpy recovery values were then fit to equation 4, using 
MicroMath® Scientist software (version 2.0) to obtain i: and p values (Table B-V-1). The 
initial values of i: and p were taken as 100 hours and 0.5 respectively as performed 
similarly elsewhere [24). 
The empirical KWW function has been shown to describe the various relaxation 
processes of amorphous materials during enthalpy relaxation process [25) . However data 
interpretation should be done cautiously, because distribution of the relaxation time 
constants is as much important as the average relaxation time constants to access 
information pertaining to molecular mobility and associated stability. In Table B-V-11 the 
average relaxation time constants along with their distribution have been reported for 
average of triplicate measurements for different molecular weight grade samples at 
different aging temperatures. A plot of logarithm of relaxation time constants (hr"1) vs. 
ratio ofTg and storage temperature (T,) is shown in Fig. B-V-7. As seen from the figure, 
mean relaxation times are non-exponential and decrease non-linearly with an increase in 
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storage temperature for all the polymers. This agrees with the literature findings for the 
non-linear dependency of relaxation time to temperature below the glass transition 
temperature [26]. Similarly a decrease in the mean relaxation time indicates an increase 
in the molecular mobility. Such a pattern is expected since the molecular mobility is 
known to increase with an increase in temperature. Further, the relaxation time constant 
for all the polymers tend to approach each other near the T g· 
Enthalpy relaxation measurements using TSPC: 
Since the electric field was turned off in TSPC measurements during sample aging, a 
comparison of enthalpy relaxation measurements between the two techniques is valid. 
When the samples were heated following the protocol described in Fig. B-V-2, a series of 
relaxation process generate the electrical signal. Jn step 1 and 2, heating the samples to 
temperatures above T g removes any electric and/ or mechanical stress, which otherwise 
would have produced noise peaks in TSC analysis. Also the thermal history of the 
samples was erased in steps 1 and 2 to generate 'fresh' amorphous samples. ln step 3, the 
samples were stored at very low temperatures, and hence the dipoles were kinetically 
frozen. The mean relaxation time (i:) (i.e. average time taken for one molecular motion to 
occur) is very large at low temperatures and thereby no molecular mobility and hence 
polarization current was generated. As the samples were heated in step 4, the relaxation 
time of the dipoles decreases, and at a given temperature domain, the rate of molecular 
relaxation matches the experimental time scales thus producing polarization current. The 
temperature where the polymer main chain exhibits maximum mobility (i.e. peak 
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polarization current) is the glass transition temperature. In step 5, beyond the glass 
transition temperature, the average relaxation time of the molecules exceeds the heating 
rate and the motion of dipoles cancel out. The net current thereby lowers and eventually 
decays to the baseline. 
The TSPC scans of PVP K 17 and PVP K30 that were aged at I 5°C below their respective 
T g for a period of up to 8 hours are shown in Fig. B-V-8. The TSPC scan demonstrates 
two distinct global relaxation peaks analogous to the TSDC scans except for the negative 
sign. As a trend, for either polymers, the peak area at PI decreased in magnitude whereas 
the peak area at P2 increase with aging time. However, the total area under the peaks at 
P 1 and P2 remained constant. 
Polarization current at P1 and Pi: 
The reduction in the area of current at P1 was observed in case of all different molecular 
weight grades of PVP. Since the aging temperature (T,) was always greater than the 
temperature domain corresponding to P1, the dipoles responsible for producing current at 
P 1 could always be considered to be in a state of sufficient mobility so that aging does not 
influence them. Hence one would expect no change in their polarization current intensity 
with aging time, when compared to that of a freshly prepared amorphous sample. 
However a decrease in the polarization current peak suggesting a progressive decrease in 
the molecular mobility of dipoles was observed. An explanation to such behavior could 
be the possible entrapment of side chains of the polymer with the main chain upon 
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densification. Upon subsequent heating of sample at the end of aging, cooperative 
molecular motions between the molecular side chains and the main chain could possibly 
explain the reduced mobility and hence polarization current. When the samples are 
heated above their T g, the main chain and side chains are free of conformational 
restrictions and could be considered 'fresh'. 
The area under the polarization current peak at P2 was seen to increase with aging period 
unlike the peak at P1. Also an increase in Tmax (i .e. temperature corresponding to peak 
maximum intensity) at P2 was seen as function of aging time (Figure B-V-8). The 
increase in the area under signal at P2 is analogous to the increase in the enthalpy 
relaxation endotherrn that is obtained at Tg from MDSC measurement. Since the aging 
temperature is below the temperature domain corresponding to P2, as the sample ages, it 
undergoes structural relaxation to attain the equilibrium state. The density of sample 
increases with an associated decrease in the free-volume. When the sample is reheated, 
the densified molecules regain their super-cooled state at their Tg. During this process, an 
increase in the molecular mobility, most likely due to a "burst effect", causes an increase 
the area of current at P2• This increase in the area at P2 was found proportional to the 
aging time. 
Polarization current peak cleaning (P1) : 
Based on the data generated so far it was not possible to obtain the enthalpy relaxation 
due to aging at the Tg, primarily due to interference from peak P1• Therefore the 
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polarization peak at Pl was 'removed' by modifying the experimental protocol. The 
modified protocol is shown in Fig. B-V-9. As seen from the protocol , a polarization step 
for (T p) 15 min. was added at the end of each aging period (step 6) to polarize the dipoles 
responsible for peak P 1• Since the samples were rapidly cooled (step 7) in the presence of 
electric field, the now polarized dipoles responsible for P1 remained in a frozen polarized 
state. Upon subsequent heating, the polarized dipoles would not produce any significant 
polarization current in the presence of electric field and the motion of main chain alone 
could be characterized. 
Following this protocol, the modified TSPC plots of PVP samples after aging for periods 
up to 8 hours are shown in Fig. B-V-10. No polarization current peak at P1 was seen in 
these scans when compared with TSPC plots in Fig. B-V-8. Favorably, the area under the 
polarization current peak at P2 could now be integrated. This area when subtracted from 
the area of polarization current due to freshly prepared amorphous sample provided the 
cumulative molecular mobility of all the dipoles that underwent enthalpy recovery. 
Correlation ofTSPC and MDSC results to estimate molecular mobility: 
Plots of cumulative normalized area of PVP samples after aging for a period up to 8 hrs 
following modified TSPC method are shown in Fig. B-V-11. Similar to the MDSC 
experiments, an initial increase in the polarization current followed by a plateau in the 
cumulative area under the peak at P2 was observed with the TSPC (modified) 
experiments. This indicated that the heat flow involving and non- heat flow involving 
techniques characterize the same phenomenon however in a different fashion. ln MDSC 
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experiments, the heat input that is necessary to bring the structurally relaxed state of 
material to its super cooled state is measured. Whereas in TSPC, the molecular mobility 
generated when the structurally relaxed material regains its equilibrium state is obtained 
from the polarization current. Therefore, the two techniques correlate in principle. ln 
order to investigate if the experimental results correlated a plot of the net current 
generated at peak P1 of structurally relaxed material and the enthalpy of recovery of the 
material that were aged for the same duration at a given aging temperature was 
constructed (Fig. B-V-8). An empirical linear relationship was observed between the data 
generated from the enthalpy recovery (MDSC) and the molecular mobility recovery 
(TSPC) techniques. 
The slope of the linear line should then represent the rate of enthalpy relaxation, which 
indicates the extent of molecular mobility. Therefore, the relative extent of molecular 
mobility of a polymer at a specified storage temperature below its respective glass 
transition temperature could be obtained. From Fig. B-V-8, the slope of linear equation 
for the polymer samples decreases in the order PVP Kl 7 > PVP K90 > PVP K30. This 
suggests that the molecular mobility is highest for PVP K 17 (Mw - 10 KDa ± - 5KDa) 
and least for PVP K30 (Mw - 58 KDa ±-5KDa). Although it is intuitive to expect a 
decrease in the molecular mobility between PVP K17 and PVP K90 (Mw- 130KDa± 
- 5KDa), due to a reduction in the molecular weight, it is counter-intuitive to expect PVP 
K90 to have higher degree of mobility when compared to PVP K30. The mean relaxation 
time data (Fig. B-V-5) also suggest the rank order for decrease in the molecular mobility 
as PVP Kl 7 > PVP K90 > PVP K30, which agrees with TSPC results. It is not 
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completely clear as to why there is such a trend in the results. One possible explanation 
for such a behavior could be the heat capacity step-change (ti. Cp) at the Tg for the 
polymer, which is the indicator of the non-equilibrium state of the amorphous phase with 
reference to its extrapolated supercooled liquid state (Fig. B-V-1 ). A larger heat capacity 
step-change (L\.Cp) at Tg would imply a greater driving force for the sample to reach 
equilibrium and hence a greater degree of molecular mobility. The higher (ti. Cp) values 
for PVP K90 when compared to PVP K30, could possibly explain for the higher degree 
of mobility in the former. However, there seems to be a balance between the two factors 
of molecular weight and heat capacity change at Tg, since although the (L\.Cp) values for 
PVP K90 is greater than PVP Kl 7, the large differences in their molecular weights could 
potentially guide the extent of molecular mobility. 
CONCLUSIONS 
In this study, we have estimated the relative extent of molecular mobility as a function of 
molecular weights for three different grades of PVP. Two analytical instruments which 
measure on different principles, one that involves heat-flow measurements and the other 
that involves a direct measurement of molecular motions, were compared. 
MDSC was used to perform enthalpy relaxation measurements to gain insight into the 
extent of molecular mobility of PVP at different aging temperatures immediately below 
their respective glass transition temperatures. The mean relaxation time constants were 
obtained by fitting the experimental results to the William-Watts equation using non-
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linear regression analysis. The mean relaxation time decreased, indicating an increase in 
the molecular mobility, as the storage temperature was approaching the Tg. 
TSC measurements revealed presence of two different global relaxation peaks in the 
polymer. The peak at lower temperatures was considered as the sub-glass transition peak 
due to the motions of the side-chain of the polymer. The intensity of current at Tg 
increased in proportion with aging of the samples analogous to the MDSC results. A 
linear empirical relation was established between the enthalpy recovery measurements 
(MDSC) and the molecular mobility recovery experiments (TSPC). To conclude, TSC 
can be used as a sensitive complimentary tool to characterize the molecular mobility of 
drug substance, polymers and their solid dispersions. 
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Table B-V-1: Characterization of relaxation temperatures in PVP 
Polymer Tg Sub-Tg llCp atTg 
(OC) (OC) (J/g/OC) 
MDSC TSC MDSC TSC (x 10) 
PVP Kl7 117±0.6 138-141 N/D* 80-85 2.560 ± 0.22 
PVP K30 165±0.7 175-179 N/D* 130-135 2.658 ± 0.017 
PVP K90 176 ± 0.4 178-182 N/D* 140-145 2.818 ± 0.058 
* Not Detected 
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Table B-V-11: Average relaxation time constants obtained from enthalpy relaxation 
measurements 
Super- Polymer Average Distribution !:i H., 
cooling relaxation time parameter of (J/g) 
constant relaxation time 
t 
Tg-5°C PVP Kl7 9.8008 0.37724 1.28 
PVP K30 10.2705 0.3943 1.2911 
PVP K90 12.192 0.18899 1.3885 
Tg-15°C PVP K17 25.879 0.33294 3.8400 
PVPK30 57.660 0.23877 3.8733 
PVP K90 12.704 0.42671 4.1655 
Tg-30°C PVP K17 443.59 0.39169 7.6800 
PVP K30 2473.0 0.39514 7.7466 
PVP K90 829.00 0.42273 8.331 
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Figure B-V-1 
Schematic representation of the glass transition temperature (Tg) and loss in enthalpy 
during aging studies 
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Figure B-V-2 
Experimental protocol for conducting enthalpy relaxation (MOSC) and mobility recovery 
(TSPC) experiments. The bold lines indicate zones where the data are recorded. For 
TSPC measurements, the electric field is turned on during this period. The dotted line is 
the Tg of the polymer. T0 is the initial temperature (150°C below T g); T, is the aging 
temperature (varies from 5° to 30°C below Tg); and Tris the final temperature (15°-20°C 
above the T g). The significance of numbers is provided in the text. 
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Figure B-V-3 
(a) Schematic demonstration of the principle of Thermally Stimulated Currents. 
Reproduced from www. setaram. com (b) Schematic demonstration of the glass transition 
phenomenon in typical thermally stimulated depolarization current experiment. 
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Figure B-V-4.a 
(a) MDSC heat capacity scans of PYP demonstrating the T g and the heat-capacity step 
change at Tg. A single Tg is noticed for all the three molecular weight grades of PVP. 
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Figure B-V-4.b 
(b) Thermally Stimulated Depolarization Currents of PVP K30 demonstrating two 
different global relaxation peaks: P1 and P2. 
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Figure B-V-5.a 
MDSC non-reversing heat flow scans demonstrating the enthalpy relaxation of PYP with 
storage time at l 5°C below the respective Tg: for PYP Kl 7; 
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Figµre B-V-5.b 
MDSC non-reversing heat flow scans demonstrating the enthalpy relaxation of PVP with 
storage time at l 5°C below the respective Tg: for PVP K30; 
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Figure B-V-5.c 
MDSC non-reversing heat flow scans demonstrating the enthalpy relaxation of PVP with 
storage time at 15°C below the respective T8: fo r PVP K90; 
0.075 
0.065 
0.055 
0.045 
0.035 
160 165 170 175 180 185 190 195 
Temperature {°C) 
187 
Figure B-V-6 
Enthalpy relaxation of PVP obtained using MDSC with storage time at 15°C below the 
respective Tg. (a) PVP Kl 7; (b) PVP K30; and (c) PVP K90 
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Figure B-V-7 
Variation oflogarithm of relaxation time constant ('t) with scaled temperature Tgrr., 
obtained using fitting the enthalpy relaxation data to the empirical KWW stretched non-
exponential equation . ... PVP K 17; e PVP K30; and • PVP K90. 
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Figure B-V-8 
Thermally stimulated polarization currents of (a) PVP Kl 7; and (b) PVP K30 undergoing 
structural relaxation at Tg-l 5°C. With storage time, the sub-Tg peak decreases in its area 
while the Tg peak increases for both the polymers. 
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Figure B-V-9 
Modified experimental protocol for structural relaxation ofthennally stimulated 
polarization currents. An additional isothermal step # 6 for 15 min. is added at the end of 
aging period with the electric field turned ON. 
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Figure B-V-10.a 
Thennally stimulated polarization currents following the modified experimental protocol 
for PVP Kl 7 that was aged at Tg-l 5°C. Using the modified protocol, the sub-Tg peak 
current peak is not produced (compare with Fig. B-V-8). 
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Figure B-V-10.b 
Thermally stimulated polarization currents following the modified experimental protocol 
for PVP K30 that was aged at Tg-l 5°C. Using the modified protocol , the sub-Tg peak 
current peak is not produced (compare with Fig. B-V-8). 
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Figure B-V-10.c 
Thermall y stimulated polarization currents fo llowing the modified experimental protocol 
for PVP K90 that was aged at Tg-15°C. Using the modified protocol, the sub-Tg peak 
current peak is not produced (compare with Fig. B-V-8). 
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Figure B-V-11 
Net current (i.e. difference in the area under current at Tg peak of structurally relaxed 
sample and fresh sample) plotted against the storage time for PVP aged at respective Tg-
I 50C. (a) .& PVPK17;(b)ll PVPK30;and(c:. PVPK90. 
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Figure B-V-12 
Relationship between the enthalpy recovery measurements from MDSC and mobility 
recovery measurements from modified TSPC. The slope ofline is indicative of relative 
rate of relaxation and hence molecular mobil ity. 
,-._ 
bll 3.5 
-~ PVP K30 
'-' 
;;.-, 3 / y = 0.0558x + 1.7831 ""' Q,> R2 = 0.8262 > 2.5 Q I PVPK90 (j Q,> ""' ...... PVPK17 Q 
1.5 ;;.-, t y = 0.2212x - 2.6645 
Q., R2 =0.9383 
<:.: 
..c: 
..... 
= 0.5 
~ 10 20 30 40 50 60 
Net Current@ Tg (x 1012 Amperes) 
196 
SECTIONC 
APPENDIX A 
Principles of Modulated Differential Scanning Calorimeter 
Differential Scanning Calorimeter (DSC): 
The principle of DSC is to heat the sample and reference pan at a linear rate and measure 
the heat flow absorbed by the sample (endothermic) or liberated from the sample 
(exothermic) when it undergoes a physical or chemical transformation. Thermal events 
like melting, glass transition, enthalpy relaxation and dehydration are some of the 
endothermic events; whereas recrystallization and most decomposition are part of 
exothermic processes. The heat flow differences between the sample and empty pan are 
accurately measured (expressed in mW) and are used to quantify the magnitude of 
transformation. 
One of the limitations of DSC is the difficulty in interpreting the heat flow if multiple 
processes are involved over the same temperature range. For instance, a moisture removal 
and glass transition processes can occur between 60° - I 00°C, and hence it is not possible 
to resolve the two signals. The sensitivity of the experiment can however be improved by 
decreasing the sample mass or heating rate; whereas the resolution to separate transitions 
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can be increased by increasing the sample mass or heating rate. Therefore to obtain a 
balance between the sensitivity and resolution is challenging. 
Modulated Differential Scanning Calorimeter {DSC): 
Modulated Differential Scanning Calorimeter (MDSC, trade mark of TA Instruments 
Inc.,) has developed a technique that heats the sample by applying sine wave modulations 
to an underlying standard linear heating rate. By choosing a suitable modulation 
parameter that includes an amplitude and period of osci llation, complex heat flow 
processes can be resolved with greater sensitivity. The heat flow data is deconvoluted 
into reversing and non-reversing heat flow signals using a discrete Fourier Transform 
algorithm [I]. The reversing heat flow involves transformations like glass transition 
phenomenon, melting, and dehydration whereas the non-reversing heat flow signal 
detects enthalpy relaxation, recrystallization, moisture loss, and decomposition. The other 
advantages of MDSC include the measurement of heat capacity and heat flow in a single 
experiment; separation of complex transitions into more easily interpreted components 
and increased sensitivity and resolution for detection of weak transitions with accuracy 
for measurement of crystallinity and amorphous contents. 
Principles of Operation: 
In DSC, the differential heat flow or heat flux is expressed using the thermal equivalent 
of Ohm's Law as: 
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where dQ = heat flow 
dt 
t:i.T = temperature difference between the reference and sample 
R0 = thermal resistance of constantan disc 
(1) 
In MDSC, the same heat flux is modified using sinusoidal temperature oscillation. The 
heating rate is dependent upon three experimental variables: underlying heating rate, the 
amplitude of modulation and the period (frequency) of modulation. 
A different way of expressing equation 1 is as follows: 
dQ = C (dT)+ f(t .T) 
dt p dt 
where dQ = heat flow 
dt 
dT . 
- = heating rate 
dt 
Cp = thermodynamic heat capacity 
t = time; T = absolute temperature 
(2) 
f (t, T) = function of time and temperature which governs the calorimetric 
response of kinetically controlled chemical or physical phenomenon. 
In equation 2, the heat capacity term is expressed as the reversing heat flow and the 
kinetic events are expressed as the non-reversing heat flow. 
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Discrete Fourier Transformation [2] is used to deconvolute the heat flow signals as 
follows: 
CP =Kc, •(Q•.,PJ•(Per:d) 
Tamp 2 
where Cp = Heat capacity (J/g/0 C) 
Kcp = Heat capacity calibration constant 
Qamp = Heat flow amplitude (mW) 
Tamp= Temperature amplitude (0 C) 
Period = Modulation period (sec). 
The heat capacity term multiplied by underlying heating rate gives the reversing heat 
flow. The non-reversing heat flow is obtained from the difference between the total heat 
flow and the reversing heat flow signals. 
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Figure A-I 
A schematic of the cross-section of a typical MDSC sample cell is reproduced from the 
operating manual TA Instruments for Modulated DSC. 
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APPENDIX B 
Phase Behavior of Amorphous Molecular Dispersions: Determination of the 
Degree and Mechanism of Solid Miscibility 
(Supporting data to chapter 1) 
Figure 8-1 
Chemical structures of(a) Trehalose; (b) Dextran and (c) PVP 
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Figure B-2 
(a) X-ray diffraction patterns oftrehalose dihydrate untreated and lyophilized. 
Lyophili zed trehalose is rendered amorphous. (b) X-ray diffraction patterns of 
lyophilized dextran and solid dispersions of dextran containing 50% and 90%w/w 
trehalose showing their amorphous nature. 
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Figure B-3 
Moisture sorption and de-sorption profile oftrehalose at 25°C [sorption (O); de-sorption 
PJJ. The sudden change in the rate of moisture uptake oftrehalose at relative humidity 
greater than 45% indicates the crystall ization. Recrystall ized trehalose is very stable even 
at 5%RH since no significant weight loss is observed in the de-sorption profile. 
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Figure 8-4 
Reproducibility MDSC reversing heat flow of 40%w/w trehalose-in-dextran showing the 
phase separation and crystallization oftrehalose 4 days storage at 50°C I 75%RH 
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Figure B-4 
Reproducibility MDSC reversing heat flow of 40%w/w trehalose-in-dextran showing the 
phase separation and crystallization oftrehalose 13 days storage at 50°C I 75%RH 
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Figure B-5 
Reproducibility MDSC reversing heat flow of 40%w/w trehalose-in-dextran showing the 
phase separation and crystallization of trehalose 23 days storage at 50°C I 75%RH 
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Figure B-6 
Reproducibility MDSC reversing heat flow of 40%w/w trehalose-in-dextran showing the 
phase separation and crystall ization oftrehalose 34 days storage at 50°C I 75%RH 
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Figure B-7 
MDSC reversing heat flow of 40%w/w trehalose-in-dextran showing the phase separation 
and crystall ization oftrehalose stored at 23°C I 75%RH 
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Figure B-8 
MDSC total heat flow of 40%w/w trehalose-in-dextran showing the plasticized T g and 
crystallization oftrehalose when stored at 40°C I 75%RH 
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Figure B-9 
MDSC reversing heat flow of 30%w/w trehalose-in-dextran showing the phase separation 
and crystallization oftrehalose stored at 40°C / 75%RH 
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Figure B-10 
MDSC total heat flow of30%w/w trehalose-in-dextran showing the plasticized Tg and 
crystallization of trehalose when stored at 40°C I 75%RH 
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Figure B-11 
MDSC total heat flow of30%w/w trehalose-in-dextran showing the plasticized Tg and 
crystalli zation of trehalose when stored at 50°C I 75%RH 
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Figure B-12 
MDSC reversing heat flow scans of physical mixture (I: I) of amorphous trehalose and 
dextran showing that liquefied trehalose does not plasticize dextran by mixing with it 
during heating at I °C/min. 
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Figure B-13 
MDSC reversing heat flow scans of 10%w/w trehalose-in-dextran solid dispersions 
prepared below the solid solubility limit. Physical stability is observed by the absence of 
melting endotherm of crystalline dihydrate at 96°C or increase in the Tg value to 225°C 
from the initial value of 210°C for freshly prepared sample. 
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Below are some of the comments (bold) of the anonymous reviewers when the 
manuscript was submitted to Phannaceutical Research. Our response follows. The 
manuscript was accepted for publication. 
"There is no conclusive evidence to show that water is not responsible for Tg2 
reduction. It is a well known plasticizer. Perhaps, an experiment with different RH 
values and same temperature would have delineated this effect. How do you explain 
the reduction of Tg2 (207 - 210) at 40175 as compared to 196-203 at 23175? Also, in 
the dextran-trehalose mix, the solid solubility decreased from 18 to 12% when the 
water content decreased from 16.5 to 11 %. Therefore, moisture also does seem to 
have an effect on Tg2 reduction." 
Response: We also demonstrated that water acts as a plasticizer. It reduces the Tg of the 
mixtures to 22-25°C as shown in Fig. B-14. However, the reduction that we see in the Tg 
values in our experiments is due to the "solubilized" trehalose. 
During the DSC experiments, water is driven away from the sample (8-12 mg), when it 
is slowly heated at t °C/min rate, at temperatures above 100°C. 
To test whether the reduction in T g2 values was the result of the moisture retained in the 
dispersions, dextran (containing no trehalose), which was previously exposed to 50°C I 
75% RH for a month and contained l 1% w/w water, was heated. Its Tg2 was 225°C 
(Fig.B-15); which was identical to the T g of original sample that had - 3% w/w moisture 
content. Th.is finding indicates that water did not influence the T g2 values during the 
heating scan in DSC. 
Secondly, the Tg2 values of heat flow scans of l 0% w/w trehalose-dextran mixtures that 
were exposed to various stability conditions and contained varying levels of moisture are 
demonstrated in Fig B-16. They all are consistent with that of the freshly prepared 
samples (Fig. 2a in the manuscript) indicating that moisture did not influence Tg2. 
2 16 
Reduction in Tg2 (from 225°C) can be explained by the solubilization of trehalose in the 
polymer. For instance, trehalose mixtures above their solubility limit (i.e. 20%, 30%, 
40% and 70%) were crystallized when they were exposed to stability conditions and their 
Tg2 values increased to 207-2 I 0°C (at 50°C/75% RH). On the other hand, the samples 
containing I 0 % trehalose (the concentration below the solubility limit), showed no 
crystallization and Tg2 changes confirming that, reduction in Tg2 values reflects the 
complete miscibility oftrehalose with the polymer. 
Water however, seems to impact Tg2 by facilitating the phase separation and 
crystallization of trehalose, as described in detail on PI 2, under "Mechanism of phase 
separation and solid solubility". Our data demonstrates that T g2 values of the samples 
were 196-203°C at 23°C 175% RH and 207-210°C at 40°C 175% RH. Such a change in 
Tg2 values, which corresponded to a decrease in solid solubility from I 8% to I 2%, is 
probably due to the increase in storage temperature as described on PI 5 under "Effect of 
temperature and moisture on solid solubility". Nevertheless, the temperature cannot be 
the only factor since no significant difference in solubility, was noticed between 40°C I 
75% RH and 50°CI 75% RH given the RSD. Therefore, water may have an affect on the 
Tg2 values by altering solid solubility. 
We have ongoing studies specifically addressing the impact of temperature and moisture 
on the solid solubility. We plan to submit that work to this journal as a follow up study. 
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Figure B-14 
MDSC scans showing the plasticized Tg values of 40% w/w trehalose in dextran mixtures 
that were exposed to 50°C/ 75%RH conditions. 
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Figure B-15 
DSC scans of dextran that was exposed to 50°C/75%RH for one month and containing 
11 % w/w moisture. The sample was heated in MDSC at the rate of I °C/min, with 
±0.266° every 50seconds to 240°C. 
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Figure B-1 6 
MDSC reversing heat flow scans of I 0% w/w trehalose-dextran mixtures that were 
exposed to stability conditions. No crystallization of trehalose was observed. Also the 
Tg2 values were consistent with Tg of freshly prepared sample (- 210°C). 
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"It would always be good to support the DSC characterization with other methods 
such as X-ray diffraction, NMR, FfIR etc. Is it possible to show any evidence of H2 
bonding for the reduction of Tg2 as claimed? The deviations in fig 2 arc not 
conclusive." 
Response: The FTIR spectroscopy was perfonned on the freshly prepared samples to 
detennine the nature of interactions between trehalose and dextran. However, no 
meaningful interpretation of the -OH stretch (free vs. bound), could be made as a result 
of the presence of multiple hydroxyls of trehalose, dextran and water (Fig. B-17). XRD 
and NMR were not used for these mixtures due to accessibility problems. Currently we 
have easier access to XRD and are using it as the supporting tool in the remaining 
studies. 
Regarding the concerns that you raised about the certainty of deviations in Fig. 2, we can 
only say that the experiments were carried out with three batches and our standard 
deviations were very small. 
22 1 
Figure B-17 
Hydroxyl stretches of freshly prepared trehalose-dextran amorphous mixtures as obtained 
with FT-IR. 
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" It is so easy to identify Tg in Figs. 2a & 2b. However, it is not so apparent to 
believe Tgl and Tg2 in Figs 3a & 3b. Can a raw MDSC heat flow plot be shown to 
demonstrate the existence of Tg in those cases?" 
Response: Thank you. A raw MDSC heat flow plot is now shown. 
Figure B-18 
MDSC raw heat flow scans to depict the presence ofTg1 and Tg2 values 
a-tt : k •:Tlti: .. m-c .:,...,. :._. 
:it:z : s.u:o-. 
Ut ,..,,. :Tt .. "cl 
C-..t lift.11 -.V1;, .,. 411rc -.o.:iwc.'SO:oc 
DSC 
- : 1:r.;o:x>11k 1Tlt S.oe 10-
~;l,bll\IW 
,..., fff :W-k~ I: : .. 
-0.020 409/• wlw trehalose mixture exposed lo S0°C/7S°le RH for 2 days 
~ 
=:: -0.030 
" ;.: 
202.91 "C( 
50 JOO I SO 200 250 
Temperature 
-0.020 ~---------------------
40% w/w trchalose mixture exposed to 50°C/75o/o RH for 4 days 
-0.025 
50 100 150 200 250 
Temperature 
223 
~ 
Figure B-19 
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Figure B-20 
MDSC scans showing the plasticized T g values of 40% w/w trehalose in dextran mixtures 
that were exposed to 50°C/ 75%RH 
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"Why there arc no recrystallization/melting peaks in Fig. 3? If the phase 
segregation happened as illustrated in Fig. 7, anhydrate form could be formed. 
Why not?" 
Response: Yes it could. However, under hot-stage microscope, we observed that 
trehalose undergoes the glass transition and subsequently liquefies before nucleating to 
anhydrate form . The presence of polymer is likely to inhibit the nucleation of anhydrate 
form and as the result; no recrystallization/melting peaks are seen. 
"Is there any fundamental difference between dextran-trchalosc and PVP-
trehalose? Tg (eq) of the former case is so close to the melting point of trehalose, 
but not for the PVP dispersed system.". 
Response: The difference between trehalose-dextran and trehalose-PVP mixtures is, the 
most likely, the extent of miscibility of the sugar and the respective polymers. 
In general, the degree of miscibility of the components may depend upon factors 
including (1) molecular sizes of two components i.e. two sugars are easy to mix when 
compared to two polymers; (2) the differences in the Tg of individual components i.e. the 
smaller the differences in Tgs, the lower is the difference in their relative molecular 
mobility at mixing temperature; (3) structural similarities between two components i.e. 
like dissolves like; and ( 4) potential for interactions between the components i.e. 
interactions promotes mixing. 
The chemical structure of trehalose and the dextran repeat unit are very similar and also 
there is a potential for hydrogen bonding between the two components. For PVP mixtures 
the difference between the Tg of PVP (167°C) and trehalose (119°C) is less when 
compared to dextran (225°C) and trehalose. Also, the interactions between trehalose -OH 
and the basic C=O of PVP is considered stronger than trehalose-OH and dextran - OH . 
The Tg'q found in the trehalose-dextran mixture was lowered from 225°C to the values 
that happen to coincide with the melting temperature of anhydrous trehalose for samples 
226 
that were stored at 40°C and 50°C/75%RH storage conditions. This was a coincidence! 
Similar reduction in Tg values for PVP mixtures was seen from I 68°C to I 58°C due to 
trehalose dissolution in PVP. 
Calculations of the thermodvnamic parameters 
The excess enthalpy, entropy and free energy of mixing of trehalose with dextran and 
PVP were calculated using the theoretical equations provided below. The calculation 
involves binary mixtures and their phase stability behavior. ln the presence of water, the 
mixtures are however considered as ternary. Although there is a difference between a 
two-phase mixing and three-phase mixing, the free energy minimum of mixing ( Fig. 7; 
manuscript I), shows that the thermodynamic stability of the system is expected at its 
maximum around 20%w/w trehalose-concentration. Our observations showed that T g2 
values reached a plateau suggesting "equilibrium" of the three phase system that 
corresponded to 12-18% trehalose concentration, i.e. values closer for the predicted 
system with no water. Although the calculations are made based on the trehalose-polymer 
interactions, it may be more than a coincidence. 
The molar enthalpy of polymer I, having glass transition temperature T gl , in its glassy 
state, at a temperature T, is given as: 
{I) 
Similarly, the molar enthalpy in liquid state H: (T) can be described as: 
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I I fT - / H, (T) = H, (T81) + C p1dT T,, (2) 
According to Ehrenfest's theory of second-order transition; H : (T, ,) = H ,• (T, ,), and so 
equations (I) and (2) can be equated at T g l . 
For a miscible blend containing polymer P1 and sugar S2 with weight fractions w1 and w2 
respectively, and undergoing a single glass transition temperature Tg12, the enthalpy of 
mixture, H 11 (Jig) can be described by the relation (30): 
(3) 
where H 1 and H 2 are the enthalpy in either liquid or glassy states of polymer and sugar 
respectively, and l'!.H.,ix is the enthalpy of mixing. 
The enthalpy of mixing can be described as a function of temperature (7) and weight 
fraction (w), in the liquid or glassy states. By following Ehrenfest's theory, the function 
H(T,w) is continuous at Tg12, (i.e. H :, (T, 12 ) = H ,', (T, 12 )), and hence the following 
equations can be given: 
I fT.,u-/ fT,u-1 I H 12 (T812 , w) = w, Cp1 dT + w2 C .idT +l'!.H.,ix r.1 r,2 (4) 
g f Tx11-g f T, u-g g f/ 12 (T, ,,, w) = w1 C p1dT + w2 C . , dT + l'!.H mix r,1 T, z (5) 
Also, since l'!.H mix = l'!.H !ix + l'!.HM,.fmL< and !'!.HM••'"'" = 0 , rearranging equations ( 4) and 
(5) at T g12, we have: 
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(6) 
where Mi!,, (Jig) =Mi~'" - Mi !u; t;.C, = C~ - C! ; Mi m" is the enthalpy of mixing, 
and Tg1 and Tg2 are the glass transition temperatures of polymer and sugar respectively. 
The entropy of mixing can also be calculated in a manner similar to the above performed 
calculations, and is described as: 
I fT" fT,z '\' 
-t;.S"'" (J/g/°K) = M !,, -t;.S"'" = w1 t;.C, ,d In T + w2 t;.C, 2d lnT- RL..., X , ln X , r. 12 r,,. 12 
(7) 
where t;.S"'" =M!" +t;.S,drolm" ; M ,d,almu =-RL: X, ln X ,; R is the gas constant andX1 
is the mole fraction of component i of the mixture. X1 has been converted to weight 
fractions to adjust the units for M ,d,nlmu to J/g/°K. 
In order to numerically calculate the thermodynamic functions, it is necessary to obtain 
the heat capacity of individual components of the mixture as a function of temperature in 
their glassy and liquid states. The heat capacity function of a polymer is typically of the 
form C, =a+ bT , where a and b are constants. 
By substituting the expression for Cp in equations (6) (or (7)), the enthalpy (or the 
entropy) of mixing can be calculated: 
- Mi mu = w,J'" [(a, +b,T)1 -(a, +b,T)' ]dT + w,J"' [(a 2 +b2T) 1 -(a2 +b, T) ' ]dT (8) r,. 12 r, 12 
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Upon calculating the enthalpy and entropy, the free energy of mixing can be calculated 
using the following equation: 
(9) 
Heat capacity-Temperature scans oflyophilized dextran 
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Heat capacity values of dextran at different temperatures 
File : C: ... \06260209DexTrelyo_l , 0.001 Run Date : 27 - Jun - 02 04 : 29 
Program : Universal V2 . 6D Run Number : 274 
TA Instruments Thermal Analysis -- DSC Standard - Modulated 
Sample : Dextran lyophilized 
Size : 3 . 7630 mg 
Cell Constant : 1 . 0689 
Operator : Madhav 
Method : Heat capacity changes 
Comment : Heat only 
Exotherm : Up 
Temperature Complex Cp Temperature Complex Cp 
•c J/g;•c •c J/g/°C 
36 . 85 1. 815 161.85 1 . 570 
41. 85 1. 842 166 . 85 1 . 585 
46 . 85 1. 867 171 . 85 1 . 600 
51. 85 1. 883 176 . 85 1. 614 
56 . 85 1 . 886 181 . 85 1 . 630 
61. 85 1.872 186.85 1. 645 
66 . 85 1. 843 191. 85 1. 660 
71. 85 1. 806 196 . 85 1 . 677 
76 . 85 1 . 765 201 . 85 1 . 694 
81. 85 1 . 723 206 . 85 1. 711 
86 . 85 1. 681 211 . 85 1. 733 
91 . 85 1. 640 216 . 85 1 . 763 
96 . 85 1 . 603 220 . 85 1. 812 
101 . 85 1 . 572 221.85 1. 834 
106 . 85 1 . 545 222 . 85 1 . 867 
111 . 85 1. 525 223 . 85 1 . 910 
116 . 85 1. 511 224 . 85 1. 960 
121. 85 1. 503 225 . 85 2 . 008 
126 . 85 1. 4 99 226 . 85 2 . 049 
131 . 85 1. 4 99 227 . 85 2 . 078 
136 . 85 1 . 504 228 . 85 2 . 093 
141.85 1. 512 229 . 85 2 . 099 
146 . 85 1 . 521 230 . 85 2 . 101 
151.85 1. 534 231.85 2 . 100 
156 . 85 1. 550 232 . 85 2 . 099 
233 . 85 2 . 099 
Heat canacit}:'. eguat ions for dextran: 
Supercooled state ( C~) ~ 1.7894 + 0.00 196 T 
Glassy state ( C ! ) ~ 1.223 + 0.0041 T 
t. c, cc~ - c; i ~ o.s664 - o.00214 T 
231 
Plot of c; VS. Temperature for lyophil ized dextran 
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Heat Capacity- Temperature scans of Lyophilized PVP 
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Heat capacity values of lyophilized PVP at different temperatures 
File : C: ... \0617025PVP Tre Lyo 1 , 0 . 001 Run Date : 18-Jun-02 14 : 11 
Program : Universal V2 . 6D - Ru0 Number : 237 
TA Instruments Thermal Analysis -- DSC Standard - Modulated 
Heat capacity equations for PVP: 
Sample : Lyophilized PVP 
Size : 2 . 8410 mg 
Cell Constant : 1 . 0689 
Operator : Madhav 
Method : Mdsc2 
Comment : Heat only 
Exotherm : Up 
Temperature 
•c 
36 . 85 
41. 85 
46 . 85 
51 . 85 
56 . 85 
61 . 85 
66 . 85 
71 . 85 
76 . 85 
81. 85 
86 . 85 
91. 85 
96 . 85 
101 . 85 
106 . 85 
111.85 
116 . 85 
121 . 85 
126 . 85 
131 . 85 
136 . 85 
141. 85 
146 . 85 
151 . 85 
156 . 85 
161 . 85 
166 . 85 
171.85 
176 . 85 
181.85 
186 . 85 
191. 85 
196 . 85 
Complex Cp 
J/g/°C 
2 . 170 
2 . 192 
2 . 229 
2 . 269 
2 . 285 
2 . 276 
2 . 256 
2 . 222 
2 . 174 
2 . 122 
2 . 070 
2 . 018 
1. 979 
1. 94 8 
1. 930 
1. 923 
1. 925 
1. 936 
1. 950 
1. 968 
1. 992 
2 . 013 
2.037 
2 . 065 
2 . 106 
2 . 183 
2 . 301 
2 . 373 
2 . 387 
2 . 397 
2 . 409 
2 . 423 
2 . 435 
Supercooled state ( C~) = 1.951 + 0.0025 T 
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Glassy state ( C! ) = 1.4468 + 0.0041 T 
t. C, ( C~ -C!) = 0.5042 - 0.0016 T 
Plot of C! vs. Temperature for lyophilized PVP 
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Heat Capacity - Temoerature scans of Lyophilized Trehalose 
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Heat capacity values of lyophilized trehalose at different temperatures 
File : C: .. . \303039DexTre0 , 1 Tg- detect 1 . 001 Run Date : 7-Mar-03 12 : 16 
Program : Universal V2 . 60 Run Number : 93 
TA Instruments Thermal Analysis -- DSC Standard - Modulated 
Sample : Lyophilized Trehalose Size : 7 . 8980 mg 
Cell Constant : 1 . 0742 
Operator : Madhav 
Method : MDSC 2 
Comment : Detect Heat capacity 
Exotherm : Up 
Temperature Complex Cp 
•c J/g/°C 
36 . 85 1. 576 
41. 85 1 . 606 
46 . 85 1. 643 
51. 85 1. 686 
56 . 85 1.704 
61. 85 1 . 723 
66 . 85 1. 741 
71. 85 1. 74 2 
76 . 85 1. 757 
81. 85 1 . 766 
86 . 85 1 . 781 
91 . 85 1 . 795 
96 . 85 1.817 
101 . 85 1. 838 
106 . 85 1. 870 
111 . 85 1. 912 
116 . 85 2 . 031 
Heat capacity equations trehalose: 
Supercooled state ( C~) = 3.1246 + 0.0019 T 
Glassy state ( c; ) = 1.4833 + 0.0036 T 
t.C,(C~ -C!J = I.6413 - 0.0017T 
Temperature 
•c 
121 . 85 
126 . 85 
131 . 85 
136 . 85 
141. 85 
146 . 85 
151.85 
156 . 85 
161. 85 
166 . 85 
171. 85 
176 . 85 
18 1. 85 
186 . 85 
191. 85 
196 . 85 
201 . 85 
206 . 85 
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Sample calculation for the enthalpv of mixing: 
Ir,. . t JT,2 t - DH.,;,=w, [(a,+b,T) -(a,+b,T)' ]dT+w2 [(a 2 +b2T) -(a, +b2T) ' ]dT T1u T611 
where w1 = weight fraction of trehalose, 
w2 = weight fraction of polymer, 
T,, = glass transition temperature for trehalose, 
T, 2 =glass transition temperature for polymer, 
T112 = glass transition temperature for trehalose-polymer mixture, 
a1 = y-intercept of linear equation of heat capacity vs. temperature for trehalose, 
b1 =slope oflinear equation of heat capacity vs. temperature for trehalose, 
a,= y-intercept oflinear equation of heat capacity vs. temperature for polymer, 
b2 =slope of linear equation of heat capacity vs. temperature for polymer. 
To calculate the enthalpy of mixing for a 40%w/w trehalose - in - dextran mixture: 
Supercooled state (C~ 1) = 3.1246 + 0.0019 T 
Glassy state ( C! 1) = 1.4833 + 0.0036 T 
L'lCp 1(C~ -C! ) = 1.6413 - 0.00!7T 
Supercooled state ( C~ i) = I . 7894 + 0.00196 T 
Glassy state ( c; 2) = 1.223 + 0.0041 T 
L'1Cp2 ( C~ -C! ) = 0.5664 - 0.00214 T 
- DH.,,,= (0.4*(1 .6413*(391 - 442))-0.4*(0.0017)*((391 *39 1 )/2-(442*442)/2) + 
0.6*(0.5664 *( 497-442) )-0.6*(0.00214 )*( 497*497)/2-( 442 *442)/2)) 
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Enthalpy of mixing for trchalosc - dextran mixtures 
Trehalose Dcxtran Tg mixture lili! i.r 
Wt. fraction Wt. fraction (OK) (J/g) 
0 I 497 0 
O.J 0.9 482.36 14.55 
0.2 0.8 467.50 24.93 
0.3 0.7 454.4J 3 I.OJ 
0.4 0.6 442.33 33 .54 
0.5 0.5 43 I.OJ 32.93 
0.6 0.4 421.22 29.85 
0.7 0.3 412.40 24.68 
0.8 0.2 403.97 17.41 
0.9 0.1 397.21 9.32 
0 391 0 
Since, the enthalpy of mixing, l!.H mfr= l!.H;drolmi< + l!.H !,, , and l!.HM, nlmi< = 0 , the excess 
enthalpy of mixing is equal to total enthalpy of mixing as given in the above table. 
Excess entropy of mixing for trehalose - dextran mixtures 
Trehalose 
Wt. fraction 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
Dextran 
Wt. fraction 
J 
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
O.J 
0 
Tg mixture 
(OK) 
497 
482.36 
467.50 
454.4J 
442.33 
431.01 
421.22 
412.40 
403.97 
397.21 
391 
M ,:u 
(X 103) 
(J/g/K) 
0 
3J.88 
55.42 
69.94 
76.66 
76.20 
69.88 
58.37 
41.54 
22.43 
0 
To calculate the entropy of mixing, the ideal entropy of mixing is added to the excess 
entropy as described by the equations below; 
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D.Sm,, = D.S!,, +D.S,drolm« ; D.Sidrolm« = -R'I,X, lnX,; R is the gas constant and X; is the 
mole fraction of component i of the mixture. X; needs to be converted to weight fractions 
to adjust the units for 6Sid,almu to J/g/°K as conducted below. 
Calculation of ideal and total entro11y of mixing: 
Wt. Mol.Wt Wt. Mot.Wt 
Trehalose Trehalose Dextran Dextran 
0 342 I 71000 
0.1 342 0.9 71000 
0.2 342 0.8 71000 
0.3 342 0.7 71000 
0.4 342 0.6 71000 
0.5 342 0.5 71000 
0.6 342 0.4 71000 
0.7 342 0.3 71000 
0.8 342 0.2 71000 
0.9 342 0.1 71000 
342 0 71000 
Term In (term Term M idealmix Afmit 
A* A) B~ In (term 8) M idMlmi.x (corrected)§ (Xl03) 
(X 102) (X 103) (X 102) (Xl05) 
0 100 0 0 1.48 0 
95.84 -42.43 4.15 -3.1 8 1 .436833 1.56 31.90 
98. 10 -19.08 1.89 -3 .96 0.77926 1 1.75 55.43 
98.88 -11.17 I. I I -4.49 0.507611 2.00 69.95 
99.28 -7.19 0.71 -4.93 0.353851 2.33 76.67 
99.52 -4.80 0.47 -5.34 0.252576 2.80 76.21 
99.67 -3.20 0.32 -5.74 0.179422 3.49 69.88 
99.79 -2.06 0.20 -6.18 0. 123032 4.64 58.37 
99.87 -1.20 0.12 -6.72 0.077215 6.90 41.55 
99.94 -0.53 0.053 -7.53 0.037945 13.49 22.44 
0 0 0 292.39 0 
24 1 
*Term A = ~Tenn B = 
[ 
( Wt fahalru• / ) / MWTrelralose 
[ 
( Wt°'-'""" / W ) ] / M De.xtrm1 
Wf Trehnlose 
Wt De.xtro11 '"'"'~w,,,,.,.,. + ··{,w I Jv. / M fk:ctran 
§ M M .. lm" (corrected for units to J/g/°K) = M M,.1.," * 
(Wt ,,.,.,.,. * MWfohalM• 
1
+ Wt D<x,mn *MW lk«mn ) 
Free energy of mixing for trehalose - dextran mixtures 
Free energy of mixing, t:.Gm" = tlH m'' -T,,,M .," 
DJ{ mix M mi:c T,12 llGml'f 
(J/g) (X 103) (oK) (J/g) 
(J/g/oK) 
0 0 497 0 
14.55 3 1.90 482.36 -0.83 
24.93 55.43 467.50 -0.98 
3 1.01 69.95 454.4 1 -0.77 
33 .54 76.67 442.33 -0.37 
32.93 76.2 1 431.01 0.082 
29.85 69.88 421.22 0.4180 
24.68 58.37 412.40 0.60 
17.4 1 41.55 403.97 0.63 
9.32 22.44 397.21 0.41 
0 0 391 0 
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Enthalpy of mixing for trehalosc - PVP mixtures 
Trehalose PVP Tgmixture l'!J{ £ mlf 
Wt. fraction Wt. fraction (OK) (Jig) 
0 I 441 0 
0.1 0.9 430.21 5.80 
0.2 0.8 424.05 9.14 
0.3 0.7 420.61 11.43 
0.4 0.6 415.8 12.58 
0.5 0.5 411.33 12.74 
0.6 0.4 406.38 11 .62 
0.7 0.3 401.41 9.34 
0.8 0.2 398.15 7.18 
0.9 0.1 395.09 4.44 
1 0 391 0 
Since, the enthalpy of mixing, Af-lmL,= f!J/ ;deatmit +Af-/!u, andM-l it1ealmix =0, the excess 
enthalpy of mixing is equal to total enthalpy of mixing as given in the above table. 
Excess entropy of mixing for trehalose - PVP mixtures 
Trehalose PVP Tg mixture f1S!lr 
Wt. fraction Wt. fraction (OK) (X 103) 
(J/g/K) 
0 1 441 0 
0.1 0.9 430.21 13.86 
0.2 0.8 424.05 22.04 
0.3 0.7 420.61 27.77 
0.4 0.6 415.8 30.74 
0.5 0.5 411.33 31.32 
0.6 0.4 406.38 28.75 
0.7 0.3 401.41 23.24 
0.8 0.2 398.15 17.95 
0.9 0.1 395.09 11.17 
0 391 0 
To calculate the entropy of mixing, the ideal entropy of mixing is added to the excess 
entropy as described by the equations below; 
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mole fraction of component i of the mixture. X; needs to be converted to weight fractions 
to adjust the units for D.S;d,nlmu to J/gl°K as conducted below. 
Calculation of ideal and total entro('.1y of mixing: 
Wt. Mot.Wt Wt. Mot.Wt 
Trehalosc Trehalosc PVP PVP 
0 342 1 58000 
0.1 342 0.9 58000 
0.2 342 0.8 58000 
0.3 342 0.7 58000 
0.4 342 0.6 58000 
0.5 342 0.5 58000 
0.6 342 0.4 58000 
0.7 342 0.3 58000 
0.8 342 0.2 58000 
0.9 342 0. 1 58000 
I 342 0 58000 
Term In (term Term 6.S ideal mi:c 6.Smir 
A* A) B~ In (term B) 6.Sideal mLc (corrected)§ (Xl03) 
(X 102) (X 103) (X 102) (Xtos) 
0 100 0 0 0 0 
94.96 -51. 70 5.03 -2.98 1.65 3. 17 13.82 
97.69 -23.31 2.30 -3.77 0.91 1.96 22.02 
98.64 -13.66 1.35 -4.29 0.59 1.46 27.75 
99.12 -8.80 0.87 -4.73 0.4 1 1.19 30.73 
99.4 1 -5.87 0.58 -5.13 0.29 1.02 31 .31 
99.60 -3.92 0.39 -5.54 0.21 0.90 28.74 
99.74 -2.52 0.25 -5.98 0.1 4 0.82 23.23 
99.82 - 1.47 0.14 -6.52 0.09 0.77 17.94 
99.93 -0.65 0.06 -7.33 0.04 0.74 11.1 6 
0 0 0 0 0 
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§ 6.S,,,.1. ;, (corrected for units to J/g/°K) = 
6.SldMlmu * ( * l I * ) 
Wl Trthalo.st MWTtrhalost + W. PVP MWpyp 
Free ener !!V of mixing for trehalose - PVP mixtures 
Free energy of mixing, !:!..G,,,a = tlH ,,,a - Tg121lS111u 
t:iH,,,u 6.S.;, Ts12 6.G.;, 
(J/g) (X 103) (oK) (J/g) 
(J/g/oK) 
0 0 44 1 0 
5.80 13.82 430.2 1 -0. 16 
9. 14 22.02 424.05 -0.2 1 
11.43 27.75 420.6 1 -0.24 
12.58 30.73 4 15.8 -0.20 
12.74 31.31 41 1.33 -0. 14 
11.62 28.74 406.38 -0.06 
9.34 23.23 40 1.41 0.0 15 
7. 18 17.94 398. 15 0.033 
4.44 11.1 6 395.09 0.027 
0 0 391 0 
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APPENDIX C 
Phase Behavior of Amorphous Molecular Dispersions: Role of Hydrogen 
Bonding in Solid Solubility and Kinetics of Phase Separation 
(Supporting data to Manuscript II) 
Phvsical stabilitv of amorphous drug substance 
It is seen from Fig. C-1, that both the amorphous drugs undergo recrystallization after 
glass transition phenomenon while heating in DSC. This indicates the instability of 
drugs in their amorphous phases. Based on the DSC scans it is inferred that 
indoprofen is a relatively stable crystalline molecule due to its high heat of fusion. 
Also it is expected to be relatively unstable in its amorphous phase due to its lower T8 
(50°C) and lower recrystallization temperature (72°C). 
246 
Figure C-1 
Heat flow scans of amorphous and crysta ll ine griseofulvin exhibiting the phys ical 
transitions 
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Figure C-2 
Heat !low scans of amorphous and crystalline indoprofen exh ibiting the physical 
transitions 
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Spectroscopic investigation of drug crystallization patterns: 
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In order to understand the nature of interactions between drug molecules in 
their amorphous and crystall ine forms a spectroscopic investigation was conducted. 
Such a study would provide information on the various routes through which the drug 
molecules crystallize. Vibrational spectroscopy is a technique that is well established 
and is typically used to study specific interactions. IT-IR spectroscopy was used in 
this study to probe into the state of functio nal groups of drugs in their amorphous and 
crystalline states and the spectra are shown in Fig. C-3 . Differences are evident 
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between the two forms of both the drugs in the carbonyl stretch region of 1750 cm· ' 
and 1600 cm·' . 
Griseoful vi n has three methoxy units and two carbonyl groups as shown in 
Fig. la (chapter 2). On its FT-IR spectra, in addition to broadening of peaks in the 
amorphous sample, a weak peak at l 739cm·' was seen for crystalline fo rm indicating 
the presence of unbound C=O groups (Fig. C-3A). Also a strong peak at l 598cm·' 
presumably due lo the carbon-carbon structural ordering of molecules is seen in 
crystalline form and is absent in amorphous phase. Since there are no signi ficant 
differences in the peak pattern of carbonyl groups between the amorphous and 
crystalline griseofulvin, it is possible that the functional groups do not involve 
through interactions during drug crystallization. 
lndoprofen has two carbonyl groups: a) C=O of -COOH group and b) C=O of the 
amide in pyrrolidone ring (Fig. C-38). ln the case of crystalline indoprofen, a weak 
peak at 1728cm·' and a strong peak at 1697 cm· ' was seen. The presence of a high 
intensity peak at lower wave-numbers relative to peak at 1728cm· ' (t. v=J lcm·') 
indicates that the C=O of -COOH is largely present in a bound stale. The band at 
I68 Icm·1 is assigned lo the C=O of pyrrolidone ring. In the case of amorphous 
indoprofen, the peak al l 728cm·' has much higher intensity when compared to the 
peak at 1697cm·', indicating that the C=O of -COOH are relatively "free". Actually, 
the peak at l 728cm· ' is characteristic of free C=O of - COOH groups where the -OH 
group is hydrogen bonded lo a di ffe rent functional group. The carbonyl band of -
COOH group where both C=O and -OH groups are free appear at l 750cm·' . It the 
amorphous state, in addition to band at 168 lcm·' , a broad band at 1648cm·' was 
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observed. This band was assigned to the hydrogen bonded C=O the pyrrolidone ring 
(ti. v=33cm- 1). The C=O of pyrrolidone ring could most likely be bonded to -OH 
group of -COOH. This would agree with previous observation of free carbonyl group 
of -COOH stretch at l 728cm·' instead of l 750cm·'. Therefore it can be concluded 
that indoprofen molecules crystallize by fom1ing cyclic dimers between two -COOH 
units of individual molecules. 
Figure C-3 
FTIR carbonyl stretching of amorphous and crystalline A) griseofulvin and B) 
indoprofen 
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Figure C-4 
MDSC reversing heat flow scans of 30%w/w griseofulvin-in-PVP solid dispersions 
exposed to 40°C/69%RH for (a) 2 days and (b) 4, 6, and 10 days 
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Figure C-5 
MDSC reversing heat flow scans of 30%w/w griseofulvin-in-PVP solid dispersions 
exposed to 40°C/69%RH for (a) l l , l 5 days and (b) 35 days 
-0.01 
~ 
~ 
;: 
0 
ii: -0.02 
.. 
.. 
:c 
> 
~ 
-0.03 
Exo Up 
~ -0.0 1 
~ 
;: 
0 
~ -0.02 
" 
= > 
.. 
a: 
-0.03 
15 days 
·--·--
----
_ _ ~163_99•c 15 days 
--·--- ··-- . 
11 days ~~:;;--
------
---... .. _ 
11 days 
Temperature 
35 days_ 
----·---- ·--·- 162 55°C --~
35 days------ -- --. 
-·-------~~~~---
35 days 
~----­
---
---
---~09•c 
...,_ ____ _ 
-0.04 +----~---~---~---~---~----! 
-50 50 JOO 150 200 250 
Exo Up Temperature 
252 
Figure C-6 
MDSC reversing heat flow scans of 30%w/w griseofulvin-in-PVP solid dispersions 
exposed to 40°C/69%RH for 65 , 75 and 90 days 
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Figure C-7 
MDSC reversing heat flow scans of20%w/w griseofulvin-in-PVP solid dispersions 
exposed to 40°C/69%RH for (a) 2 days and (b) 6 days 
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Figure C-8 
MDSC reversing heat flow scans of20%w/w griseofulvin-in-PVP solid dispersions 
exposed to 40°C/69%RH for(a) 4, 6, IO days and (b) JO, 15 days 
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Figure C-9 
MDSC reversing heat flow scans of 20%w/w griseofulvin-in-PVP solid dispersions 
exposed to 40°C/69%RH for (a) 50, 60, 70 days 
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Figure C-10 
MDSC reversing heat flow scans of l 0%w/w griseofu lvin-in-PYP solid dispersions 
exposed to 40°C/69%RH for (a) 2, 3, 4, 6, 10 days and (b) 6, 10, 60 days 
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Figure C- 11 
MDSC reversing heat flow scans of30%w/w indoprofen-in-PVP solid dispersions 
exposed to 40°C/69%RH for (a) I, 7, 15 days and (b) 15, 36 days 
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Figure C- 12 
MDSC reversing heat flow scans of 30%w/w indoprofen-in-PVP solid dispersions 
exposed to 40°C/69%RH for 50, 75, 90 days 
-0.01 
~ 
~ -0.02 
'" "' 
= 
.. 
"' CZ:: -0.03 
90 days __ 
90day~--~ -- ~~~~-
75 day&---. 144.79°C 
-- -
75 days ·---~-=~ 127 .43oC 
75 days ·-........_....__ -~--
---.---.~46.230C 50 days- ----.. --- . 
50days --- -- ==~-"----- 147.3~°C -- ~ ~-.llU,_~~·-
141.880C  
-0.04 +------------------------~-="=-==~-l 
-50 50 JOO 150 200 250 
Exo Up Temperature 
259 
Figure C-1 3 
MDSC reversing heat flow scans of 20%w/w indoprofen-in-PVP solid dispersions 
exposed to 40°C/69%RH fo r (a) I, 2, 9 days and (b) 15 days 
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Figure C- 14 
MDSC reversing heat flow scans of20%w/w indoprofen-in-PVP solid dispersions 
exposed to 40°C/69%RH for (a) 36, 54 days and (b) 55, 70, 90 days 
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Figure C-15 
MDSC reversing heat flow scans of I 0%w/w indoprofen-in-PVP solid dispersions 
exposed to 40°C/69%RH for (a) 0, I, 2, 16, 36, 54 days and (b) I, 2, 9, 16 days 
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Figure C-1 6 
MDSC reversing heat flow scans of I 0%w/w indoprofen-in-PVP solid dispersions 
exposed to 40°C/69%RH fo r (a) 18, 36, 55 days and (b) 35, 55, 70 days 
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Figure C- 17 
MDSC reversing heat flow scans of PVP solid dispersions containing (a) 30%w/w 
griseofulvin and (b) 20%w/w griseofulvin, exposed to 40°C/0%RH for 34 days. No 
significant deviations in T 8 are seen indicating that moisture is essential to cause 
phase-separation and crystallization of griseofulvin. 
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Figure C-18 
MDSC reversing heat flow scans of PVP solid dispersions containing (a) I 0%w/w 
griseoful vin exposed to 40°C/0%RH fo r 34 days. 
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Figure C- 19 
MDSC reversing heat flow scans of PVP solid di spersions containing (a) 30%w/w 
indoprofen and (b) 20%w/w indoprofen exposed to 40°C/0%RH for 34 days. 
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Figure C-20 
MDSC reversing heat flow scans of PVP solid dispersions containing (a) I 0%w/w 
indoprofen exposed to 40°C/0%RH for 34 days. 
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Estimation of the Rate of Phase Separation of Griseofulvin and lndoprofen from PVP 
Solid Dispersions 
To estimate the kinetic rate of phase separation of the drug from the polymers, the 
changes in the Tg of the mixture were utilized to calculate the fraction of the drug that 
had phase-separated. It is assumed that with increasing phase-separation of drug from 
the polymer, the Tg of the mixture would increase and eventually reach to Tg of pure 
polymer when no drug remains miscible. 
Based on this assumption, a mixture having Tg equalt lo that of a freshly prepared 
sample was accounted as I 00% miscible mixture. Likewise a Tg of I 67°C indicated a 
0% miscible mixture. Accordingly, the percentage of drug miscible was calculated at 
a specific storage time (t) as follows: 
(I-a), =l Tg(potpr1er1 -Tg2<r1 
Tg(poly~r) -Tg(initiaf) 
where a is the amount of drug phase separated, Tg(polymc•) is the 167°C, Tg(;n;1;,1) is the 
Tg of freshly prepared sample and is dependent on the composition of drug present, 
T g2(t) is the Tg of the mixture at the specified storage time/. 
Upon obtaining the fraction of drug phase separated with storage time, the phase 
separation rate constant was estimated by using a first -order rate equation: 
(- ln{l -a)] =kt 
where k is the rate constant for phase separation. 
A first order rate equation was applied since it seemed to best fit the data when 
compared to other rate equations. 
Phase separation rates were determined from average ofn=3 Tg values at every time 
point. 
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Table C-1: Griseofulvin kinetics of phase separation from 30%w/w solid 
dispersions 
Days Tg 167°C- Tg a I- a -lln(I- a)I 
(1) coq (x IO') 
0 131 36 0 1 0 
1 159 8 77 0.222 1.504 
2 155 12 66 0.333 1.098 
5 160 7 80 0.194 1.637 
9 162 5 86 0.138 1.974 
11 161 6 83 0.1 66 1.791 
15 163 4 88 0.111 2. 197 
35 163 4 88 0.111 2. 197 
60 164 3 9 1 0.083 2.484 
70 166 1 97 0.027 3.583 
90 167 0 100 0 
Table C-ll: Griseofulvin kinetics of phase separation from 20%w/w solid 
dispersions 
Days Tg 167°C-Tg a 1- a -lln(I- a)J 
(I) coq (x 102) 
0 142 25 0 1 0 
2 164 3 88 0.12 2. 120 
6 161 6 76 0.24 1.427 
10 163 4 84 0.16 1.832 
15 160 7 72 0.28 1.272 
30 164 3 88 0. 12 2.120 
60 166 1 96 0.04 3.218 
70 166 1 96 0.04 3.2 18 
90 167 0 100 0 
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Table C-Ul: Griseofulvin kinetics of phase separation from 10% w/w solid 
dispersions 
Days Tg 167°C -Tg a 1- a -lln(I- a)i 
(t) (oC) (x 102) 
0 156 II 0 I 0 
2 156.35 10.65 3 0.968 0.032 
3 160.49 6.5 1 40 0.59 1 0.524 
6 162.86 4. 14 62 0.376 0.977 
10 163.42 3.58 67 0.325 1.1 22 
39 165.35 1.65 85 0.15 1.894 
50 166. 17 0.83 92 0.075 2.584 
60 166.34 0.66 94 0.06 2.8 13 
75 166.74 0.26 97 0.023 3.744 
Figure C-2 1 
Plot of - ln(l-a) vs. time for griseofulvin-PVP solid dispersions to obtain the rate 
constant fo r drug phase separation. 
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Table C-JV: Indoprofen kinetics of phase separation from 30% w/w solid 
dispersions 
Days T• 167°C -Tg a 1- a -fln(l - a ) ( 
(t) (OC) (x JO') 
I 117 50 0 I 0 
7 119 48 4 0.96 0.040 
15 127 40 20 0.8 0.223 
36 137 30 40 0.6 0.5 10 
50 140 27 46 0.54 0.616 
75 143 24 52 0.48 0.733 
90 143 25 50 0.50 0.694 
Table C-V: Indoprofcn kinetics of phase separation from 20% w/w solid 
dispersions 
Days T• 167°C-Tg a 1- a -fln(I- a)) 
(t) (OC) (x JO' ) 
I 129 38 0 I 0 
2 130 37 2 0.973 0.026 
9 130 37 2 0.973 0.026 
16 133 34 10 0.894 0. 111 
36 135 32 15 0.842 0. 171 
54 143 24 36 0.63 1 0.459 
70 143 24 36 0.631 0.459 
95 144 23 39 0.605 0.502 
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Table C-VI: Indoprofen kinetics of phase separation from IO% w/w solid 
dispersions 
Days T, 167°C -Tg a I- a -lln( I- a)I 
(1) c·q (x 10') 
I 144 23 0 I 0 
2 145 22 4 0.956 0.044 
9 146 21 8 0.913 0.090 
16 147 20 13 0.869 0. 139 
36 147 20 13 0.869 0. 139 
54 147 20 13 0.869 0. 139 
70 148 19 17 0.826 0. 19 1 
90 148 19 17 0.826 0.191 
Figure C-22 
Plot of - ln( l-a) vs. time for indoprofen-PVP solid dispersions to obtain the ra te 
constant for drug phase separation. 
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APPENDIX D 
Phase Behavior of Amorphous Molecular Dispersions: Determination of Solid 
Solubility in Ternary Solid Dispersions 
(Supporting data to Manuscript JU) 
Figure D-1 
MDSC reversing heat flow scans of solid dispersions containing PVP, indoprofen and 
sugar ester 01570. A composition dependent single T • is evident for the freshly 
prepared ternary solid dispersions. With an increase in the surfactant concentration, 
the T, of the mixture decreases. A 65:30:05 (7. 14%w/w); B 60:30: 10 ( 14.20%w/w); 
C 70:30: 15 {I 7.64%w/w); D 50:30:20 (28.5%w/w); E 70:30:30 (39%w/w); F 
40:30:30 (42%w/w). The compositions are given as PVP: lndoprofen: sugar-ester. 
The numbers within the brackets are for the percentage surfactant in the overa ll 
mixture. The increase in the baseline at temperatures above I 80°C indicates the 
decomposition of the surfactant. 
~-0.01 
., 
.. 
::c -0.02 
> 
~ 
F 
E 
D 
c 
B 
A 
Temperature 
273 
Figure D-2 
MDSC reversing heat flow scans of PVP: lndoprofen: Sugar-ester in the ratio 
60:30: IO that were stored at 40°C/69%RH for different storage intervals. The Tg of 
I I 4°C at the end of 15 days was less than the Tg of I 23°C (see chapter 3) 
corresponding to solid solubility of sugar ester in PVP at 40°C/69%RH. The fraction 
of indoprofen dissolved in PVP was therefore not influenced (neither increased nor 
decreased) by the presence of sugar ester. 
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Figure D-3 
MDSC reversing heat fl ow scans of PVP: Indoprofen: Sugar-ester in the ratio 
65:30:05 that were stored at 40°C/69%RH for different storage intervals. The Tg of 
l 14°C at the end of7 days fo r this composition indicates that the final Tg value 
(l 14°C) is not influenced by the initial surfactant concentration (see Fig.A4-2). The 
fraction of indoprofen dissolved in PVP was not influenced (neither increased nor 
decreased) by the presence of sugar ester. 
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Figure D-4 
MDSC reversing heat flo w scans of PVP: griseoful vin: pluronic in the ratio 40:50: 10 
those were stored at 40°C/69%RH for 2 days. Phase separation of griseofulvin is seen 
from the shift in T8 from I 13°C to I 62°C. In addition, the surfactant - Pluronic F87 
crystallizes completely as indicated by the melting at 70°C and the shi ft in Tg of PVP 
to 162°C. The approach described in this study was found useful to identify the 
physical stabi lity of this product at 40°C/69%RH conditions. 
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APPENDIX E 
Crystallization Kinetics of Amorphous Griseofulvin under Low Moisture 
Content 
(Supporting data to Ma nuscript IV) 
Table E-1: XRD calibration plot to determine the kinetics of griseofulvin 
crystallization. 
A physical mixture of crystall ine and amorphous griseofulvin was prepared using 
20%w/w of lithium fluoride (LiF) as the internal reference. The peak height of 
crystalline griseoful vin peak and lithium fluoride were measured and their ratios 
(crystalline griseoful vin : LiF) were plotted against the percentage of crystalline 
griseoful vin in the sample. 
% w/w crystalline Peak height ratio Average 
griseofulvin in 
total griseofulvin 
(i.e. 80% of 
sample) 
30% 
50% 
70% 
!crystalline 
griseofulvin/ 
LiF] 
0.5754 
0.5841 
0.6732 
0.3216 
0.835 
0.928 
0.892 
0.7735 
0.9 146 
1.02 1 
1.129 
0.835 
0.538575 
0.857 125 
0.9749 
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Figure E-1 
XRD calibration plot of peak ratio of crystall ine griseofulvin and lithium fluoride 
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Table E-11: Heat of recrystallization of amorphous griseofulvin in physical 
mixtures of crystalline and amorphous griseofulvin for the construction of 
calibration plot 
Percent Heat of recr)'stallization (Jig) Average heat of Standard 
Amorphous Batch I Batch 2 Batch 3 recrystallization deviation 
JI 
JOO 6 1.38 62.36 60.3 1 6 1.35 1.025 
90 54.12 53.9 55.2 1 54.4 1 0.70 1 
80 49.9 50.26 49.98 50.04 0.189 
50 29.95 29.35 30.05 29.78 0.378 
40 24.74 24.53 23.92 24.39 0.425 
20 14.05 13.95 14.56 14.18 0.327 
10 7.554 7.378 8.04 7.657 0.342 
0 0 0 0 0 0 
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Figure E-2 
MDSC calibration plot of heat of griseo fu lvin crystall ization and percentage of 
amorphous griseoful vin in the sample. 
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Isothermal crystalli zation studies 
Figure AE-3 
MDSC nonreversing heat flow scans of amorphous griseofulvin undergoing 
isothermal crystallization at 43%RH . As crystallization occurs, the amorphous 
fraction in the sample decreases and hence the area under the crystallization peak 
decreases. To quantify the percentage of griseoful vin in the amorphous stale, the DSC 
calibration plot and the heat of crystallization (i.e. area under the crystallization 
curve) is used. 
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Figure E-4 
MDSC nonreversing heat flow scans of amorphous griseofulvin undergoing 
isothem1al crystall ization at 43%RH. 
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Figure E-5 
MDSC nonreversing heat flow scans of amorphous griseofulvin undergoing 
isothermal crystallization at 32%RH. 
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Figure E-6 
MDSC nonreversing heat flow scans of amorphous griseofulvin undergoing 
isothermal crystallization at 0%RH. 
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Choosing appropriate rate equation to fit the isothermal crystallization data of 
amorphous griseofulvin: Hancock-Sham equation and KJMA equation 
To determine the crystallization rate constant for the isothem1al griseofulvin 
crystallization, the fraction of griseofulvin crystallized with storage time is fit to the 
Hancock-Sharp equation. 
ln[-ln(l-a)] =In B+ mint (AS-I) 
where a the fraction of drug that has crystallized, t is the storage time, B is a 
constant and m is a constant relating to the mechanism of griseofulvin crystallization. 
The kinetic equations for the most common mechanisms that are believed to operate 
in solid-state alteration are presented in Table B-IV-lll, chapter 4. 
In order to find the equation that best fits the crystallization rate, the equation that has 
the m value closest to the slope obtained in the Hancock-Sharp fit was chosen, which 
is KJMA rate equation (m = I). To counter-verify, the crystallization data obtained is 
fit to all the equations listed in Table B-IV-III, chapter 4. 
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Table E-111: Fit of crystallization data to various kinetic rate equations. KJMA; 
Fl - - ln{I - a) rate equation was chosen since them value form Hancock-Sharp 
fit was closest to 1.00. Also the R2 value with KJMA fit was 0.9918, which can be 
considered very well. 
time a l -(l -a)Y, l -(l -a)Y, - ln(l -a) [- ln(l -a))Y, 
KJMA 
0 0 0.666667 0 0 0 
I 4.2 0.680667 0.02 1225 0.042908 0.02 1454 
2 3.8 10673 0.679369 0.019238 0.038852 0.019426 
4 22.70 178 0.742339 0. 120806 0.257499 0. 12875 
6 29. 10884 0.763696 0. 15803 1 0.344024 0.1720 12 
IO 41.224 0.80408 0.233345 0.531437 0.2657 18 
14 57. 150 11 0.857167 0.345402 0.847467 0.423734 
19 72.452 1 0.908 174 0.475 139 1.289244 0.644622 
24 83.08537 0.9436 18 0.588726 1.776991 0.888496 
32 86.92267 0.956409 0.638374 2.03429 1.017145 
40 92.89982 0.976333 0.733538 2.64505 1.322525 
R' 0.9044 0.9639 0.9044 0.9918 0.9918 
slope 2.502 0.0196 0.0083 0.0678 0.0339 
time [- ln(l -a)]Y, a' (1-a) ln(l -a) +a 
0 0 0 0 
I 0.0 14303 0.00 1764 0.000895 
2 0.0 1295 1 0.00 1452 0.000735 
4 0.085833 0.05 1537 0.027975 
6 0. 114675 0.084732 0.047205 
10 0. 177 146 0. 169942 0.099883 
14 0.282489 0.3266 13 0.208362 
19 0.429748 0.524931 0.369361 
24 0.59233 0.6903 18 0.530282 
32 0.678097 0.755555 0.603 196 
40 0.88 1683 0.863038 0.7411 95 
R' 0.9918 0.9666 0.9775 
slope 0.0226 0.0244 0.0202 
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time [1 -(1-a)Y,]' (1-2a 13)-(1-a)Y, 
0 0.444444 0.666667 
I 0.463307 -5.21333 
2 0.46 1542 -4.17374 
4 0.55 1068 -171.124 
6 0.583232 -281.775 
IO 0.646545 -565.806 
14 0.734735 -1088.04 
19 0.824779 -1749. 1 
24 0.890415 -2300.39 
32 0.914718 -25 17.85 
40 0.953226 -2876. 13 
R' 0.9249 0.9666 
S!ll}JC 0.0138 -81.391 
Figure E-7 
Demonstration of the griseofu lvin crystallization data fit to various equations 
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Table E-rv: Fit of griseofulvin crystallization data at 0%, 32% and 43% RH to 
the KJMA rate equation. Average of n=3 repetitions were fit to the equation. 
0%RH 32%RH 
time a - Ln{l -a) time a -ln{l- a ) 
KJMA KJMA 
0 0 0 0 0 0 
2 2.05 0.020713 I 0 0 
26 35.97909 0.44596 3 0 0 
36 38.053 0.47889 1 5 7.283242 0.075621 
43 45.45099 0.60607 1 8 18.10035 0.199675 
51 53.46397 0.764943 15 45.143 0.60044 
63 69.22366 1.178424 20 65.146 1.054002 
25 83 .152 1.321254 
33 79.82443 1.600698 
44 87.79331 2.103186 
R' 0.9555 R' 0.9885 
sl~ 0.0169 sl~ 0.0509 
43%RH 
time a - ln{l -a) 
KJMA 
0 0 0 
I 4.2 0.042908 
2 3.8 10673 0.038852 
4 22.70178 0.257499 
6 29.10884 0.344024 
10 41.224 0.531437 
14 57.15011 0.847467 
19 72.4521 1.289244 
24 83.08537 1.776991 
32 86.92267 2.03429 
40 92.89982 2.64505 
R' 0.9918 
sl~e 0.0678 
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APPENDIX F 
Measurement of sub-glass transition molecular motions of Poly (vinyl 
pyrrolidone): comparison of the utility of thermally stimulated current (TSC) 
and modulated differential scanning calorimeter (MDSC) 
(Supporting data to Manuscript V) 
Figure F-1 
Reproducibility scans to demonstrate the heat capacity change and glass transition 
temperature in PVP K 17 
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Figure F-2 
Reproducibili ty scans to demonstrate the heat capacity change and glass transition 
temperature in PVP K30 
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Figure F-3 
Reproducibility scans to demonstrate the heat capacity change and glass transition 
temperature in PVP K90 
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Figure F-4 
MDSC non-reversing heat flow scans of PVP Kl 7 exhibiting enthalpy relaxation 
when subj ected to 5°C below their glass transition temperature of l l 7°C. The area 
under the non-reversing heat flow increases, indicating progressive enthalpy 
relaxation to the equilibrium supercooled state. 
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Figure F-5 
MDSC non-reversing heat flow scans of PVP Kl 7 undergoing enthalpy relaxation at 
storage temperature l 5°C below l I 7°C. 
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120 140 
MDSC non-reversing heat flow scans of PVP Kl7 undergoing enthalpy relaxation at 
storage temperature 30°C below l I 7°C. 
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Figure F-7 
MDSC non-reversing heat flow scans of PVP K30 undergoing enthalpy relaxation at 
storage temperature 5°C below I 66°C. 
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160 180 200 
MDSC non-reversing heat flow scans of PVP K30 undergoing enthalpy relaxation at 
storage temperature I 5°C below I 66°C. 
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Figure F-9 
MDSC non-reversing heat flow scans of PVP K30 undergoing enthalpy relaxation at 
storage temperature 30°C below J 66°C. 
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Figure F-10 
MDSC non-reversing heat flow scans of PVP K90 undergoing enthalpy relaxation at 
storage temperature 5°C below J 75°C. 
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Figure F-11 
MDSC non-reversing heat flow scans of PYP K90 undergoing enthalpy relaxation at 
storage temperature l 5°C below l 75°C. 
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MDSC non-reversing heat flow scans of PVP K90 undergo ing enthalpy relaxation at 
storage temperature 30°C below l 75°C. 
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